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CHAPTER 1 
INTRODUCTION  
 
1.1 Motivation 
 Cancer is the second leading cause of death globally according to the World Health 
Organization. Especially dangerous and lethal are the breast cancers that have genetic mutations 
for surface receptors utilized in drug therapy.[1] This resistance calls for new and innovative 
treatments that be optimized for cancers based on an individual patient basis/cancer 
phenotype.[2] Nanoparticle based diagnostics and therapeutics have recently emerged as a novel 
platform for management and mitigation of cancer at all stages. Gold nanostructures, 
specifically, have multiple characteristics that make them ideal for cancer theranostics including: 
(i) high biocompatibility, (ii) ease of bioconjugation, (iii) ability to tune their plasmon resonance 
to absorb tissue penetrating near infrared light, (iv) their use as contrast agents, and (v) ability to 
convert light to heat when excited at the plasmon resonance for photothermal ablation of cancer 
cells. Further, due to their adaptability as a platform, the nanoparticles affect the battle against 
cancer in multiple different strategies. These theranostic gold nanoprobes can be incorporated 
into point of care diagnostic (POCD) systems for biomarker detection, used as theranostic probes 
to delivery multiplex SERS receptor imaging and photothermal therapy or be involved in future 
immunotherapy[3] treatments.  
 In this work we demonstrate the use of near-infrared light absorbing multibranched gold 
nanoantennas (MGNs) to simultaneously deliver diagnostic and therapeutic (theranostic) 
capabilities in cancer models. More aggressive cancer cell lines require approaches that are 
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versatile and multifunctional, and the possibilities for the usage in diagnostics or therapeutics for 
these theranostic MGNs are abundant. 
 
1.2 Cancer Biology 
1.2.1 Overall Physiology 
 According to the WHO, there were 14.1 million new cancer cases, and the disease 
accounted for 8.2 million deaths.  Cancer is the second leading cause of non-communicable 
disease death behind only cardio vascular disease. As viewed by Figure 1.1, the disease is 
worldwide and will thus require a global effort in treatment. 
 
Figure 1.1: Cancer mortality rates across the globe as provided by WHO. Rates are per 100000 
population and age standardized for both sexes. Data courtesy of World Health Organization 
(WHO) for cancer statistics in 2012.  
 
 Cancer is the uncontrollable, unadulterated, and immortal capability of the cells to 
multiply and divide without end.[4, 5] These out of control growths can be visualized in vivo 
with the formation of neoplasms.[6-8] The cell becomes stuck in the on state for the cell cycle 
and continues to replicate, making more and more genetic and proteomic material and 
information. This cycle is depicted in Hanahan’s diagram of the “Hallmarks of Cancer” (refer to 
Figure 1.2). 
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Figure 1.2: Schematic of Hallmarks of Cancer. As previously explained by Hanahan et al[9], 
there is both the breakdown in regulatory pathways and the amplification of uncontrollable 
growth. Figure modified from its original version.  
 
 These attributes are an indicator of where healthy human cells are along the lines of 
malignant cell progression or necessary steps that must be scientifically met to be considered an 
aggressive cell. Six genetic modifications[9] occur that result in the following phenotypes: (a) 
self-sufficiency in growth signals, (b) insensitivity to growth-inhibitory (anti-growth) signals, (c) 
evasion of programmed cell death (apoptosis), (d) limitless replicative potential, (e) sustained 
angiogenesis, and (f) tissue invasion and metastasis (Figure 1.2). Cells can enter these genetic 
mutation pathways through a multitude of pathways, but none will escape the cycle. 
 
1.2.2 Receptor and Biomarker Targeting 
 Cancer metastasis is really where the lethality comes in as it is the metastatic cells that 
can break off and mutate to another organ, continuing to grow and develop or even 
differentiate.[10, 11] Thus, to avoid metastasis of tumors, early detection and treatment is 
necessary. With these theranostic MGN platforms, there is a two-prong approach to increase 
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cancer detection accuracy and sensitivity. For this plan we will manufacture (i) Biodiagnostic 
SERS assay for ultrasensitive early detection of PSA biomarker and (ii) Actively targeted 
Theranostic MGN platforms for SERS imaging and PTT. Both technologies rely on protein 
detection. Thus, protein localization, expression, and concentrations are the most important 
biological indicator when trying to improve cancer SERS detection. 
 Protein levels in the blood or serum (biomarkers) or proteins attached on the surface of 
the cancer cells (receptors) can both provide vital information in determining the presence of 
tumor tendencies. Since it is really this technology of detecting macromolecules, specifically 
proteins, through a SERS-beacon, that makes the multiplex capacities of the SERS MGNs 
impressive and useful, these biomarkers and receptors have to be the focus. Cancer is known to 
have uncontrollable cell cycle rates and uncontrollable rates of protein synthesis, which can also 
lead to excessive or overexpression of a particular receptor on the cell surface[12-14] or an 
overly high concentration of a mature biomarker in the blood[15, 16], both of which can be 
utilized for early detection.[17, 18]  
 
1.3 Plasmonic Nanoparticles 
1.3.1 Fundamentals of Plasmonics 
 To study the optical properties of nanoparticles, one has to also understand the behavior 
of electromagnetic (EM) waves on the nano level and do so by dissecting waves into their 
constituent parts. The study of light and other EM waves on the nanoscale level is known as 
nanophotonics. Within this field of nanophotonics, there is a subdivision called plasmonics that 
studies the interaction of EM waves with the electron cloud of metal materials. Within 
plasmonics, there are surface plasmon polaritons (SPP) which occur when EM waves couple to 
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the collective electron oscillation of a dielectric film creating a propagating wave that can be 
used as a waveguide.[19, 20]  The other phenomenon, called a localized surface plasmon (LSP), 
happens when electrons within a single nanoparticle begin to oscillate, not propagate, upon 
incident EM wave excitation.[21] As seen in Figure 1.3, upon irradiation, electron cloud will 
begin to oscillate from side to side creating a dipole moment and forming a plasmon resonance. 
Further, this excitation creates a localization of concentrated electron ‘hot spots’ which create 
very strong EM fields that decay within tens of nms away from the surface. If the incident light 
source is at the resonant wavelength of the metal nanoparticle, coupling proceeds leading to 
enhancements in a variety of applications. 
 
Figure 1.3: Diagram of charge oscillations resulting in plasmons for metal nanoparticle. 
Oscillations occur upon irradiation with electromagnetic wave. Figure modified from its original 
version.[22] 
 
1.3.2 Variations in Synthesis, Size, and Shape 
 Plasmonic wave coupling for nanostructures usually occurs with EM waves in the visible 
and NIR region, where gold and silver absorb and scatter light the strongest. Gold and silver are 
usually chosen for nanoparticle synthesis because of their high electron density, which leads to a 
higher probability of hot spot formation upon excitation.[21] The capabilities of several shape- 
and size-controlled gold nanostructures have been studied in the past decade, [23, 24]  [25, 26] 
and some are already in clinical trials[27, 28]. A representative demographic of the shapes and 
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size of particles is presented in Figure 1.4a to Figure 1.4i. The geometry and size of the 
nanoplatform required is dependent on the application. By modulating the dimensions of GNS 
the relative contribution of absorption and scattering to the total extinction cross-section can be 
controlled.[29] While smaller nanostructures predominantly absorb light, larger nanostructures 
are largely scattering. However, it has been demonstrated that for complex anisotropic 
nanostructures the absorption and scattering properties is not a linear relationship of the size 
rather dependent on their unique geometry.[30]   
 Scattering and absorption properties of the nanoparticles also help determine their 
applications. Highly scattering gold nanostructures are extensively utilized as contrast agents for 
optical imaging using a simple dark-field microscope,[31] and for computed tomographic (CT) 
imaging.[32]  Nanostructures with large scattering cross-sections and high polarizability also 
enhance the Raman signal of molecules in their vicinity enabling surface-enhanced Raman 
scattering (SERS) based imaging. Lastly, it has to be considered, when moving into in vivo 
applications, that the resonance of the synthesized nanostructures overlap with the first NIR 
window as previously reported by Weisslader. As to not lose at on any additional signal from 
tissue or protein absorption, the platform  should have a resonance of ~660 nm to 900 nm (Figure 
1.4k), in the range of low absorption by hemoglobin and water (Figure 1.4j). 
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Figure 1.4: Synthesis of plasmonic nanostructures and tuning resonance to first NIR window for 
biological applications. (a-i) Electron microscopy conveys the wide distribution of shapes and 
sizes possible through various synthesis methods.[33] (j) For optimal tissue penetration with 
laser source, the wavelength needs to be in the range where proteins, water, and other 
macromolecules absorb the irradiation the least, as previously reported by Weissleder.[34] (k) 
This range highlighted in pink for  visualization, ~660 nm to 900 nm, has strong overlap with the 
maximum plasmon resonance of MGNs, making them well suited for theranostic purposes.  
 
1.3.3 Biological Applications 
Engineered gold nanostructures (GNS) have emerged as a promising new platform in 
nanomedicine due to their unprecedented ability to manipulate incident photons and 
subsequently scatter or absorb light, properties which have been extensively harnessed in 
biomedical diagnostics and targeted therapeutics.[35, 36]  Unlike conventional chemotherapy 
drugs or small-molecule imaging agents, GNS offer several advantages for nanomedicine. These 
include (i) high biocompatibility and reduced toxicity governed by surface ligands,[37] (ii) 
passive accumulation at tumor sites due to the enhanced permeability and retention (EPR) 
effect,[38] (iii) ease of bioconjugation enabling functionalization with multiple targeting groups 
for active tumor targeting,[39] (iv) increased stability and stealth characteristics aided by 
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hydrophilic polymer conjugation,[40] (v) straightforward systemic delivery which enhances 
circulatory half-life,[41] (vi) ability to deliver hydrophobic drugs and nucleic acids to cells by 
selective binding to the metal surface,[42, 43] and (vii) and integration with contrast agents for 
visualization of intracellular localization and tracking nanoparticles in vivo.[44-46]  
The fact that these nanoparticles can be synthesized is significant, but it is all of the 
applications that they can be used that is the true breakthrough. Some of the many industries that 
plasmonic nanoparticles can enhance include: biosensing for bacterial or viral detection, drug 
delivery and discovery, solar cells, photothermal ablation, and waveguides.[47]  
 
1.4 Surface Enhanced Raman Spectroscopy (SERS) 
1.4.1 Raman Spectroscopy 
 The biosensing technique that works the best with the optical properties of the 
nanoparticles is Surface Enhanced Raman Spectroscopy (SERS). Raman spectroscopy was 
discovered in 1928 by the Indian scientist C. V. Raman. Raman observed that when one shined 
monochromatic light on a material, a majority of that light was scattered off at the same color, 
refer to diagram, Figure 1.5c green beam). However, he noticed that there was a very small 
fraction of light that scattered with a different color representing a different energy of scattered 
light (red beam in Figure 1.5c). He surmised that this subset of scattered light was in fact 
interacting with the vibrational states of the material itself, which in turn manipulated the energy 
of the exiting light, refer to Figure 1.5a (before) and 1.5b (after).[48]  The small fraction of light 
that possessed this unique phenomenon was later coined as Raman scattering after its inventor. 
Raman scattering has both Stokes and Anti-stokes vibrations (Figure 1.5d), but the Stokes are 
primarily focused on for the sensing spectroscopy. The difference between Anti-stokes and 
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Stokes Raman is the difference in the initial and final energy levels being reversed (Figure 1.5d). 
Through the Raman vibrational phenomenon, one can detail the chemical environment of a 
molecule. Very similarly to infrared spectroscopy, different vibrational, bending, and stretching 
modes are obtained due to the inherent nature of a molecule behaving in response to the 
surrounding atoms. By observing these various bands, a Raman footprint can be created that can 
be used to identify a compound, and this footprint is the basis for Raman spectroscopy.[49]   
 
Figure 1.5: Fundamentals of Raman spectroscopy and SERS enhancement. (a-b) Observing the 
connection between molecule vibration to the resulting Raman scattered electromagnetic wave. 
Seeing the molecule before (a) and after (b) Raman scattering. (c) Cartoon demonstrating the 
typically small percentage (red) of Raman scattered light that results upon illumination, with the 
majority of exiting light existing as Rayleigh scattering (green). (d-e) Jablonski energy diagrams 
showing difference in energies for Rayleigh, Raman, and Surface Enhanced Raman Scattering.  
 
1.4.2 Surface Enhanced Raman Scattering 
 Even though Raman spectroscopy was created in the 1920’s, the field did not really gain 
traction until much later in the 20th century due to its weak signal in comparison to fluorescence 
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and Raleigh Scattering. Fluorescence has a scattering cross-section of 1E-15 cm2/molecule while 
Raman has a value of 1E-31 cm2/molecule.[50]  There were multiple seminal events that lead to 
the adoption of Raman spectroscopy as a viable detection tool. To begin with, there was the 
development of the laser in the early 1960s which provided a monochromatic light source 
powerful enough to supplement Raman scattering. However, even with the laser source, Raman 
scattering was not strong enough to be preferred over the other probing technologies. This 
impedance was changed with the accidental observation of SERS by Fleishmann et al. in 1974 
with his roughened silver electrode chemistry with pyridine.[51]  Fleishmann was actually trying 
to monitor the chemical reaction between silver and pyridine and thought to roughen the silver 
electrodes as to optimize the surface area to increase reaction sites. What he did not realize was 
that by etching the silver, he was creating very sharp edges of which the localization of electrons 
would occur creating very strong EM fields. He witnessed very intense Raman scattering which 
was not quantitative with the chemical reaction that he was performing. Then in 1977, both 
Jeanmaire & Van Duyne and Albrecht & Creighton again saw the same “giant Raman effect” 
which could not be explained simply by the increase in scatterers.[52-55]  Both groups proposed 
the mechanism of electromagnetic enhancement with slight deviations in their explanations of 
the concept. A diagram is provided in Figure 1.5e showing the idea of SERS excitation going to 
a higher energy level, and thus, the resulting, Raman relaxation energy would be increased. 
Therefore with the knowledge of utilizing plasmonic nanoparticles to provide enhanced Raman 
signal and with improvements in both laser technology and chemistry in the 1980s, the field of 
SERS exploded over the next 40 years up to present times. 
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1.4.3 Plasmonic Enhancement Mechanisms 
 The enhancement of the Raman signal occurs via two different pathways both of which 
take advantage of the plasmonic properties of the nanoparticle. The more robust enhancement 
mechanism occurs via electromagnetic enhancement which is defined by the localization of 
electrons creating very powerful EM fields (Figure 1.6a) that interact strongly with the incident 
light source.[56-58]  These powerful near fields cause the Raman photons to localize within the 
small volumes providing more ample opportunities for the Raman photons to interact with the 
vibrational states of the detectable molecule.[59, 60] This near-field enhancement is usually 
along the lines of 4-6 orders of magnitude. The second enhancement mechanism, known as 
chemical enhancement, only occurs when a chemical bond is formed between the plasmonic 
particle and the molecule to be detected. In chemical enhancement, the Fermi levels of the 
nanoparticle and the detected molecule align (Figure 1.6), and hot electron transfer occurs (from 
particle to vicinal molecule) to facilitate the electron transferring to the excited state.[61, 62]  
The hot electron transfer lowers the energy required to achieve the excited state by providing an 
alternate route. This allows more electrons to go to the excited state which means upon 
relaxation more photons will be localized around the detectable molecule leading to 
enhancement. The chemical enhancement increases the signal by two orders of magnitude.  
 Lastly, if the nanostructure has the proper anisotropic geometry, the enhancement 
properties of the nanoantenna effect can also be utilized. Nanostructures consist of “antenna-
like” spherical core that absorbs incident light and routes the light through the protrusions 
concentrating it at the tips. This unique geometry of MGNs gives rise to the amplification in the 
core and further confinement of electrons in small volumes leading to even further enhanced 
fields, and this process has the coined term “nanoantenna effect”. These near-field configurations 
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of branched nanostructures enable a range of technological applications from highly sensitive 
localized surface plasmon resonance (LSPR) sensing,[63] to surface enhanced spectroscopies, to 
biomedicine,[64] and thermoplasmonics[65]. 
 
Figure 1.6: Plasmonic enhancement mechanisms of gold nanostructures. (a) Electromagnetic 
enhancement with strongest fields localized on the pointed tips, due to the smallest volume of 
electron confinement. (b) Chemical enhancement occurring when the Fermi energy of the bond 
or vicinal molecule aligns with the gold nanoparticles. (c) Structures representative to 
Multibranched Gold Nanoantennas (MGNs)[66] demonstrating the nanoantenna effect upon 
irradiation with electromagnetic wave. Amplification occurs in the core with further confinement 
of the fields on the tips.  
 
1.4.4 SERS Biological Applications 
 With these enhancement mechanisms, SERS becomes a better biosensing tool than both 
localized surface plasmon resonance (LSPR) and fluorescence as it possesses multiple 
characteristics that the other techniques do not. SERS (1E -21 M detection limit)[67] is more 
sensitive than LSPR (1E-12 M detection limit)[54] while, at the same time, being more specific. 
In addition, unlike fluorescence, SERS is capable of multiplex detection because of its narrow 
peaks.[17] 
 Once the enhancement mechanisms were elucidated, groups began optimizing the 
nanoparticle shape to achieve the greatest SERS enhancement factors and sensitivities. For 
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ensemble SERS, enhancement factors usually range from 1E8 to 1E10, while single particle SERS 
has shown the capability to obtain values as great as 1E14 enhancement.[48, 61]  As far as 
sensitivities, it has been demonstrated that as the nanoparticle forms more sharp tipped 
structures, the analyte detection limit decreases. Spheres have a detection limit of 1 nM while 
nanorods have been shown to detect concentrations down to 100 pM.[68, 69]  The limit 
plummets once there is the introduction of a structure with multiple pointed tips such as a 
nanostar (limit = 1E-21 M).[70]  The reason for this very low detection limit is due to the fact that 
these multiple pointed tips provide an abundance of electron hot spots that create an ultra-strong 
near field effect by creating junctions with neighboring MGNs. These junctions prove to be 
significant in the planar sandwich based biomarker detection systems later. In addition to 
detection studies, there are cellular mapping experiments performed, where nanoplatform SERS 
tags are providing information about the surface receptor coverage for both cell and tissue 
studies.[13, 71]  
 
1.5 Plasmonic SERS Substrates for Biomolecular Detection  
1.5.1 Paper-Based 
 Now that the SERS mechanisms, instruments, and nanoparticles have been optimized, a 
variety of applications are being explored. Engineers and scientists are both beginning to 
understand the importance and potential of this sensing technology. Groups have begun to utilize 
various substrates including cellulose paper to make the plasmonic nanostructure diagnostic 
probes more practical for use with handheld Raman instruments.[72]  A paper substrate allows 
for a flexible, cheap and robust probe that can be readily used in the field (refer to Figure 1.7). 
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The flexibility and malleability of the MGN-paper substrate lend to its ability to continue 
through exhaustive testing without losing its sensing properties (Figure 1.7b-1.7c) .  
 
Figure 1.7: Applications of plasmonic SERS substrates for biomolecular detection. (a) 
Visualized under Transmission Electron Microscopy (TEM), the nanoparticles are seen adhered 
to the porous paper substrate. (b) The flexibility of the substrate allows for detection on 
contoured surfaces (apple) for real world applications. (c) Further, the SERS enhanced flexible 
substrate allows for a laboratory ready diagnostic tool with the potential use of being 
incorporated for portable (d) SERS measurements in the field. 
 
 Another application for these SERS substrates is in point of care macromolecular 
detection for bacterial or viral species.[73] Lastly, this tool is providing real time molecular 
biological tracking of various biochemical molecules during a cell cycle. This is being used to 
observe and trace cell replication in real time.[74]  With all of these applications on the horizon, 
it is an exciting time for the SERS community. Since its inception, SERS has become more and 
more useful as a sensing tool, and with these new avenues opening up, the applications seem 
endless. In addition, there has been a recent push to make portable substrates that are capable of 
sample collection on site. Researchers have worked to create these SERS systems that are 
capable of detection limits that are as low as possible to detect any early onset of a disease. To 
attain these low detection limits, scientists have looked to various forms of spectroscopy in the 
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hopes of developing reliable point of care diagnostic (POCD) systems as depicted in Figure 1.7d 
that would allow for real time, sensitive, and accurate information.  
The porosity of the MGN-paper as visualized under transmission electron microscopy 
provides the necessary flexibility to perform contoured swab tests as on the apple (Figure 1.7b). 
This malleability and versatility are ideal when trying to detect analytes through binding events 
or interactions specifically with the MGNs. However, when determining the platform to coat 
with MGNs to prepare the sandwich assay, the consideration of the complexities of MGN-
sandwich architecture (refer to Figure 3.9a in Chapter 3) and the amount of binding events and 
specific or non-specific interactions that are occurring must be accounted. Thus, when building a 
complex system for ultrasensitive detection, the porosity creates an issue of structural stability, 
and thus why it was decided to move the sandwich assay for ultrasensitive PSA on MGN-glass to 
ensure the MGN dimer occurred, and the junction formed. 
 
1.5.2 Planar Substrates 
 It is the belief among medical professionals that the earlier a disease or illness can be 
detected, the higher the likelihood that it can be treated or averted. Thus physicians and medical 
scientists alike have been looking for better methods of detecting macromolecules such as 
transcription factors, hormones, proteins, or nucleic acids that are biomarkers for certain 
diseases. These medical professionals are looking for systems that are not only robust and 
effective, but that are also portable and easy to use. To be an effective system, the 
instrument/probe must be able to detect the targeted molecule at very low concentrations in order 
to discover these diseases at their earliest onset point, thus allowing a higher chance for 
treatment. SERS provides a very low detection limit, as well as the capability to have multiplex 
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detection because of the narrow peak widths in the resulting spectra. This multiplex capability 
allows one to trace and track multiple components all at the same time. 
 To create these low create these low detection systems, researchers have developed 
nanoparticle substrates that when combined with a Raman beacon can be utilized to detect low 
concentrations of protein or other macromolecules. Li et al. has performed a sandwich assay on a 
glass substrate covered in gold nanotriangles with top nanoparticle probes where they detected 
human immunoglobulin G (IgG) in concentrations all the way down to 0.5 pg/mL.[16]  Wu et al. 
performed a half-sandwich assay with gold/silver nanorods on glass substrates in which they 
utilized multiplex detection of p53 and p21 transcription factors in an early cancer detection 
assay.[17]  Finally, Penn et al. performed a full sandwich assay with spherical nanoparticles 
sandwiching IgG on gold coated membranes for a detection limit of 1 ng/mL.[75] Current work 
utilizing MGN-glass sandwich system for SERS enhanced detection of the Prostate Specific 
Antigen (PSA) is ongoing using a Raman reporter (pMBA) acting as beacon and an antibody 
(antiPSA) acting to give specificity in the PSA detection. In addition, the PSA will be 
sandwiched between two layers of MGNs via a MGN-glass substrate system that will provide 
extremely high near-field enhancements. We believe our MGN sandwich system, we will be able 
create an ultra-sensitive biodiagnostic tool in the detection of PSA and that this system will be 
specific for only PSA because of the presence of the multiple targeting ligand, antiPSA. 
 
1.6 Theranostic Nanoparticles for Cancer Medicine 
1.6.1 Multi-Modal Imaging  
 There have been many advances in the field of plasmonics for cellular and tissue 
imaging. Researchers have used gold nanoparticles as enhanced contrast agents in magnetic 
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resonance imaging[76], photoacoustic tomography[77] and photothermal optical coherence 
tomography (PT-OCT)[78] to increase spatial resolution. Plasmonic nanostructures are ideal 
contrast agents for PT-OCT due to their radiative properties of which provides light scattering in 
tissue enhancing the contrast as well as non-radiative properties which converts absorbed light to 
heat thus creating temperature gradients in tissues that lead to changes in refractive index, which 
the instruments are more sensitive in detecting. In addition, nanoparticles have been utilized in 
fluorescence imaging[79] and surface enhanced Raman scattering (SERS) imaging[80] to 
increase sensitivity of the tracking molecule or beacon via electromagnetic and chemical 
enhancement, which allows for better cellular tracking. PT-OCT uses the localized heating 
events provided by the plasmonic nanostructures to create better contrast in imaging. The 
nanoparticles are acting to enhance the image with PT-OCT, but whereas in SERS they enhance 
the Raman signal intensity. 
 While PT-OCT provides high volume spatial resolution, SERS imaging provides high 
sensitivity. A collaborative study using dual-modal PT-OCT/SERS imaging on Athymic nude 
mice growing human xenograft tumors demonstrated that signal could be observed for both 
spectroscopies after providing circulation time post retro-orbital injection (Figure 1.8). SERS-tag 
labelled MGNs accumulated at the tumor, as seen by the appearance of the 1580 cm-1 peak of 
pMBA (Figure 1.8a). Further, the temperature gradient provided by the light to heat conversion 
efficiencies of the MGNs provided a global picture of were the MGNs accumulated throughout 
the volume of tumor. Thus, there is temporal, sensitive and multiplex capabilities of SERS that is 
complimented with the 3-D volume imaging of deep tissue by PT-OCT (Figure 1.8c). 
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 Lastly, SERS or the theranostic nanoparticles could be combined with other 
spectroscopies as well that require multiplex technology. Spectroscopies such PET, MRI, or CT 
could also be combined with the SERS imaging for a dual-modality approach to detection.       
 
Figure 1.8: Dual-Modal PT-OCT/SERS imaging in vivo with single MGN platform. (a) Raman 
footprint recorded at the tumor site post systemic injection with SERS-labelled MGNs, showing 
peak at 1580 cm-1 for paramercaptobenzoic acid (pMBA). (b) Simultaneous Photothermal 
Optical Coherence Tomoography (PT-OCT) was also measured showing the global distribution 
of the MGNs. (c) Table provided stressing how the two spectroscopies are complimentary to 
another.  
 
1.6.2 Multi-Modal Therapeutics 
 When metal nanostructures are excited with resonant photons, the photoexcitation of the 
electron gas results in rapid non-equilibrium heating. The initial electronic excitation is followed 
by relaxation at subpicosecond timescales by means of electron-electron scattering which results 
in rapid increase in the surface temperature of the metal.[81, 82] The rapid heating is followed by 
cooling to equilibrium by energy exchange between the electrons and the lattice phonons. In the 
first several hundred picoseconds following excitation, the lattice cools via phonon-phonon 
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coupling resulting in heat dissipation into the medium surrounding the nanostructure (depicted in 
cartoon for Figure 1.9a). Thus, when GNS bound to cancer cells are illuminated a large 
temperature difference between the hot nanostructure surface and the cooler surrounding 
biological medium occurs resulting in abrupt local temperature increase and corresponding cell 
death.  
 Once researchers understood the fundamentals of PTT, they began to think of creative 
ways to use the heating effect in drug delivery. Yavuz et al. created gold nanocages and loaded 
them with doxorubicin, a cancer therapeutic, and then a thermal linker polyer, pNIPAAm, to 
control the release of the drug through temperature. This temperature was controlled by 
nanocage photothermal heating.[83] This concept is represented in Figure 1.9b. It is the 
phothermal conversion, itself, required to break the linker and release the drug.  
 Besides their heating properties, researchers began to see gold nanoparticles as 
nanocarriers that acted as vessels for drug delivery and were inert spectators of the drug therapy 
(Figure 1.9c) Han et al. used gold nanospheres as carriers of DNA, which were cleaved off via 
Ultra-Violet light, in which the gold nanoparticle was completely inert in the mechanism.[84] 
Both heat and light are exogenous stimuli, but there are also plenty of endogenous stimuli for 
which gold nanoparticles have been used for in drug delivery such as pH, ionic strength, and 
ligand concentration that are beyond the optics focus of this work.  
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Figure 1.9: Multifunctional and combinational therapeutic approach offered by gold 
nanoplatforms. Diagramed are three different therapeutic approaches offered by gold 
nanostructures including: (a) photothermal therapy, (b) drug delivery using NIR light to convert 
light to heat to break linker, and (c) drug delivery via UV light to break linker where nanoparticle 
is simply acting as shipping vessel.  
 
1.6.3 Cancer Theranostics 
 The past two decades have witnessed a tremendous increase in GNS based diagnostic 
agents, and therapeutic actuators. Theranostic agents can simultaneously target, diagnose, and 
deliver a therapeutic function enabling highly specific disease detection and treatment in a single 
clinical procedure. GNS based theranostic nanoprobes have been developed by either combining 
a single imaging and therapeutic technique, or integrating dual-modality diagnostics with 
multiple therapeutic functionalities. Nearly a decade ago, before the term theranostic was coined, 
the theranostic potential of nanoshells was demonstrated with simultaneous dark field imaging 
and photothermal therapy.[85-87]  This was soon followed by the use of nanorods[88] and other 
core-shell GNS[89, 90] for imaging and therapy of malignant cells in vitro. In present times, 
there is a representative list that takes advantage of all the unique optical properties of the gold 
nanoparticles to combine them into unique theranostic treatments (refer Table 1.1) 
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 To be successful against these deadly cancers, there must be the incorporation of both 
therapy and imaging. Thus, theranostic nanoparticles such as liposomes or other polymer 
encapsulations started to develop that offered both diagnostic information and therapy at the 
same time. However, what these particles lacked was the photothermal therapy (PTT) of the 
plasmonic nanoparticles. Thus, the ability to create heat from light is what separates the PNS 
from the other therapeutics and is what makes their therapy the most effective. The ability to 
perform PTT for heating and drug release in combination with the diagnostic capability put these 
gold nanoparticles at the forefront of the theranostic age. Such multifunctional nanostructures 
simultaneously enable highly specific detection of a disease followed by targeted, image-guided 
treatment all within a single clinical procedure. 
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Table 1.1: Examples of theranostic plasmonic nanostructures and their corresponding diagnostic 
and therapeutic modalities. List is representative of current progress in the nanomedicine field. 
Plasmonic 
Nanostructure 
Diagnostic 
Modality 
Therapeutic 
Function 
Targeted Cell Line Ref. 
SiO2/Au/Fe3O4 
Nanoshells 
MRI, NIR 
fluorescence 
Photothermal SKBR3 breast cancer  
[91, 92] 
SiO2/Au Nanoshells PET Photothermal OVCAR3 ovarian cancer [93] 
U87 human glioblastoma [94] 
Fe3O4/SiO2/Au 
Nanoshells 
MRI Photothermal A431 human epithelial cancer [95] 
Polymer/Au 
Nanoshell 
Ultrasound Photothermal HeLa cervical cancer  
[96] 
Micelle/Au 
Nanoshell 
MRI Light induced 
drug release 
HeLa cervical cancer  
[97] 
Hollow Au 
Nanospheres 
PAT Photothermal U87 human glioblastoma transfected with 
luciferase gene 
 
[98] 
 
Nanostars 
 
Two-photon 
fluorescence 
Photothermal SKBR3 breast cancer  
[99] 
SERS ROS generation BT549 breast cancer [100] 
Nanoroses MRI, Dark-field 
scattering 
Photothermal Primary peritoneal macrophages [101] 
Au nanoparticle- 
nanobubbles 
Dark-field 
scattering 
Photothermal C4-2B prostate cancer [102] 
 
Au nanoparticles 
 
CT imaging Drug Delivery PC3 prostate cancer [103] 
PAT Photothermal SCK breast carcinoma [104] 
 
 
 
 
 
 
Au nanorods 
 
SERS Photothermal HeLa cervical cancer [105] 
NIR fluorescence Photodynamic, 
Photothermal 
SCC7 Squamous cell carcinoma [106] 
Two-photon 
fluorescence 
Drug Delivery A549 human lung cancer [107] 
NIR fluorescence Photodynamic, 
Photothermal 
A549 human lung cancer [108] 
SERS, NIR 
Fluorescence 
Photodynamic HeLa cervical cancer [109] 
X-ray, CT Radiation, 
Photothermal 
MGC803 gastric cancer [110] 
MRI Photothermal KB human epidermoid oral carcinoma [111] 
Dark field, 
Fluorescence 
Drug Delivery, 
Photothermal 
LoVo human colorectal 
cancer [112] 
Dark field Photothermal A375 human umbilical vein cancer [113] 
Fluorescence Photothermal HeLa cervical cancer [114] 
PET Drug Delivery U87MG human malignant glioma [115] 
MRI = magnetic resonance imaging  NIR = near-infrared   PET = positron emission tomography 
PAT = photoacoustic tomography  ROS = reactive oxygen species 
CT = computed tomography  SERS = Surface enhanced Raman scattering 
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1.6.4 Immunoimaging and Immunotherapy 
 The upregulation of immune checkpoint receptor programmed death protein 1, PD-1, 
expressed on activated CD8+ T-cells, impedes effector T-cell function by binding to its ligand, 
PD-L1.[116-118]  Upon binding, interferons (IFN-γ) produced by activated T-cells upregulate 
PD-L1 expression which contributes to immunosuppression in the tumor microenvironment. 
Cancer immunotherapy, particularly blockade of inhibitory pathways such as PD-L1, has 
recently driven a perspective shift in the treatment of multiple cancers.[119-121] This 
underscores the significance of PD-L1 as a target receptor for immunoimaging.  
 The new medicinal field of immunotherapy, utilizing one’s own immune system in 
treating disease, has allowed theranostic gold nanoplatforms another opportunity to provide 
unique and beneficial cancer treatment. By identifying, tracking, and understanding the immune 
system pathways to the point where it can be determined which receptor to manipulate for a safe, 
endogenous, and recruited therapy can be administered. To this point, PD-L1 receptor coverage 
has been linked to candidacy for immunotherapy with antiPDL1 antibodies on an individualized 
case basis.[2, 122] Theranostic nanoplatforms could be used for SERS imaging in detecting the 
PD-L1 expression on the surface of tumor and then, subsequently perform photothermal therapy, 
PTT-triggered drug release, or T-cell recruitment to administer therapy. Current multiplex SERS 
studies are being performed to demonstrate the potential of immuno-imaging by targeting the 
PD-L1 receptor which is a vital interaction in the T-cell immune checkpoint.[116, 122, 123] 
Further studies are investigating these EGFR and PD-L1 receptors in human xenograft models 
through in vivo SERS imaging. Additionally, current ongoing studies in utilizing antiPD-L1 as a 
therapeutic agent[3, 117, 124] open the avenue for combinational theranostic probes with 
multiple therapeutic or diagnostic modalities. The theranostic MGNs could induce the 
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recruitment of a heat shock protein or another immune response that could be used as to trigger 
immunotherapy.[125, 126] The high biocompatibility, photothermal capability, and 
straightforward surface chemistry make the MGNs a prime candidate for further theranostic 
individualized medicinal studies. 
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CHAPTER 2 
INVESTIGATING THE SYNTHESIS, GEOMETRY-DEPENDENT PLASMONIC 
TUNABILITY, AND PHOTOTHERMAL PROPERTIES OF MULTIBRANCHED GOLD 
NANOANTENNAS  
 
2.1 Summary 
 In this chapter, we synthesized multibranched gold nanoantennas (MGNs) of variable 
geometry by a one-step seedless approach using 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) as a capping and reducing agent. This approach enables us to modulate the MGNs 
geometry by controlling three different parameters: [HEPES], [Au+3], and pH of HEPES buffer. 
By altering the MGNs morphology with minimal increase in the overall dimensions, the plasmon 
resonances were tuned from visible to NIR range. The MGNs plasmon resonances demonstrated 
a non-intuitive blue-shift when pH > pKa of HEPES which we attributed to emergence of charge 
transfer oscillations formed when MGNs cluster to dimers and trimers. Further, due to the 
presence of multiple sharp protrusions, the MGNs demonstrated a refractive index sensitivity of 
373 nm/RIU, which is relatively high for this class of branched nanostructures of similar size. 
Finally, the sharp protrusions of MGNs also give rise to intense photothermal efficiencies; ~54 
°C was achieved within 5 minutes of laser illumination demonstrating the efficacy of MGNs in 
therapeutic applications. By modulating the mass density of MGNs, the laser flux, and time of 
illumination, we provide a detailed analysis of the photothermal characteristics of MGNs. Due to 
intense photothermal characteristics and NIR plasmon resonance, the MGNs were shown to be 
viable candidates for usage in future theranostic studies. 
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2.2 Introduction 
Metal nanostructures interact with light generating surface plasmons that are governed by 
the nanostructure shape, size, and composition.[1, 2] While optical resonances of simple 
isotropic nanostructures are controlled by manipulating their size, the resonances of hierarchical 
anisotropic nanostructures are complex function of their geometry.[3-8] By controlling the 
morphology of such complex anisotropic nanostructures, the optical characteristics can be 
selectively tuned to achieve desirable properties.[9] Branched gold nanostructures are complex 
architectures with plasmon resonances that can be tuned by modulating the protrusion length and 
density with minimum alteration of the overall dimensions.[10-15] Typically, branched 
nanostructures have a core that serves as an efficient nanoscale antenna which couples to the 
protrusions routing incident light in unique and distinct ways.[16] Unlike other antenna-like 
geometries such as nanorods and nanobipyramids where the antenna strength can only be 
enhanced by increasing their size, in branched nanostructures the antenna efficiency can be 
increased by manipulating the protrusion length and number density without significantly 
altering the overall dimensions.[1, 17] This intense nanoantenna effect generates unprecedented 
electromagnetic near-fields at the sharp tips of the branched nanostructures which decay 
exponentially within tens of nanometers from the particle surface, thus confining regions of 
enhanced fields to spatially distinct regions relative to the particle.[18] These near-field 
configurations of branched nanostructures enable a range of technological applications from 
highly sensitive localized surface plasmon resonance (LSPR) sensing,[12, 13] to surface 
enhanced spectroscopies,[19] to biomedicine,[20-23] and thermoplasmonics.[24] 
The growth of anisotropic gold nanostructures requires a selective capping agent since 
gold has a symmetric face-centered cubic lattice. A range of star-shaped branched nanostructures 
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have been synthesized by seed mediated growth processes in aqueous media with 
cetyltrimethylammonium bromide (CTAB),[16] polyvinylpyrrolidone,[12, 14] and sodium 
citrate[22] as shape-directing capping agents. While the seeded-growth method is effective, this 
two-step approach often gives rise to polydispersity, low yield of MGNs, or generates other 
shapes due to minor heterogeneities in the gold seed. Such heterogeneous star-shaped mixtures 
with shape impurity impact the plasmonic properties resulting in plasmon damping, linewidth 
broadening, and mediocre ensemble LSPR sensing capabilities (although single particle LSPR 
sensing yields excellent results).[16, 25, 26] In this work we have synthesized multibranched 
gold nanoantennas (MGNs) by a one-step seedless approach using HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) as a capping and reducing agent. HEPES is a biological buffer 
extensively utilized in biochemical reactions, cellular applications, and in some cell culture 
media.[27-29] Here we demonstrate that HEPES mediated MGN fabrication has several 
advantages.  
First, unlike other techniques where the concentration of Au3+ ions is the only parameter 
that controls plasmonic tunability, in this work we show plasmon resonances can be tuned from 
the visible to the near-infrared by modifying three different parameters: concentration of HEPES, 
concentration of Au3+, and pH of the buffer. Therefore by modulating these distinct chemical 
parameters, the geometry (i.e. protrusion length and protrusion density of MGNs) can be altered 
to achieve desired optical properties. Second, since the MGNs are synthesized in a biological 
buffer, this allows unambiguous manipulation for biochemical and biomedical applications 
without the need for tedious ligand or solvent exchange for biocompatibility. Third, eliminating 
the seed-step in this HEPES method enables straightforward scale-up of MGNs with high 
reproducibility in both the plasmon peak positions and widths. Heterogeneities during scale-up 
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resulting in linewidth broadening is a known obstacle in the seeded growth approach.[30] The 
HEPES mediated MGNs generate relatively narrow peak widths giving rise to extraordinary 
LSPR sensing capabilities. The MGNs synthesized in this work have an ensemble refractive 
index sensitivity of 373 nm/RIU, which is relatively high for similarly sized branched 
nanostructures of this class. Finally, the multiple sharp protrusions and corresponding 
nanoantenna effect of MGNs gives rise to intense light to heat conversion efficiency. We 
investigated the photothermal characteristics and subsequent rise in temperature of MGNs 
resonant with a near-infrared laser at 808 nm. A temperature increase to 54 °C was measured 
with a thermal camera within 5 minutes of illumination. By modulating the mass density of 
MGNs, the laser flux, and time of illumination, an investigation of MGNs photothermal 
capabilities was performed.  
 
2.3 Results and Discussion 
MGNs were synthesized by reducing Au3+ precursor with HEPES as a reducing and 
capping agent.[31] The geometry of MGNs were varied by modulating the concentration of 
HEPES buffer from 30 – 360 mM while keeping the concentration of Au3+ precursor constant at 
20 mM and pH constant at 7.4 ± 0.1. As the HEPES concentration was increased, larger MGNs 
with longer protrusion lengths were formed. The morphological evolution of MGNs with 
increasing HEPES concentration was characterized with scanning electron microscopy (SEM) 
and transmission electron microscopy (TEM) shown in Figure 2.1. SEM micrographs 
demonstrate the three dimensional morphology of MGNs. At 30 mM HEPES concentration, 
spherical gold nanoparticles of 36 ± 3 nm diameters are formed with very small protrusions 
(Figure 2.1c). At 100 mM, well-defined MGNs with short protrusions and overall dimensions of 
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41 ± 4 nm are formed (Figure 2.1d) which increases to 50 ± 3 nm at 160 mM (Figure 2.1e). The 
MGNs size increases to 58 ± 4 nm at 300 mM HEPES (Figure 2.1f).  
 
Figure 2.1: Scanning electron microscopy images of MGNs synthesized by (a) 160 mM HEPES 
buffer and (b) 300 mM HEPES buffer showing the three-dimensional morphology of the MGNs. 
Transmission electron microscopy (TEM) images of MGNs synthesized with varying HEPES 
concentration (c) 30 mM, (d) 100 mM, (e) 160 mM, and (f) 300 mM. High resolution TEM 
images of MGNs with d-spacing indicating (g)《111》facet in the MGN core and crystal plane 
twinning, and (h) growth along <111> direction for the MGN protrusion. 
 
MGN dimensions were measured from tip-to-tip of the longest branches. We have also 
included the core size relative to the branch length of MGNs (Table 2.1). The electron 
microscopy images and size analysis demonstrate that as the concentration of HEPES is 
increased, the ratio of branch length to the core size increases with minimal change in overall 
size. The increasing HEPES also increases the density of branches on MGNs. Additional TEM 
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images and histograms of yield analysis of branch densities of MGNs formed with 100 mM and 
300 mM HEPES are shown in Figure 2.2 and Figure 2.3.  
Table 2.1: Core size and branch length as a function of HEPES concentration and corresponding 
plasmon resonance. 
[HEPES] Peak 
Position 
Largest Tip-to-Tip 
Distance 
Branch 
length 
Ratio of Branch/Core 
Diameter 
30 mM 577 nm 36 ± 3 4 ± 0.5 0.143 
60 mM 620 nm 39 ± 3 11 ± 1 0.647 
100 mM 657 nm 41 ± 4 13.5 ± 2 0.964 
160 mM 704 nm 50 ± 3 Long: 23 ± 3 
 
Short: 10 ± 1 
Long: 1.353 
 
Short: 0.588 
300 mM 781 nm 58 ± 4 Long: 32 ± 4 
 
Short: 12 ± 2 
Long: 2.286 
 
Short: 0.857 
Note: With increasing concentration of HEPES, MGNs become increasingly more anisotropic 
and two different branch lengths are observed described as “long” and “short” here. Typically 
the length of 1 – 2 branches (out of 4 – 6 total branches) grew longer than the remaining 
branches.  
 
 The morphological evolution of MGNs with increasing [HEPES] is attributable to the 
amount of HEPES molecules available during the nucleation event prior to MGN formation and 
the weak adsorption of HEPES to Au along the <111> direction.[31] We performed high 
resolution TEM to investigate the role of crystal planes (Figure 2.1g, 2.1h). The measured d-
spacing from the TEM images of the MGN core (Figure 2.1g). and protrusion (Figure 2.1h) 
clearly indicate protrusion growth and MGN formation occurs along the <111> direction. 
Initially, spherical gold nanoparticles nucleate in solution and HEPES binds to the nanoparticle 
surface. At low [HEPES]/[Au3+] ratio, fewer HEPES molecules are available to bind exposing 
the different crystalline facets of gold nanoparticles for further Au3+ reduction. As the reaction 
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proceeds, more Au3+ ions are reduced on the nanoparticle surface giving rise to spherical 
morphology with very short protrusions (Figure 2.1c). As the [HEPES]/[Au3+] ratio is increased, 
more HEPES molecules bind to preferred crystallographic planes with weak or no adsorption on 
the《111》family of planes (Figure 2.1d, 2.1e). Therefore as further Au3+ reduction occurs, 
preferential growth along the <111> direction transpires resulting in MGN formation. As HEPES 
is also a reducing agent in this synthesis, more Au3+ are reduced at higher HEPES concentrations 
on the《111》crystal planes yielding longer protrusions (Figure 2.1f). 
 
	
Figure 2.2: (a-c) Representative low magnification TEM images of MGNs prepared with 100 
mM HEPES buffer. (d) Yield of MGNs derived from these TEM images as a function of number 
of branches. > 200 MGNs were analyzed. The error bars were calculated by counting the number 
of branches in MGNs in each representative TEM image taken at the same magnification. 
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Figure 2.3: (a-c) Representative low magnification TEM images of MGNs prepared with 300 
mM HEPES buffer. (d) Yield of MGNs derived from these TEM images as a function of number 
of branches. > 200 MGNs were analyzed. The error bars were calculated by counting the number 
of branches in MGNs in each representative TEM image taken at the same magnification. 
 
 By controlling the concentration of HEPES in the reaction mixture, MGN geometry is 
selectively modulated giving rise to tunable plasmon resonances from the visible to the near-
infrared. The geometry-dependent plasmonic tunability of MGNs results in a range of vibrant 
colors from purple to blue to green to gray (Figure 2.4a).with increasing [HEPES]. This color-
tunability is indicative of a shift in the plasmon resonance of MGNs to longer wavelengths with 
increase in protrusion length (Figure 2.4b). The optical resonances of a MGN arise from the 
hybridization of plasmons associated with the core and individual protrusions (Figure 2.4c).[26] 
The MGNs with short protrusions (60 mM HEPES) show a bonding plasmon mode at 620 nm, 
and an antibonding plasmon mode at 530 nm (Figure 2.4b). The antibonding mode is primarily 
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contributed by the core plasmons while the bonding plasmon resonance is predominantly 
composed of MGN protrusions but with a finite contribution of the core plasmons. A shoulder 
peak is also observed at 830 nm, which may arise from the hybridization of the plasmons of 
multiple protrusions of a MGN. The hybridization of the core and protrusion plasmons has dual 
implications: (1) it increases the extinction cross-section of the bonding MGN plasmons due to 
the admixture of the core plasmons in the bonding plasmon mode, and (2) enhances the dipole 
moment of the protrusion plasmons. The MGN core behaves as an antenna effectively increasing 
the near-field enhancements of the bonding plasmons. As the MGN protrusion length, width, and 
density increases, stronger hybridization occurs between the plasmons of the core and 
protrusions resulting in a larger energy-level splitting between bonding and antibonding 
plasmons (Figure 2.4c-ii). This enhanced hybridization gives rise to a red-shift in the MGN 
bonding plasmon mode and shoulder peak to longer wavelengths (Figure 2.4b). We anticipate 
the plasmon hybridization of symmetric MGNs where all protrusions are of equal length and 
symmetrically distributed around a core would be different than non-symmetric MGNs. 
Symmetry-breaking in nanostructures is known to give rise to higher order modes as well as 
enhance the intensity of the dark modes as asymmetry allows the dark modes to couple with the 
bright modes.[32] Non-symmetric MGNs, as observed in this work, likely gives rise to the 
shoulder peak observed in the long wavelength. As the HEPES concentration is increased, the 
asymmetry in MGNs increases (see Figure 2.1) which likely enhances the shoulder peak as well. 
A more thorough investigation of the plasmon hybridization of MGNs is currently underway to 
elucidate these mechanisms in details.  
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Figure 2.4: (a) Photograph of vials showing color tunability with increasing size of gold MGNs. 
(b) Extinction spectra of MGNs showing red shifts with increasing size achieved by controlling 
the concentration of HEPES. (c) Schematic representation of the concept of plasmon 
hybridization in the MGN. The core plasmons interact with the protrusion plasmons and form 
bonding and antibonding MGN plasmons (i). The energy-level splitting increases with increase 
in MGN protrusion length and density (ii). (d) A linear behavior of the plasmon peak positions as 
a function of increasing HEPES concentration is shown. Error bars were obtained from multiple 
(>3 ) experiments at each data point.  
 
The red-shift in the optical resonance is also attributed to phase-retardation effects which 
arise from the oscillations of the electron cloud around the MGN.[33-35] The amplitude of the 
electron oscillation is augmented with increasing MGN dimensions which consequently 
increases the period of each oscillation, also known as plasmon lifetime. The increase in plasmon 
lifetime results in a decrease of the frequency of the waves, which inversely increases or red-
shifts the plasmon wavelength.[33, 34] In addition, the increase in plasmon lifetime with 
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increasing dimensions gives rise to broadening and damping of optical resonances (Figure 2.4b). 
The broadening is also influenced by inhomogeneity in MGN geometry at high HEPES 
concentration. However, despite the heterogeneity in MGN shapes, the MGN plasmon 
resonances are relatively narrow compared to other branched nanostructures reported in the 
literature which makes them excellent LSPR sensors (see Figure 2.8 and Table 2.2). 
 The red-shift in the plasmon resonances of MGNs exhibit a linear relationship with 
increasing HEPES concentration (Figure 2.4d), demonstrating HEPES controls the MGN 
growth. The plasmons shift from 577 nm at 30 mM HEPES to 806 nm at 360 mM HEPES with a 
minimal increase of ~22 nm in the overall dimensions of the MGNs. Unlike spherical gold 
nanoparticles where a 20 nm increase in size only results in a few nm shift in the plasmon 
resonance, the significant red-shift observed for MGNs is attributed to their antenna-like 
behavior. In simple nanostructures such as nanospheres, the polarizability is governed by the 
nanosphere radius; however, in anisotropic nanostructures such as MGNs, polarizability is a 
function of their complex geometry.[25, 36] MGNs with multiple protrusions, therefore, have 
higher polarizability which gives rise to significant red-shifts in the plasmon resonances with 
only a small increase in overall dimensions.  
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Figure 2.5: (a) Plasmon peak evolution of MGNs synthesized with 300 mM HEPES over 90 
minutes. (b) Growth dynamics of MGNs of three different geometries synthesized with 300 mM 
HEPES, 200 mM HEPES and 100 mM HEPES. The experimental data were fit to a sigmoidal 
logistic function (Equation 2.1) to derive the time constant for growth. The different phases in a 
sigmoidal growth: lag phase, exponential phase, diminishing growth phase, and final saturation 
phase, are also indicated. (c) The growth time constant (k) and time at half the amplitude (t1/2) 
are plotted as a function of HEPES concentration demonstrating that MGN growth dynamics is 
driven by [HEPES] in solution.  
 
Besides plasmonic tunability, HEPES also controls the growth rate of MGN formation. 
The growth dynamics of MGNs prepared with three different HEPES concentration were 
examined to determine the relationship between the growth rate and [HEPES] in the aqueous 
media. The time-dependent growth of MGNs synthesized with 300 mM, 200 mM, 100 mM, was 
monitored for 90 mins (Figure 2.5a), and the spectral peak intensity was evaluated at different 
time points (Figure 2.5b). Reducing agents play a critical role in determining the growth 
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dynamics of metal nanoparticle formation. While fast reducing agents including citrate and 
NaBH4 initiate burst nucleation followed by exponential growth,[37] weaker reducing agents 
such as HEPES,[38] NaOH,[14] ascorbic acid,[39] and certain phage peptides[38, 40-43] give 
rise to slower growth kinetics which follow a sigmoidal behavior. MGN formation dynamics 
followed a sigmoidal growth curve and were fit to a logistic function given by: 
                                                     𝑦 = 	 %&'()*(,),-)                                                                      (2.1) 
where a is the amplitude, k is the exponential growth constant, and tc is the growth time at half 
the amplitude. Logistic functions are employed extensively to predict population growth,[44] 
cellular growth,[45] and enzymatic reaction growth.[46] The logistic function fitted to the 
experimental MGN growth dynamics is defined by four distinct parameters[47]: the lag phase 
characterizes the slow rate of Au+ ion reduction which is accompanied by a slow nucleation of 
Au atoms; this is followed by exponential growth phase which is dominated by a diffusion 
mechanism where Au atoms rapidly diffuse in solution and locate deposition sites on the [111] 
crystal planes on the Au core and subsequently grow protrusion along the <111> direction; as the 
diffusion process slows down and most of the available Au+ ions have reduced and Au atoms 
have already deposited, the formation rate diminishes which is characterized by the diminishing 
growth phase; and finally growth is completed and no change in the peak amplitude is observed 
which defines the saturation phase. Regardless of the HEPES concentration, the MGN growth is 
completed within 45 minutes. However, the growth-determining parameters k and tc 
monotonically decrease with increasing HEPES concentration (Figure 2.5c) indicating that 
HEPES plays a key role in MGN growth. The trends observed in Figure 2.5c suggest that with 
increasing [HEPES] faster Au3+ reduction occurs to accelerate nucleation of MGNs resulting in a 
diminished lag phase. Due to rapid nucleation, the reaction proceeds faster with higher [HEPES] 
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and less time is required to reach half the saturation amplitude (tc) which consequently results in 
smaller exponential growth constant (k). The trends in Figure 2.5c further support the original 
intuition that HEPES simultaneously acts as a capping and reducing agent for MGN growth. 
 
Figure 2.6: (a) Size dependent tunability of MGNs surface plasmons by modulating the [Au3+] 
showing a blue-shift with increasing Au3+. The MGNs were synthesized with 100 mM HEPES. 
(b) Plasmon peak positions of MGNs showing a linear blue-shift with increasing Au precursor 
concentration prepared with 300 mM, and 100 mM HEPES. TEM images of MGNs synthesized 
with (c) 100 mM HEPES and different [Au3+] (i) 10 mM, (ii) 40 mM, and (iii) 90 mM, and (d) 
300 mM HEPES and different [Au3+]] (i) 10 mM, (ii) 40 mM, and (iii) 90 mM. (e-f) Photograph 
of vials showing an entire spectrum of colors as the MGN morphology changed with increasing 
[Au3+]. MGNs were prepared with (e) 100 mM HEPES and (f) 300 mM HEPES. 
 
 In addition to the HEPES concentration, the geometry-dependent plasmon resonances of 
MGNs are also manipulated by altering the concentration of the Au precursor, HAuCl4, in the 
growth solution (Figure 2.6a). While keeping the [HEPES] constant (300 mM, 100 mM) and pH 
constant at 7.4 ± 0.1, [Au3+] was increased from 10–90 mM and the plasmon resonance was 
observed to blue-shift from 782 nm to 667 nm for the MGNs synthesized with 300 mM HEPES 
and from 720 nm to 535 nm for those prepared with 100 mM HEPES (Figure 2.6a, 2.6b). The 
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blue-shifts in the plasmon peak position follows a linear trend for both 300 mM and 100 mM, 
however, it saturates at ~530 nm when [Au3+] ≥ 60 mM for the MGNs synthesized with 100 mM 
HEPES indicating formation of sphere-like structures. TEM analysis of the MGNs revealed that 
at low [Au3+], MGNs with a higher density of longer protrusions are formed (Figure 2.6c-i and 
Figure 2.6d-i); the protrusion length and density decreases with increasing [Au3+] (Figure 2.6c-ii 
and Figure 2.6d-ii) and finally at 90 mM [Au3+] spherical nanostructures (Figure 2.6c-iii) or 
MGNs with very short protrusions are formed (Figure 2.6d-iii). The decrease in protrusion length 
and density with increasing Au3+ concentration can be attributed to the ratio of [HEPES]/[Au3+]. 
High [HEPES]/[Au3+] ratio results in the formation of fewer Au nuclei and a high concentration 
of HEPES binding to the nuclei. Nucleation is followed by oriented growth along the《111》 
family of planes resulting in MGNs with multiple protrusions. As the [HEPES]/[Au3+] ratio 
decreases, a larger density of Au nuclei are formed which likely cluster together leaving fewer 
binding sites for HEPES, and the clusters may also block the <111> crystallographic direction. 
This gives rise to MGNs with shorter and fewer protrusions and eventually at very high [Au3+] 
more sphere-like MGNs are formed. This geometry-dependent plasmon resonance shift is 
accompanied with color tunability of the MGN suspension. An entire spectrum of colors is 
generated for MGNs prepared with 100 and 300 mM HEPES and varying [Au3+] (Figure 2.6e, 
2.6f). 
 Plasmonic tunability was also achieved by modulating the pH of the reaction from 6.61 – 
8.6 while keeping [HEPES] constant and [Au3+] constant at 20 mM. HEPES buffer at 100 mM 
and 300 mM was prepared and the pH of the buffer was varied with 1 M NaOH. We monitored 
the pH of the reaction medium at the beginning and end of MGNs synthesis and the pH remained 
constant throughout the synthesis. The plasmon resonances of MGNs synthesized with 100 mM 
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HEPES (Figure 2.7a) demonstrated a peak at 574 nm at pH 6.61 indicating sphere-like 
nanostructure formation. TEM micrographs of the pH 6.61 reaction (Figure 2.7b-i) showed ~85 
nm Au nanospheres with very short protrusions. As the pH is increased to 7.44 the protrusion 
length increases and the MGN spherical core diameter decreases giving rise to ~ 41 nm MGNs 
(Figure 2.7b-ii). While the overall dimensions of MGNs decreases with increasing pH, the 
increase in protrusion length results in stronger coupling to light giving rise to red-shift in the 
plasmon resonance. As the pH is increased further, a non-intuitive behavior is observed, where 
the plasmon peak resonance blue shifts (pH 7.69, 8.03) and then red shifts again at high pH (pH 
8.27, 8.6). This trend was observed for MGNs synthesized with 100 mM and 300 mM HEPES 
(Figure 2.7c). This non-intuitive trend of plasmon peak position as a function of pH is explained 
both in terms of chemical transformations occurring at different pH, as well as optical 
transformations occurring in the MGN reaction mixture.  
 
Figure 2.7: Tunability of plasmon resonance of MGNs by modulating the pH of the HEPES 
buffer while keeping [HEPES] constant at 100 mM and [HAuCl4] constant at 20 mM. (b) TEM 
micrographs of MGNs synthesized at various pH with 100 mM HEPES (i) pH 6.61, (ii) pH 7.44, 
(iii) pH 8.03, and (iv) pH 8.60. The scale bar is 100 nm in b (i-iv). (c) Plasmon peak position as a 
function of HEPES buffer for 100 mM and 300 mM HEPES showing a unique trend with 
increasing pH. 
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The chemical transformation referred above is the change in charge of the HEPES 
molecule (pKa = 7.5) at different pH. The tertiary amine in the piperazine ring in a HEPES 
molecule play key roles as capping and reducing reagent for metal nanoparticle synthesis.[31, 48, 
49] Further, the HEPES/Au binding dynamics is also mediated via radical chemistry, in which 
the nitrogen atom in the tertiary amine must be a deprotonated cationic free radical to bind to Au 
ions and reduce to form Au nanoparticles.[48-50] When the pH of the reaction mixture < pKa of 
HEPES, the solution is acidic and the nitrogen in the tertiary amine is protonated. The 
protonation of the amine group in turn decreases the binding affinity of HEPES for the Au 
surface including the <111> and <110> directions. Au reduction, therefore, occurs along all the 
crystal planes resulting in the formation of spherical particles with larger radii and small 
protrusions (Figure 2.7b-i). When pH ~ pKa i.e. pH 7.44, the piperazine ring is in its neutral state 
and is not protonated. It forms cationic free radicals and preferentially binds to the different 
crystalline facets of Au except the <111> direction giving rise to MGNs (Figure 2.7b-ii). When 
pH> pKa, the ethanesulfonic acid group (pKa ~1.5) of HEPES is deprotonated and becomes 
negatively charged and increase the ionic strength of the basic solution. It has been shown that 
metal nanoparticles cluster together in solutions with high ionic strength to balance the charges 
and reach equilibrium.[49, 51] At pH (8.03) slightly greater than 7.5, the MGNs form higher-
order clusters including dimers and trimers (Figure 2.7b-iii), and at extremely high pH (8.6) 
MGNs aggregate to large clusters to counteract the excessive charges (Figure 2.7b-iv).  
The optical transformation which contributes to the unusual trend observed in Figure 2.7c 
is attributed to MGN clustering at pH > pKa of HEPES. The red-shift in the plasmon resonance 
at very high pH (pH 8.27, 8.6) can be simply explained by phase retardation effects due to the 
formation of large aggregates yielding a plasmon shift to longer wavelengths, resonance 
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broadening, and increase in aggregate peak (~ 900 nm). The blue-shift in the plasmon resonance 
at pH slightly higher than pKa (pH 7.69 and 8.03) may be attributable to the formation of charge 
transfer plasmons in closely interacting MGN dimers and trimers. Charge-transfer plasmons have 
been shown previously both experimentally and theoretically in gold nanoshell dimers,[52, 53] 
solid metal nanoparticle dimers and Yagi-Uda antennas,[54, 55] and other strongly interacting 
nanoparticle assemblies.[56] A blue-shift is expected when metal nanoparticles are either in 
contact or separated by distances short enough to permit a conductive overlap; such an overlap 
would give rise to a collective charge oscillation over the two/three particles comprising the 
dimer/trimer. When the MGN dimers/trimers are coupled within the near-field limit, the surfaces 
in the contact zone are instantaneously polarized with opposite signs for the charge. This 
enhances the stability of the charge-transfer plasmon and results in blue-shift.[52] However, 
future in-depth studies examining single MGN dimers/trimers will be needed to elucidate the 
possibility of charge transfer plasmons in overlapping MGN clusters. 
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Figure 2.8: (a) Refractive index sensing with gold MGNs synthesized with 300 mM HEPES 
showing red-shift in plasmon resonance with increasing glycerol vol.% in the aqueous 
suspension. (b) LSPR shifts of MGNs of two different sizes synthesized with 300 mM (black), 
and 100 mM HEPES (red) plotted as a function of refractive index of media. The refractive 
index was controlled by altering the glycerol vol. %. The LSPR sensitivities are indicated. The 
error bars were calculated from multiple experiments performed at each glycerol vol.%. 
 
 The surface plasmon resonances of the MGNs are highly sensitive to the alterations in 
refractive index (RI) of the surrounding medium.[57] The RI sensitivities of MGNs of two 
different sizes were measured by modifying the RI of the surrounding aqueous medium with 
additions of various volume% of glycerol.[58] MGNs were centrifuged once and re-dispersed in 
H2O (1.33), 20 vol.% glycerol (1.36), 40 vol.% (1.38), 50 vol.% (1.40), 70 vol.% (1.43), 90 
vol.% (1.46), and 100 vol.% (1.475). The numbers within the brackets are RI of the medium with 
the different volumes of glycerol additions. The plasmon resonance of MGNs red shift to longer 
wavelengths with increasing volume % of glycerol in the surrounding aqueous medium (Figure 
2.8a). As the RI of the medium increases, it screens the electron oscillation in the metal 
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decreasing the plasmon energy and resulting in a red-shift of the plasmon wavelength.[57] This 
electron screening also results in plasmon broadening and damping, which is observable 
specifically at glycerol vol.% ≥ 90%. Sensitivity, S, is defined as 𝑆 = 	 ∆12  where Δλ is change in 
plasmon wavelength relative to H2O and η is RI of the medium. S of MGNs synthesized with 100 
mM (41 nm size) and 300 mM (58 nm size) HEPES were determined from the slope of the linear 
fit in Figure 2.8b. The 58 nm MGNs had a LSPR sensitivity of 373 nm/RIU and the 41 nm 
MGNs had a sensitivity of 229 nm/RIU. The LSPR sensitivities are reproducible as indicated by 
the error bars in Figure 2.8b. The error bars were calculated from multiple experiments 
performed at each glycerol vol.%. The MGNs were stable in glycerol solutions and no visible or 
spectral aggregation was observed at low glycerol concentrations (≤ 70%). While slow 
aggregation did occur at higher glycerol concentrations, not within the time frame of LSPR 
measurements. 
The LSPR sensitivity of MGNs is compared to other nanostructure shapes of similar size, 
and also to star-shaped and other branched nanostructures (Table 2.2). We note that Table 2.2 
only represents LSPR sensitivity of ensemble measurements, single particle measurements are 
not compared here. We also note that Table 2.2 is not an exhaustive list; we have provided the 
most comparable nanostructures. A more detailed list of refractive index sensitivity of a range of 
nanostructures can be found in ref [57]. It is known that LSPR sensitivity enhances with 
increasing nanostructure size due to higher polarizability of larger nanostructures.[3, 25] It is 
therefore noteworthy that the HEPES-mediated 58 nm MGNs have higher sensitivity compared 
to the larger size nanostars from ref. [13] and [59]. The high sensitivity of HEPES-mediated 
MGNs is attributed to the intense nanoantenna effect where the multiple sharp protrusions 
interact strongly with incident light giving rise to extraordinary near-field intensities and 
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consequently enhanced sensing capabilities.[18] Despite the variations in protrusion length and 
density (Figure 2.2, 2.3), MGNs demonstrate relatively high LSPR sensitivity for this class of 
branched nanostructures. 
Table 2.2: Comparison of refractive index sensitivity of gold nanostructures of various shapes 
(Note: This table only represents ensemble measurements). 
Nanoparticle Shape Nanoparticle Size LSPR Sensitivity 
(nm/RIU) 
Ref. 
nanospheres 50 nm diameter 60 [57] 
nanocubes 44 nm edge length 83 [57] 
nanorods 26 nm length (small) 156 [60] 
nanoboxes 30 nm edge length (wall 
thickness = 15 nm) 
210 [61] 
nanobipyramids 50 nm length 212 [58] 
peanut-like nanorods 43 nm length 220 [60] 
dog-bone like nanorods 56 nm length 238 [60] 
nanorattles ~40 nm length 285 [62] 
nanoframes 42 nm wall length 516 [63] 
nanoprisms 42 nm edge length 578 [64] 
nanobranches 80 nm length 703 [58] 
nanostars ~80 nm tip-to-tip 326 [13] 
nanostars ~105 nm tip-to-tip 218 [59] 
This work: MGNs  
300 mM HEPES 
~58 nm tip-to-tip 373  
This work: MGNs  
100 mM HEPES 
~41 nm tip-to-tip 229  
 
 The light to heat conversion efficiency of plasmonic nanostructures has been explored 
extensively in nanomedicine from light induced gene therapy,[65-67] and drug delivery,[68-70] 
to photothermal ablation.[71-76] Photothermal conversion has been studied by ultrafast 
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dynamics[77] and is attributed to a combination of electron-electron scattering, electron-phonon 
coupling, and phonon-phonon coupling which results in heat dissipation to the surrounding 
media. Plasmonic nanostructures with sharp tips and protrusions are known to strongly interact 
with light generating intense near-fields and a high density of hot energetic electrons at the tips. 
These energetic electrons eventually thermalize to the surrounding medium producing heat.[78] 
The multiple sharp protrusions of MGNs, specifically those synthesized in the near-infrared, are 
ideal candidates for light-to-heat conversion both due to their unique geometry as well as spectral 
overlap with commercially available laser diodes.  
 
Figure 2.9: Thermogravimetric analysis of solid state MGNs prepared with 300 mM HEPES 
corresponding to extinction = 1.64 at 60-fold dilution factor. 
 
 Here we have probed the photothermal capabilities of MGNs resonant at ~790 nm by 
measuring the maximum temperature of the suspensions by varying the mass of MGNs in 50 µL 
droplets, as well as time of illumination and laser power. The mass of MGNs was determined by 
thermogravimetric analysis (Figure 2.9). Using an IR thermal camera, images of the MGN 
suspension (Figure 2.10ai-aii) and a deionized water control (Figure 2.10aiii-aiv) were captured 
during laser irradiation with a 808 nm NIR laser at 11.28 W/cm2. The thermal images 
demonstrate that MGNs increase the temperature by ~30 °C relative to room temperature within 
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10 minutes of illumination; however, in the absence of MGNs (control) only a 4.2 °C 
temperature increase is achieved. Since the amount of MGNs directly controls the heat generated 
by laser irradiation, MGNs at different particle masses were illuminated for 10 minutes (Figure 
2.10b). A maximum temperature of 54.9 °C was achieved within 10 minutes of laser treatment 
for a nominal amount of 184 µg. This rapid light to heat conversion with increasing mass of 
MGNs is attributed to the intense nanoantenna effect which results from the sharp protrusions 
and the corresponding electron hot spots generated in the junction of MGNs in close vicinity. 
Strong electromagnetic fields generated in these junctions gives rise to enhanced light absorption 
and thus higher light to heat conversion. 
 
Figure 2.10: (a) Infrared thermal images of an aqueous MGN suspension, mass of MGNs = 184 
µg, illuminated with 808 nm laser at (i) 0 and (ii) 10 minutes with deionized water as a control at 
(iii) 0 and (iv) 10 minutes. The MGN suspension and water were illuminated at a flux of 
11.28 W/cm2. (b) Maximum temperature achieved of varying MGN particle masses (in 50 µL 
volumes) irradiated with 808 nm laser for 10 minutes. (c) Temperature profile as a function of 
time for two different mass of MGNs as well as (d) different power densities is shown. For (d) 
mass of MGNs = 184 µg. 
 
55	
	
 Temperature as a function of time was also recorded and an exponential increase in 
temperature (Figure 2.10c) was observed for increasing mass of MGNs. It is notable that 184 µg 
of MGNs demonstrated a 23.4 °C temperature increase within one minute and only incrementally 
increased after 2 minutes. This study demonstrates the promise of MGNs for delivering 
photothermal based therapeutics in cancer cells in vitro and in vivo. Since hyperthermia and 
subsequent tumor destruction occurs within the 41–47 °C temperature range, this indicates that 
for a nominal 26 µg of MGNs in the tumor tissue, tumor ablation can be achieved.[79] Li and co-
workers have also demonstrated that ~7% of injected dose (ID) of gold nanostructures can reach 
tumors in vivo when actively targeted to cancer cell receptors via antibodies and peptides.[80] 
This indicates that if MGNs are actively targeted to cancer cells and assuming that 7% ID 
accumulates in tumors for mice with an average body weight of 20 g, only 18.57 µg/g of MGNs 
dose would be needed to achieve ~43 °C, and 131µg/g of dose would be required to achieve ~55 
°C which may be necessary for aggressive cancer cells (detailed calculations below). These 
numbers are on par with injected dose of nanorods in vivo[81] and ~53X (18.57 µg/g ) and ~7X 
(131µg/g ) less relative to nanoparticles.[82]  
Calculations of amount of MGNs that will be necessary for photothermal experiments  
According to Figure 7c in the main text, 26 µg of MGNs is sufficient to induce hyperthermia in 
tumors in vivo. This indicates that if MGNs are actively targeted to cancer cells and assuming 
that 7% of the injected dose of MGNs accumulates in tumors, then 371.428 µg of MGNs need to 
be injected. 7100×371.428	𝜇𝑔 = 26	𝜇𝑔 
If experiments were performed in nude mice (nu/nu) with an average body weight of 20 g, then 
only 18.57 µg/g of MGNs dose would be needed to achieve ~43 °C. 371.428	𝜇𝑔	𝑀𝐺𝑁𝑠20	𝑔	𝑚𝑖𝑐𝑒 	= 18.57	𝜇𝑔/𝑔 
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For the higher dosage where 184 µg is needed to induce a temperature of ~55 °C , then 131µg/g 
of dose would be required which may be necessary for aggressive cancer cells.  7100×2628.57	𝜇𝑔 = 184	𝜇𝑔 2628.57	𝜇𝑔	𝑀𝐺𝑁𝑠20	𝑔	𝑚𝑖𝑐𝑒 	= 131.42	𝜇𝑔/𝑔 
 
In addition to the length of time of laser irradiation, we also investigated the effect of 
different laser flux on the photothermal conversion efficiency of MGNs. An exponential increase 
in temperature was observed analogous to the trend seen for increasing MGN mass (Figure 
2.10d). While a maximum temperature of 56.4 °C was observed for the highest power density 
(11.28 W/cm2), a relatively high light to heat conversion was also achieved at 4.84 W/cm2 
resulting in a final temperature of 40.7 °C which is sufficient for tumor ablation. This mass-, 
time- and flux-dependent temperature increase indicates that for applications requiring benign 
temperatures (gene delivery), a short treatment time at low MGNs dosage and low flux is 
sufficient, while for photothermal therapy of aggressive cancer cells a higher MGNs dosage, 
higher laser illumination, and longer treatment time would be more suitable to generate higher 
temperatures. 
 
2.4 Conclusions 
In summary, we have demonstrated the synthesis, characterization, and geometry 
dependent tunability of plasmon resonances of MGNs formed by a straightforward, seedless, 
one-step approach using HEPES buffer. The MGN geometry is modulated by manipulating three 
different chemical parameters: [HEPES], [Au3+], and pH of reaction medium. By changing these 
parameters, the plasmon resonances were tuned from the visible to the near-infrared without 
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significant alterations of the overall dimensions. The evolution of plasmon resonances as a 
function of pH of the reaction medium demonstrated a non-intuitive blue-shift in the plasmon 
resonance when pH was slightly > pKa of HEPES which was attributed to charge transfer 
plasmons in MGN dimers and trimers; this was followed by a red-shift at pH > pKa which was 
attributed MGN clustering to larger aggregates. Finally due to the sharp protrusions of the 
MGNs, enhanced refractive index sensing capabilities were observed and sensitivity of 373 
nm/RIU was achieved. The MGNs sensitivity is relatively high for similarly sized branched 
nanostructures of this class and is attributed to the high polarizability of the MGNs mediated by 
their anisotropic geometry. The sharp protrusions and corresponding nanoantenna effect also 
gives rise to intense photothermal conversion efficiencies for a nominal MGNs mass of only 26 
µg. MGNs demonstrated an increase in temperature to 56.4 °C within 10 minutes of laser 
treatment which is analogous to other branched nanostructures shown previously.[76] The simple 
fabrication process, broad tunability of plasmon resonances, high LSPR sensitivity, and strong 
photothermal conversion efficiencies make these nanoscale antennas excellent for surface 
enhanced spectroscopies, sensing of chemical and biological analytes, thermoplasmonics, 
bioimaging and therapeutics (theranostics), and for probing fundamental optical processes. 
 
2.5 Methods 
A. MGN Synthesis. Gold MGNs were synthesized with HEPES buffer.[31] All reagents were 
purchased from Sigma-Aldrich.  
Changing Morphology through [HEPES]: The concentration of HEPES buffer in aqueous media 
was varied between 30 to 360 mM. Briefly, 3 mL of milli-Q water (18 Mohms) was added to 2 
mL of an appropriate concentration of aqueous HEPES at pH 7.4 ± 0.1 in a 15 mL centrifuge 
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tube (Corning Co.). The pH was adjusted with 1 M NaOH. The solution was mixed immediately 
by gently inverting the centrifuge tube. Next, 50 µL of 20 mM aqueous HAuCl4 was added to the 
5 mL HEPES solution followed by gentle inversion of the tube. We note that the solution should 
not be vortexed or stirred as this will disrupt particle formation. The solution was left to react at 
room temperature for 70 minutes. Upon completion, a color change in the MGN solution 
occurred ranging from purple to bluish-green to grey depending on [HEPES]. The MGNs can be 
stored at 4° C for up to a month. 
Changing HEPES/HAuCl4 ratio: MGNs were synthesized following the above procedure 
keeping [HEPES] constant at 100 mM and 300 mM pH 7.4 ± 0.1, and varying [HAuCl4] between 
10 - 90 mM. Reaction volumes and times were the same as above.  
Changing pH of Reaction:  MGNs were synthesized following the above procedure with HEPES 
concentration at 100 and 300 mM and 20 mM HAuCl4 while altering the pH of the HEPES 
buffer between 6.61-8.60 with 1 M NaOH. Reaction volumes and times were the same as above.  
Growth Dynamics Studies:  MGNs were synthesized with [HEPES] (100, 200 and 300 mM) pH 
7.4 ± 0.1 with 50 µL of 20 mM HAuCl4 as described previously, and these syntheses were 
monitored with UV-vis at different time points between 2 - 90 minutes and the maximum 
intensity in the extinction spectrum for each time point was determined.  
B. MGN Characterization. A Varian Cary 5000 UV-vis NIR spectrophotometer (Agilent 
Technologies) with dual beam capabilities was used to measure the extinction of the MGN 
solutions using a 1 cm path length cuvette.  The MGN size and geometry were characterized 
using Philips CM20T TEM at 200 keV, Osiris TEM at 200 keV, and a Zeiss Merlin SEM (Oak 
Ridge National Lab). MGN samples were centrifuged at 4000 rpm for 5 minutes (x2) and 
washed with deionized water prior to SEM/TEM sample preparation. MGN sizes were evaluated 
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from TEM images averaging over a distribution of ~100 individual stars for each HEPES 
concentration. MGNs mass was determined by Thermogravimetric Analyzer with an Instrument 
Specialist's TGA-1000. 
C. Refractive Index Sensing. For LSPR sensing, MGN syntheses for 100 mM and 300 mM 
HEPES were scaled up:  16 mL aqueous HEPES (100 and 300 mM) pH 7.4 ± 0.1, 24 mL 
deionized water and 400 uL of 20 mM HAuCl4 were reacted for 75 minutes. The solutions were 
centrifuged once at 6000 rpm for 20 min, supernatant was removed, and 3 mL of aqueous 
HEPES at pH 7.4 ± 0.1 was added to stabilize the MGNs. The refractive index of aqueous 
solutions was changed by varying the volume % of glycerol (0-100%) in the aqueous media. 
Stabilized MGNs were added to the different glycerol-water mixtures at 10-fold dilution and the 
plasmon peak positions were examined with a UV-vis NIR spectrophotometer. 
D. Photothermal Heating of Aqueous MGN Solutions. For photothermal experiments, the 
MGN synthesis for 300 mM HEPES was scaled up to a total volume of 200 mL. The MGNs 
were washed and reconstituted to 5X- 200X the original concentration using aqueous HEPES at 
pH 7.4 ± 0.1 for dilutions.  
 A 1 W near-infrared laser diode at 808 nm (L808P1WJ) was set up with current 
(Thorlabs, LDC240C) and thermoelectric controllers (TEDC200C), and the laser beam was 
collimated to a spot size of 1.2 mm diameter with a lens (C230TME-B) and a silver polished 
mirror (PF10-03-P01). All parts were purchased from Thorlabs. MGN suspensions were 
illuminated at 11.28 W/cm2 for the time- and mass-dependent measurements and at 11.28, 4.84, 
and 1.95 W/cm2 for the flux-dependent study. Power densities were measured using a power 
meter (Thorlabs, PM130D). Aqueous 50 µL droplets of MGN suspensions on glass slides were 
heated by light illumination, and the maximum temperatures of the MGN solutions were 
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monitored using an IR camera and software from FLIR Systems (T440). The water droplet size 
was ~ 3 mm and MGN droplet size ~ 1.8 mm. Temperatures were monitored for 15 minutes for 
all experiments taking readings at 0, 1, 2, 4, 6, 10, and 15 minute time points. The solution with 
MGN mass = 184 µg was used in the power density comparison. MGN particle masses were 
determined gravimetrically using TGA of solid state samples to determine the mass of MGNs 
relative to mass of HEPES ligands. The temperature rise in photothermal experiments has been 
provided as a function of the mass of MGNs present in a 50 µl droplet of suspension. 
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CHAPTER 3 
BRANCHED NANOANTENNA-INTEGRATED SUBSTRATES FOR ULTRASENSITIVE 
BIOMOLECULAR SERS DETECTION  
 
3.1 Summary 
 Platforms integrated with plasmonic nanostructures and combined with surface enhanced 
Raman spectroscopy (SERS) offer a versatile and multiplex-capable tool for ultrasensitive 
optical detection of analytes on any surface. Here, we incorporated multibranched gold 
nanoantennas (MGNs) on inexpensive filter paper to design MGN-paper dipsticks and swabs for 
SERS mediated sensing of chemicals, proteins, and pesticides adsorbed on fruit. MGNs are 
anisotropic nanostructures consisting of a core which serves as the antenna and protrusions that 
serve as emitters redistributing incident light. The nanoantenna effect gives rise to intense 
electromagnetic fields on the tips of the protrusions that enabled a detection of 100 pM of 1,4-
benzenedithiol and 100 fM of human serum albumin labeled with indocyanine green with the 
MGN-paper dipsticks. Further, MGN-paper solid swabs enabled the detection of 62.5 pg of 
solid-state 4-aminothiophenol on a planar surface, and 26.3 µg of methyl parathion adsorbed on 
an apple. Finite difference time domain simulations demonstrated that the nanoantenna effect can 
be systematically modulated by altering the core-to-protrusion ratio to generate a ~65x 
enhancement in the electromagnetic fields localized on the protrusions which may ultimately 
result in sub-femtomolar to zeptomolar detection sensitivities. Lastly, incorporating protein 
detection via SERS tag technology with the concept of junction field strength, we designed an 
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MGNs sandwich architecture using MGN-glass and obtained a detection signal for prostate 
specific antigen (PSA) at concentrations as low as 5 fg/mL. 
 
3.2 Introduction 
 Paper-based diagnostic platforms and analyte sensors have gained tremendous attention 
in the past decade due to their scalability and low cost.[1, 2] Paper-based assays can be processed 
to be flexible, portable, disposable, and easy to operate. The commercially available lateral flow 
assays (LFAs) for the detection of pregnancy hormones are excellent examples. While 
inexpensive, LFAs are limited to providing a qualitative “yes or no” type of detection and have 
poor sensitivity.[1] Alternatively, paper substrates incorporated with metal nanostructures and 
combined with a highly specific and sensitive optical diagnostic tool such as surface-enhanced 
Raman spectroscopy (SERS) enable an extraordinary limit of detection and accurate 
identification of analytes.[3, 4] Metal nanostructures when photoexcited couple incident light to 
conduction band electrons, generating surface plasmon resonances. These plasmon resonances 
give rise to both light scattering into the far-field and electromagnetic fields near the 
nanostructure surface.[5-7] The near-field and far-field properties are governed by the geometry, 
dimensions, and composition of the metal nanostructures. In this work, low-cost filter paper 
integrated with multibranched gold nanoantennas (MGNs) has been designed for the detection of 
chemical and biomolecular species mediated by SERS. MGNs are anisotropic plasmonic 
nanostructure which consist of a core that serves as the receiver antenna and the protrusions 
serve as emitters confining the re-radiated light into a localized area resulting in enhanced local 
fields.[8] By modulating the core-to-protrusion ratio, the nanoantenna effect can be manipulated 
to generate intense local fields on the protrusion tips that can couple with vicinal molecules and 
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significantly augment their optical readout.[8-12] Plasmonic nanostructure mediated optical 
enhancements have been extensively harnessed in a range of applications from surface-enhanced 
spectroscopies[13-17] and nanomedicine[18-21] to solar devices and photodetectors.[22, 23] 
 Recently SERS detection of analytes on paper substrates incorporated with metal 
nanospheres and nanorods has been investigated and sub-nanomolar sensitivities have been 
achieved.[24-28] This work reports the use of anisotropic branched nanostructures for paper 
based dipsticks and swabs for SERS-mediated chemical and biosensing. MGN integrated paper 
platforms combined with SERS offer a novel and transformational approach to ultrasensitive 
sensing of trace analytes because (i) MGNs facilitate a higher concentration of charges localized 
at the sharp tips of the protrusions due to the quasi-static lightning-rod effect,[8, 29] which give 
rise to orders of magnitude higher fields relative to spherical and prolate-shaped nanoparticles, 
(ii) the synthesis of MGNs and their incorporation on paper is straightforward enabling scalable 
manufacturing of plasmonic paper substrates, (iii) relative to fluorescence assays, Raman probes 
are not prone to photodestruction, and SERS provides excellent multiplexing capability due to 
narrow spectral widths,[30] and (iv) SERS allows rapid diagnosis and, relative to colorimetric 
sensors, provides simultaneous qualitative and quantitative detection of analytes. MGN 
integrated paper sensors when combined with inexpensive and lightweight handheld Raman 
systems will ultimately facilitate their use in remote locations providing instant results and 
unparalleled detection of trace chemicals without the need for time-consuming lab analysis.  
 In this work we demonstrate the multimodal capability of MGN-paper dipsticks and 
swabs for SERS mediated detection of chemicals and biomolecules, as well as pesticides 
adsorbed on fruits. MGN-paper dipsticks were used to detect 1,4-benzenedithiol and the lowest 
concentration detected was 100 pM and an enhancement factor (EF) of 4.7E9 which is one of the 
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highest reported EF values on porous paper substrates. The dipsticks were also utilized for 
detection of human serum albumin, a large multi-domain protein abundant in the plasma, with a 
detection of 100 fM. Further, the versatility of MGN-paper platforms was established by using 
them as swabs to detect solid state 4-aminothiophenol on a flat surface, achieving a detection of 
62.5 pg. Finally, MGN-paper solid swabs were also used to detect methyl parathion, a toxic but 
widely used organophosphate pesticide, adsorbed on an apple demonstrating that MGN-paper 
swabs would be applicable for analyte detection on any surface with varied morphology and 
curvature. The high sensitivities achieved with MGN-paper were attributed to a combination of 
chemical enhancement and electromagnetic enhancement propagated by the nanoantenna effect 
of MGNs.  
 Finite difference time domain (FDTD) simulations were performed to emphasize that the 
nanoantenna effect can be augmented by modulating the MGN morphology. These simulations 
show that significant field enhancements are achieved by controlling the morphology of MGNs 
and that the junction fields created in the small volumes of two neighboring MGNs in a dimer 
are even further augmented to surpass the field strength of the monomer MGN. Therefore, by 
incorporating protein detection via SERS tag technology, with the concept of junction field 
strength, we designed a SERS sandwich biodiagnostic assay using MGN-glass substrates and 
obtained a detection limit for prostate specific antigen (PSA) of 5 fg/mL. Sandwich architectures 
involving both top-down synthesis[31, 32] or bottom-up deposition[33] have been investigated 
for point of care (POC) diagnostic systems that offer specificity and ultra-sensitivity.[34] These 
are used for early detection[35] and even multiplex[36, 37] bar code recognition. By combining 
electromagnetic and chemical enhancements within the MGN junctions[38, 39], we are able to 
detect proteins at unmatched detection limits, allowing for these SERS systems to serve as 
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diagnostic tools in the recognition of the early onset of disease by measuring physiological 
biomarkers. As these were aqueous, proof of concept studies, future SERS sandwich assays will 
include serum analysis of PSA levels, as an indicator for early prostate cancer detection.[33, 36] 
 
3.3 Results and Discussion 
 Multibranched gold nanoantennas (MGNs) were synthesized via the HEPES-mediated 
growth method as described in our previous work.[8] MGNs consist of spherical cores with ~4-6 
protrusions, and the protrusions often varied in length (Figure 3.1a inset). Using 300 mM 
HEPES, MGNs of ~58 nm were obtained (Figure 3.1a). By modulating the concentration of 
HEPES, the plasmon resonance of MGNs can be tuned from the visible to the near-infrared.[8] 
The MGNs peak position was tuned to 800 nm to overlap with the Raman laser wavelength 
(Figure 3.1b). The experimental extinction spectrum is an ensemble measurement, and, due to 
variations in the number of protrusions and length of protrusion, a broad resonance is expected. 
FDTD simulations were performed on a single MGN with overall dimensions 50 nm from tip-to-
tip and a core diameter of 10 nm. Simulated results demonstrated good overlap with 
experimental peak position but with narrow bandwidth consistent with those observed for single 
particle measurements.[10, 11] Prior to acquiring Raman spectra, cellulose filter paper was 
soaked in MGN solution; the filter paper demonstrated a color change upon saturation with 
MGNs (Figure 3.1c inset). Paper soaked in MGNs (MGN-paper) had an estimated coverage of 
~90-95 % (Figure 3.1c). High magnification scanning electron microscopy (SEM) micrograph 
(Figure 3.1d) shows the three dimensional topography of the MGN-paper which suggests MGNs 
have multiple binding conformations. The orientation of MGNs on the paper substrate directly 
controls analyte binding and the corresponding enhancements observed in the SERS spectra. 
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Figure 3.1: (a) TEM micrographs of MGNs demonstrating their anisotropic geometries (inset 
shows high magnification image of a single MGN). (b) Ensemble extinction spectrum of the 
synthesized MGNs overlaid with simulated extinction spectrum of a single MGN. (c) SEM 
micrograph of MGN-paper showing % coverage. Inset displays the associated color change of 
the filter paper upon MGN saturation. (d) High resolution SEM of the MGN-paper showing the 
topography of the paper with different MGN orientations. 
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Figure 3.2: (a) SERS detection of 1 mM 1,4-Benzenedithiol (BDT) using MGN-paper. (b) SERS 
spectra of varying [BDT] taken with MGN-paper showing the detection of the 1560 cm-1 peak 
down to 100 pM. (c) Spectral intensity of the 1560 cm-1 peak as a function of log([BDT]) 
displaying a linear increase in intensity with increasing log([BDT]). The error bars represent >3 
measurements per concentration. Linear Fit:  y = 1367.72x + 15286.51 with an R2 = 91.8 %. 
  
 The sensitivity of MGN-paper dipsticks was analyzed with a model molecule, 1,4-
Benzenedithiol (BDT), which is known to form a strong covalent bond with gold surface via the 
thiol groups. The MGN-paper dipsticks were soaked in varying concentrations of BDT ranging 
from 1 mM to 100 pM; the dipsticks were allowed to dry followed by acquiring Raman spectra 
at multiple areas of the MGN-paper. SERS spectra of 1 mM BDT was used to identify the 
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Raman footprint (Figure 3.2a) which shows five pronounced peaks consistent with those found 
in the literature.[24, 25] The peak at 1560 cm-1 is due to phenyl ring stretching; 1179 cm-1 due to 
C-H bending; 1065 cm-1 due to the contribution of multiple modes including C-S stretching, C-H 
in-plane bending, and phenyl ring breathing. The peaks at 734 cm-1 and 355 cm-1 are due to the 
7a and 6a vibrational modes of the benzene ring respectively in accordance to Wilson 
notation.[40, 41] To probe the detection limit of MGN-paper dipsticks, we focused on the 1560 
cm-1 peak of BDT due to the strong interaction of MGNs with phenyl rings. We note that while 
nanorods have been shown to bind strongly to moieties corresponding to the 1065 cm-1 peak of 
BDT,[25] the MGNs interact with ring structures thus amplifying the 1560 cm-1 peak. We 
observed this process during the synthesis of MGNs where the [110] planes interacted strongly 
with the piperazine ring structure of the 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) molecule during the capping step.[8]  
 The lowest concentration that yielded an observable SERS signal with MGN-paper 
dipsticks was 100 pM of BDT as shown in Figure 3.2b which is on par with that reported in the 
literature.[25] The high SERS detection limit of BDT on MGN-paper is attributed to a 
combination of the electromagnetic and chemical enhancements. Electromagnetic enhancement 
is contributed by the nanoantenna effect arising from the light that is redistributed through the 
MGN core to the protrusions. This results in intense electromagnetic field hot spots localized on 
the tips of the protrusions which further amplify the SERS signal. The CE is contributed by the 
dynamical charge transfer of hot electrons created upon photoexcitation of MGNs. Hot electrons 
are typically long-lived and can transfer into the lowest unoccupied molecular orbital (LUMO) 
of BDT. The electron subsequently transfers back to the metal with modified internal molecular 
vibrations which is followed by Stokes scattering giving rise to chemical enhancement. The 
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chemical enhancement is mediated by the covalent bond formed between the thiol group of BDT 
and Au, resulting in the direct interaction of the electronic states of BDT with those of MGNs. 
 We observed slight deviations in the 1560 cm-1 peak position between concentrations of 
BDT which we attributed to variations in binding conformations of BDT, i.e. the angle of the 
BDT molecule depending on the orientation of the MGN protruding from the paper 
substrate.[42]  Also note that the Raman peaks arising from the cellulose of the filter paper do not 
overlap with the BDT Raman footprint. The intensity of the 1560 cm-1 SERS peak on MGN-
paper was plotted as a function of the log([BDT]) and the lowest concentration detected was 100 
pM. A linear increase in spectral intensity was observed (Figure 3.2c) demonstrating MGN-paper 
can quantifiably probe picomolar concentrations of analyte molecules. 
 We quantified the enhancement factor (EF) of MGN-paper in detecting BDT molecules 
by using pristine filter paper soaked in BDT as a control. The enhancement factor control assay 
was performed on a plain filter paper instead of MGN-paper (see experimental section). For the 
control paper, 250 µL of 28.82 mM BDT solution was used while 250 µL of 100 pM BDT was 
utilized for the MGN-paper. EF was calculated using the following equation: 
    𝐸𝐹 = 	 %&'(&%()*)+ ×-()*)+-&'(&                                                               (3.1) 
where ISERS and IRaman are the intensities of BDT on MGN-paper and plain filter paper 
respectively, and NSERS and NRaman are the number of molecules of BDT on MGN-paper and 
plain filter paper respectively. Since both assays (plain filter paper vs. MGN-paper) utilized 250 
uL of volume for the dip test, the number of molecules of BDT for each system is calculated by 
multiplying the concentration by the volume and by Avogadro’s number. It is assumed that in 
both cases the BDT molecules will adsorb on the paper similarly which implies the number of 
BDT molecules within the laser spot for either the plain filter or MGN-paper depends only on the 
75	
concentration of the BDT solution used. EF can then be calculated by accounting for the relative 
number of molecules illuminated with the same laser intensity for the plain filter paper vs. the 
MGN-paper. The MGN-paper gives an enhancement factor of 4.7E9 for BDT which, to our best 
knowledge, is one of the highest reported values for paper-based SERS substrates.  
 In addition to probing BDT molecules, the sensitivity of plasmonic paper dipsticks was 
also analyzed for detection of human serum albumin (HSA), a large multidomain protein 
synthesized in the liver and the most abundant protein in the blood plasma.[43] The Raman 
footprints of proteins are typically weak and difficult to distinguish. Therefore, proteins are often 
conjugated with Raman tags that allow for more precise analysis. In this study, HSA was labeled 
with indocyanine green (ICG) and the Raman peaks of ICG were analyzed to determine the 
concentration of HSA. ICG, a US Food and Drug Administration (FDA) approved dye, is known 
to completely bind to plasma proteins with 95% bound to albumin after intravenous 
injection.[44] Due to this strong association of ICG to HSA and ICG’s well-known Raman 
spectral characteristics, it was utilized as a Raman reporter to detect HSA. Figure 3.3a shows a 
photograph of a MGN-paper dipstick with HSA-ICG in phosphate buffer. The dipsticks were 
prepared by soaking MGN-paper in HSA for two hours followed by soaking in ICG solution for 
two hours in a HSA:ICG ratio of 2:1. The Raman footprint of HSA-ICG conjugate on MGN-
paper was determined by probing a ratio of 42 µM HSA:21 µM ICG (Figure 3.3b). The peaks 
observed were consistent with that observed previously by Kneipp et al.[45] To assess HSA 
detection sensitivity on plasmonic paper we focused on the 1258:1294 cm-1 double peak which is 
attributed to the methyl groups that protrude off of the ring structure of ICG.[46-48] By varying 
the HSA:ICG ratio the lowest concentration that yielded an observable SERS signal was 100 fM 
of HSA on MGN-paper (Figure 3.3c). 
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Figure 3.3: (a) A photo of the MGN-paper dipstick used for protein detection. (b) SERS 
detection of 42 µM:21 µM human serum albumin:indocynanine green (HSA:ICG). The ratio of 
[HSA]:[ICG] was kept constant at 2:1. (c) SERS spectra of varying [HSA]:[ICG] taken with 
MGN-paper showing the detection of the 1258:1294 cm-1 double peak down to 100 fM.  
 
 At concentrations below 100 fM there is insufficient HSA bound to the MGN-paper 
which results in ICG directly adsorbing on the MGN-paper. This lack of HSA can be observed 
by the double peak overlapping to form one broad singlet at 10 fM (Figure 3.3c). Further, we 
performed control experiments of ICG alone to assess HSA/ICG binding conformations. MGN 
paper was dipped in 20 µM ICG for 2 hours (no HSA), followed by air drying for 2 hours prior 
to SERS measurements. Raman measurements were also recorded on solid ICG. The spectra 
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were normalized to their 1294 cm-1 peaks and the relative intensities of the 1258 and 1294 cm-1 
peaks were examined (Figure 3.4). In the presence of HSA, the ratio of the 1258:1294 cm-1 peaks 
is nearly 1:1, while for both the ICG alone bound to MGN-paper and ICG solid, the ratio of 
1258:1294 cm-1 peaks is ~0.6. This dip in the 1258 cm-1 peak has been observed previously when 
ICG binds to a gold surface alone.[45] This difference in the ratio of the 1258:1294 cm-1 peaks is 
attributed to the conformational stability of ICG in the presence of HSA. The polymethine 
groups of ICG are stabilized when bound to HSA relative to solid ICG or when ICG binds to the 
MGN-paper by itself.[19, 49] To observe how this conformational stability changes as the 
HSA/ICG concentrations are lowered, we compared the peak ratios for the whole range of 
HSA/ICG tested (Table 3.1). As the [HSA] decreases, there is a conformational shift by the ICG 
molecule within the confines of its HSA complex. This can be observed by the 1258:1294 cm-1 
ratio decreasing from 1:1 at higher HSA/ICG to ~0.7 at low HSA/ICG concentrations. However, 
this conformational shift is distinct from the ICG bound to the MGN-paper itself (ratio = ~0.6). 
This definitive difference between the two cases is observed in the lack of signal demonstrated 
by the ICG controls at low concentrations as described in the next section. 
 
Figure 3.4: SERS detection of 42 µM:21 µM HSA:ICG with MGN-paper dipstick (black). SERS 
detection of 20 µM ICG with MGN-paper dipstick (red). Raman of solid ICG (blue). Spectra 
were normalized to their respective 1294 cm-1 peaks and then stacked for comparison. Boxed 
region focuses on the intensity ratios of the 1258:1294 cm-1 peaks for each sample.	
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Table 3.1: Comparison of the ratio of 1258 to 1294 cm-1 peak intensities within the double peak 
of various human serum albumin (HSA)/indocyanine green (ICG) probes to determine their 
respective binding conformations. 
Probe with Substrate Ratio of 1258:1294 cm-1 peaks 
HSA/ICG with MGN-paper (42 µM/21 µM) 0.962 
HSA/ICG with MGN-paper (1 µM/500 nM) 0.717 
HSA/ICG with MGN-paper (1 nM/500 pM) 0.712 
HSA/ICG with MGN-paper (100 fM/50 fM) 0.676 
HSA/ICG with MGN-paper (10 fM/5 fM) *N/A 
ICG with MGN-paper (20 µM) 0.600 
ICG solid 0.644 
*The ratio for 10 fM/5 fM HSA/ICG could not be calculated because of the overlapping of the 
double peak to form a broad singlet. 
 
 To test whether there was any non-specific interactions occurring between the ICG and 
MGN-paper as the concentration of HSA/ICG was lowered, further control experiments were 
performed with 500 nM and 500 pM ICG. As the HSA decreases to a very low concentration, 
there is a possibility that the ICG molecules could find their way to the MGN-paper surface and 
be enhanced. However, no ICG SERS signal was obtained in the absence of HSA at the low 
concentrations of 500 nM and 500 pM (Figure 3.5). Without the added stability from the HSA, 
the ICG does not provide any signal. These control tests with ICG alone at low concentrations 
validate that, for low detection, the SERS signal only arises when the MGN-paper-HSA-ICG 
system obtains the proper conformation, and this is only possible in the presence of HSA. Thus, 
our MGN-paper dipstick, when used in conjugation with the ICG-labeled HSA, is a viable 
protein detection tool. 
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Figure 3.5: SERS detection of 20 µM ICG with MGN-paper dipstick (black). Attempted SERS 
detection of 500 nM (red) and 500 pM (blue) ICG with MGN-paper dipstick displaying the 
absence of ICG molecules. The Raman spectra of the MGN-paper (orange) is provided to 
distinguish peaks originating from the MGN-paper substrate itself. Spectra were normalized to 
the maximum peak for each corresponding sample and then stacked for comparison. Boxed 
region focuses on the intensity ratios of the 1258:1294 cm-1 peaks for each sample. 
 
 We note that enhancement factor could not be established for HSA detection due to the 
intense fluorescence signal from ICG on plain filter paper without MGNs (control experiment). 
Since fluorescence is a stronger phenomenon than Raman scattering, the Raman peaks were not 
observable for the control experiment which consisted of 1.022 mM:511 µM HSA:ICG on plain 
paper. This observation is consistent with that noted previously by Kneipp et al.[45] In the 
presence of MGNs, the metal quenches the fluorescence signal from the ICG molecule allowing 
the Raman footprint to be displayed.[18, 19] This study demonstrates that the MGN-paper 
dipsticks will ultimately enable the development of point of care diagnostics for the detection of 
a range of biomolecules from antibody-antigen to DNA/RNA, with the use of appropriate Raman 
tags. This work can be further extended to label-free detection of proteins on plasmonic paper 
albeit at the expense of high sensitivity.  
 While MGN-paper dipsticks are suitable for detecting probe molecules in solution, for 
solid analytes present in trace quantities dipsticks would be less practical. Plasmonic paper-based 
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swabs are ideal for ultrasensitive detection of solids present on either planar or non-planar 
surfaces. We demonstrate the efficacy of MGN-paper swabs for detection of two different solid 
state analytes:  4-Aminothiophenol (4-ATP) on a flat surface, and methyl parathion on an apple. 
Since solid state samples were analyzed, all detection values were reported in grams instead of 
concentration. 4-ATP is a model molecule that has been extensively investigated for SERS on 
rigid substrates, such as Si and glass, due to the strong Raman cross-section of the phenol moiety 
and 4-ATP’s affinity to bind to Au surfaces via the thiol group. We therefore chose 4-ATP for 
our initial assessment of the detection sensitivity of MGN-paper swabs. The analysis was 
performed by dissolving the 4-ATP in ethanol and dropping a 100 µL volume over a 4 cm2 area 
of a clean bench top. The solution was allowed to completely dry followed by swabbing the area 
with a wetted MGN-paper to detect the 4-ATP (inset of Figure 3.6a). The Raman footprint of 4-
ATP (Figure 3.6a) is described by the Wilson notation for benzene ring modes:  1577 cm-1 is due 
to the C-C stretching and 8b ring modes; 1172 cm-1 due to C-H bending and 9a ring modes; 1075 
cm-1 due to C-S stretching and 7a ring modes; 1003 cm-1 due to the C-C bending as well as 18a 
ring modes; and 387 cm-1 due to the C-C torsion modes.[50-54] As discussed previously, since 
MGNs interact strongly with ring structures, the 1577 cm-1 peak was chosen to probe the 
sensitivity of the MGN-paper swabs. The lowest concentration of 4-ATP that yielded an 
observable SERS signal with MGN-paper swabs was 62.5 pg (Figure 3.6b), which is relatively 
low compared to that observed previously.[28] We note that the Raman peaks from the filter 
paper without 4-ATP (at ~1040 cm-1 and 1340 cm-1) do not interfere with the vibrational 
footprint of 4-ATP. We attribute this high sensitivity of MGN-paper swabs to the 
electromagnetic enhancement and chemical enhancement as discussed earlier. Overall the MGN-
paper dipsticks have a higher sensitivity relative to the swabs (100 pM BDT vs. 5 nM 4-ATP), 
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which has been observed previously for paper-based SERS substrates.[25] This is likely because 
chemical interactions between molecules and the MGN surface occur more readily in solution vs. 
in the solid state enabling a higher SERS signal with the dipsticks as compared to the swabs. 
This initial analysis demonstrates that MGN-paper swabs are ideal for ultrasensitive detection of 
trace analytes and will be suitable for field use. We therefore chose a real-world analyte, methyl 
parathion, adsorbed on an apple and examined the detection on MGN-paper swabs.  
 
Figure 3.6: (a) SERS detection of 12.5 µg of 4-Aminothiophenol (4-ATP) using MGN-paper. 
Inset shows the use of MGN-paper swab on the bench top for 4-ATP detection. (b) SERS spectra 
of varying masses of 4-ATP detected with MGN-paper demonstrating the sensitivity of the 1577 
cm-1 peak down to 62.5 pg. (c) Photo showing the use of MGN-paper swab for detecting methyl 
parathion adsorbed on an apple. (d) SERS spectra of 26.3 µg of methyl parathion on MGN-paper 
displaying the Raman footprint. 
 
 Methyl parathion is a toxic, organophosphorus chemical agent commonly utilized as a 
pesticide on fruits and vegetables.[55, 56] Methyl parathion was dissolved in ethanol, and a 100 
µL volume was dropped over a 4 cm2 area of a thoroughly cleaned apple. A wetted MGN-paper 
was swabbed across the apple surface (Figure 3.6c), and, subsequently, Raman spectra were 
recorded. The SERS footprint of the 26.3 µg methyl parathion detected by the MGN-paper swab 
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(Figure 3.6d) shows the 1586 cm-1 peak due to phenyl ring stretching mode, 1345 cm-1 peak due 
to the symmetric stretching mode of the NO2 group, 1110 cm-1 peak due to C-N vibrational 
mode, and the 861 cm-1 peak due to the P-O stretching mode.[57] We note that the Raman 
footprint of methyl parathion did not overlap with any of the broad peaks from the filter paper 
itself. The low sensitivity of MGN-paper swab in the detection of methyl parathion is attributed 
to two effects:  (1) unlike 4-ATP, methyl parathion does not have a thiol or amine group to form 
a covalent bond with the MGN surface which precludes any chemical enhancement; (2) unlike 4-
ATP which was detected on a planar, non-porous surface, the porosity and curvature of the apple 
surface result in some of the methyl parathion seeping through the skin resulting in lower 
available concentrations of methyl parathion for detection. However, this study demonstrates the 
versatility of MGN-paper and its ability to detect a multitude of chemicals due to the intense 
electromagnetic fields generated on the MGN protrusions.  
 We have thus far demonstrated that MGN-paper dipsticks and swabs enabled detection of 
100 fM of labeled proteins, 100 pM of label-free analytes, and 62.5 pg of solid-state chemicals. 
These detection ranges result from the intense nanoantenna effect where light is redistributed 
from the spherical MGN core (antenna) to the protrusions (emitters).[5] The nanoantenna effect 
creates localized hotspots on the tips of the protrusions resulting in enhanced SERS signal of 
analytes in proximity to MGNs. We use FDTD simulations to demonstrate that this antenna 
behavior can be substantially improved by modulating the geometry of MGNs. The results of 
this simulation may ultimately enable us to achieve sub-femtomolar to zeptomolar.[34] 
sensitivities by modulating junction plasmonic effects. 
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Figure 3.7: Finite difference time domain (FDTD) simulations of MGNs with spherical cores of 
diameter (a) 10 (a), (b) 25, and (c) 40 nm. Profiles were collected at a wavelength of 790 nm. A 
plane wave of intensity one was injected along the x-axis with propagation occurring along the 
y-axis. Color bars represent the intensities of the resulting electric fields. The insets display the 
actual geometries of the respective MGNs being simulated. (d) Bar graph of electric field 
enhancement as a function of core/protrusion ratio is shown with images of the respective MGNs 
above each bar. Actual |E|2/|E0|2 values for increasing core/protrusion ratio are as follows:  152 
(0.2), 878 (0.5), and 9830 (0.8).  
 
 Symmetric MGNs with six protrusions were simulated (Figure 3.7a-3.7c) by keeping the 
overall dimensions constant at 50 nm (i.e. tip-to-tip distance across the MGN) and varying the 
diameter of the core to 10 nm, 25 nm, and 40 nm. A plane wave was injected along the x-axis, 
and propagation along the y-axis was observed to calculate electric field enhancements. The 
color profiles represent the field intensity with the corresponding numerical values displayed to 
the right on the color bar. The electric-field intensity profiles at 790 nm (Figure 3.7a-3.7c) 
clearly demonstrate (1) the nanoantenna effect where the near-fields are localized on the tips of 
the protrusions and (2) the enhancement in nanoantenna effect with increasing core diameter of 
MGNs. Increasing dimensions of the antenna results in enhanced light scattering by the MGN 
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core; the scattered light is subsequently redirected to the protrusions. The MGN protrusions then 
emit the amplified light to the tips which is observable in the simulated near-field intensity 
profiles.  
 The nanoantenna effect can be further understood by the plasmon hybridization model of 
MGNs discussed in our previous work.[8] The plasmon resonances and corresponding 
electromagnetic fields of an MGN arise from the hybridization of the core and individual 
protrusion plasmons.[58] Plasmon hybridization results in an antibonding mode which is 
primarily contributed by the core plasmons while the bonding mode is predominantly composed 
of MGN protrusions but with a finite contribution of the core plasmons. An increase in the core 
diameter results in an increase in the admixture of the core plasmons in the bonding plasmon 
mode of the protrusions. This subsequently amplifies the dipole moment of the protrusion 
plasmons. The enhanced nanoantenna effect is reflected in Figure 3.7d where the intensity of the 
electric-field enhancements are shown as a function of increasing core-to-protrusion ratios from 
0.2 (10 nm core) to 0.5 (25 nm core), and 0.8 (40 nm core). The electric field enhancements were 
calculated by dividing the near-field intensity by the incident field intensity. A 5.8x and 64.7x 
enhancement is observed in near field intensities as the core-to-protrusion ratio is increased from 
0.2 to 0.5, and 0.8 respectively.  
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Figure 3.8: a) Finite difference time domain (FDTD) simulation of a 25 nm core MGN dimer. 
Profile was collected at a wavelength of 790 nm. A plane wave of intensity one was injected 
along the x-axis with propagation occurring along the y-axis. Color bar represents the intensity 
of the resulting electric field. The inset displays the actual geometry of the dimer. (b) Bar graph 
of electric field enhancement as a function of MGN dimerization is shown with images of the 
respective MGNs above each bar. Actual |E|2/|E0|2 values for monomer vs. dimer of 25 nm core 
MGNs are as follows:  878 (Monomer, 790 nm), 1930 (Dimer, 790 nm), and 311000 (Dimer, 
1100 nm). The dimers were calculated with a gap distance of 1 nm between adjacent MGNs and 
showed a 2.2x enhancement at 790 nm with a 354.2x enhancement at 1100 nm over a single 
MGN. (c) Simulated extinction spectrum of a dimer of 25 nm core MGNs displaying diminished 
monomer peak with enhanced dimer peak. 
 
 In addition to the nanoantenna effect, electric field can also be enhanced by MGN 
clusters. As evident from Figure 3.1c-3.1d the MGNs are closely packed on the filter paper 
which will result in strong interaction between adjacent MGNs giving rise to intense hot-spots. 
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These hot-spots will directly contribute to the observed SERS signal on MGN paper dipsticks 
and swabs. Nanoparticle clusters, specifically dimers of nanostructures, have been extensively 
studied to engineer hot-spots for SERS applications.[59-66] To understand the effect of 
interparticle interaction between adjacent MGNs, we have performed FDTD simulations of 
dimers of MGNs where each MGN has a core diameter of 25 nm and 50 nm overall dimension 
(Figure 3.8a). The interparticle distance between MGNs is 1 nm which results in a 2.2x 
enhancement at 790 nm and a 354.2x electric field enhancement at 1100 nm (Figure 3.8b). This 
dramatic increase in the electric field enhancement upon dimerization is further displayed by the 
increased dimer mode at 1100 nm at the expense of a diminishing monomer peak in the 
simulated extinction spectra (Figure 3.8c). These calculations demonstrate by manipulating the 
gap distance and number of MGNs in a cluster, hot-spots can be engineered to yield intense 
electromagnetic fields which can directly contribute to improved SERS signal on any substrate. 
This also implies MGN trimers, quadrumers, and higher-order clusters will give rise to even 
higher enhancement in SERS signal of molecules within the MGN junctions.  
The results of these simulations have several implications:  (1) it enables design rules to 
build MGNs and other plasmonic nanoantennas with enhanced near-field intensities which will 
amplify signal transduction in a range of surface-enhanced spectroscopies; (2) it demonstrates a 
route to develop plasmonic paper dipsticks and swabs with unparalleled SERS detection 
capabilities to ultimately reach near-zeptomolar sensitivity; and (3) it also provides an approach 
for SERS detection in both in-vitro and in-vivo applications where the size of the nanoantenna 
must be <100 nm to improve cellular delivery and permeation. We also note that in our previous 
work we have demonstrated that by altering the concentration of the gold precursor and the pH 
of the HEPES buffer, the geometry of the MGNs can be modified to increase the core-to-
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protrusion ratio.[8] While these simulations provide emphasis on the core to protrusion length 
ratio only, we anticipate that the protrusion width and density will also likely effect the plasmon 
hybridization and the resulting energy-level splitting between bonding and antibonding plasmons 
which consequently impacts the nanoantenna effect.  
	
Figure 3.9: MGN-glass sandwich architecture for Prostate Specific Antigen (PSA) detection. (a) 
Schematic of Biodiagnostic SERS assay demonstrating the PSA molecule to be detected (red) 
through a SERS tag (purple, pMBA) beacon bound to the top probe MGNs. (b) Scanning 
electron microscopy of MGN-glass after 3-5 nm gold sputtering to enhance conductivity of glass 
substrate. Inset, a representative brightfield image of a MGN-glass batch preparation. (c) UV-vis 
spectroscopy of both the liquid phase and solid state MGN-glass, showing a blue shift due to 
refractive index change of the medium.  
88	
Various nanostructures[33, 38, 39] and morphologies[67-69] can be utilized for these 
SERS sensing assays depending on the plasmonic material incorporated. The multiplex and 
ultrasensitive[34, 37] properties of these platforms are attracting interest. The tool, however, of 
making proteins detectable, which normally have weak Raman cross-sections[70], via SERS-
beacon plasmonic nanoparticle enhancement is of great significance in the design and 
development of theranostic nanoprobes.[69, 71] 
Dimer simulations revealing that junctions between two neighboring MGNs could create 
tremendous field strengths provided data to support the concept of the complex sandwich 
architecture SERS assay for biomarker detection. To construct the assay, planar glass was 
utilized, and MGNs were incorporated into MGN-glass substrates. Again, integrating protein 
detection via SERS beacon technology with the concept of junction field strength, we 
synthesized antiPSA-pMBA-MGNs top probes for the Sandwich assay. Methods for the 
Biodiagnostic assay are provided in Appendix B. Briefly, two layers of MGNs in near proximity 
to one another create hot spot, junction fields leading to strong detection of signal even if a low 
concentration of analyte is present. Schematic of the Biodiagnostic SERS assay is provided in 
Figure 3.9a. The assay is meant to capture and detect the antigen (Prostate Specific Antigen) 
even in low concentration because of the plasmonic enhancement of the pMBA 
(paramercaptobenzoic acid) beacon via the MGNs SERS enhancement. Electron 
microscopy(Figure 3.9b) reveals the surface coverage of the MGN-glass substrates utilized in the 
study with particle layer visualized with a color change after MGN coating (Figure 3.9b inset). 
MGNs for MGN-glass preparation were synthesized with peak resonance at ~800 nm, expecting 
a blue shift when moving to the solid MGN-glass substrate due to the refractive index change of 
the surrounding medium (water to air) (Figured 3.9c). Also, ideal resonance for both the MGN-
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glass bottom layer and the top functionalized antiPSA-pMBA-MGNs is in this range as to align 
with the 785 nm laser utilized in the SERS studies and potential NIR lasers for therapies. 
	
Figure 3.10: SERS Biodiagnostic assay for ultrasensitive PSA detection via MGN junction 
geometry. (a) SERS sandwich control verifying that the 1580 cm-1 peak arises from the pMBA 
bound in the antiPSA-pMBA-MGNs beacon (maroon arrow). Also, displayed is the 4 peak 
pattern from 1000 – 1200 cm-1 corresponding to the antibody and PEG branching (green arrows). 
(b) Sandwich control demonstrating that the 1580 cm-1 peak only displays with the antiPSA-
pMBA-MGNs top probe bound (maroon circle). (c) Sensitivity study measuring ISERS1580 for 
[PSA] concentrations ranging from = 5 fg/mL to 100 µg/mL (blue spheres). BSA control refers 
to sandwich assay with no target (PSA) present (orange star), and the specificity control (green 
triangles) refers to the IgG protein taking the place of the target (PSA) protein in the sandwich 
assay. BSA = (Bovine Serum Albumin), PSA = Prostate Specific Antigen, IgG = 
Immunoglobulin G. 
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After designing and constructing the MGN-glass SERS biodiagnostic assay, experiments 
were performed to determine the detection limit and fidelity of the system for false positives and 
specificity. To begin, the SERS peak selected for detection/quantification had to be 
distinguishable from all the rest of the peaks and footprints that were present in the complex 
system. Thus, the 1580 cm-1 peak[72, 73] for the antiPSA-pMBA-MGNs SERS beacon was 
selected to be the indicator of a positive result (Figure 3.10a, maroon arrow). Further, four peak 
pattern, in the 1000-1200 cm-1 region, occurred upon the addition of OPSS-PEG-antiPSA to the 
pMBA-MGNs and is thus attributed to the antibody and PEG branching (Figure 3.10a, green 
arrows). The density of peaks located in the region of the 1074 cm-1 peak of pMBA were 
deterrents in selecting this peak for detection. Therefore, it was determined that the 1580 cm-1 for 
pMBA beacon was the correct peak to monitor for successful PSA detection. 
Within the SERS sandwich assay, the signal was only obtained with the presence of the 
MGN top probe of the junction (Figure 3.10b). Refer to maroon circle around 1580 cm-1 peak, 
corresponding to antiPSA-pMBA-MGNs top probes (Figure 3.10b). To test the sensitivity limit 
of the junction system for detection of [PSA], concentrations were tested from 5 fg/mL to 100 
µg/mL (Figure 3.10c, blue spheres). After data processing, ISERS1580 as a function of the log 
([PSA], pg/mL) was plotted, and the points were fit to a sigmoidal growth curve with similar 
equation as used in Chapter 2 (refer to Equation 2.1). Signal was still detectable even with 
concentrations as low as 5 fg/mL [PSA]. In this linear regime, a bottom monolayer of substrate 
MGNs is assumed. 
In addition, the Bovine Serum Albumin (BSA) alone control, with no target (PSA) 
present, was performed. For this test, the sandwich assay was completed with same steps except 
for buffer addition instead of antigen incubation (Figure 3.10c, orange star). No signal above 
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baseline was observed for this control. Lastly, Specificity control was performed, repeating the 
biodiagnostic assay except incubating with non-specific protein, Immunoglobulin G (IgG), 
instead of the target antigen (PSA). The control was attempted with multiple [IgG] 
concentrations, and no signal was observed (Figure 3.10c, green triangles). Thus, the lack of 
signal from either the BSA control assay or the IgG specificity control, demonstrates that the 
SERS sandwich assay has low probability for false positives with non-specific binding. The 
absence of signal from the IgG control demonstrates that the PSA detection will outcompete non-
specific proteins when it comes time to move the assay into serum studies. The specificity of the 
two antibody layers for the binding event of the correct antigen (PSA), provide the assay with 
high fidelity while the two MGNs in a junction event, as part of the MGN-glass sandwich assay, 
provide unmatched detection limits. These characteristics of the Biodiagnostic SERS system 
make it ideal for real-world applications. 
 
3.4 Conclusions 
 In summary, this work demonstrates the integration of MGNs on inexpensive filter paper 
to design dipsticks for SERS mediated label-free chemical detection of a concentration as low as 
100 pM and labeled-protein detection of a concentration of 100 fM. Further MGN-paper swabs 
were also constructed for analyte sensing, and 62.5 pg was the lowest concentration detected, as 
well as detection of real-world samples, such as pesticides on a fruit. The experimental results 
and analysis provided by FDTD simulations demonstrate that the intense nanoantenna effect of 
MGNs gives rise to both electromagnetic and chemical enhancements which enable such high 
sensitivities on both porous, flexible and planar, rigid substrate. We anticipate the results of this 
work will help establish the SERS mediated MGN-substrates as a rapid response platform for a 
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range of applications including food quality control, quantification of water contaminants, 
biothreats such as anthrax detection for national security, explosive and chemical warfare 
detection, environmental sensing, as well as human health monitoring such as detection of cancer 
biomarkers and blood-type testing. The low cost of paper and straightforward synthesis of MGNs 
will ultimately enable commercialization of a MGN-paper point-of-care assay with extraordinary 
sensitivity, specificity, with rapid and reliable readout, and high scalability. Further the 
incorporation of the MGNs SERS-beacon technology for protein recognition, permitted the 
ultrasensitive detection of prostate specific antigen (5 fg/mL, PSA), and we envision that this 
technology will prove to be a vital theranostic tool in vivo, as well. The plasmonic MGNs are 
quite unique due to their versatility across substrates and their usage for a variety of biosensing 
tests, both properties making them ideal for real-world applications.[36] 
 
3.5 Methods 
A. MGN-paper Synthesis. All reagents were purchased from Sigma-Aldrich except 1,4-
Benzenedithiol (Alfa Aesar). As described previously, MGNs were synthesized via the HEPES-
mediated growth process.[8] Briefly, the reaction was scaled up to 250 mL:  100 mL of 300 mM 
HEPES pH 7.4 ± 0.1, 150 mL of milli-Q water (18 MΩ), and 2.5 mL of 20 mM aqueous 
HAuCl4; mixed by inversion and left to react at room temperature for 75 minutes. Reaction 
volume was then concentrated down to ~ 3 mL by centrifugation (6000 rpm for 20 min) with an 
additional spin of the supernatant to capture all of the MGNs. Next, Whatman cellulose filter 
paper (Grade #2, 42.5 mm, 8 µm pores) was soaked in the concentrated MGN solution for ~ 40 
hours with constant shaking. Upon saturation, MGN-paper was rinsed with milli-Q water, dried 
with N2 stream, and allowed to air dry for 3.5 hours.  
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B. MGN-paper Characterization. A Varian Cary 5000 UV-vis NIR spectrophotometer 
(Agilent Technologies) was used to measure the extinction of the MGN solutions using a 1 cm 
path length cuvette. The MGNs were characterized using a Philips CM20T TEM at 200 keV and 
an Osiris TEM at 200 keV. MGN-paper was visualized using a Zeiss Merlin SEM; samples were 
sputtered with ~3-5 nm layer of Au prior to SEM. 
C. Raman Measurements and Analysis. Using an Invia Raman microscope (Renishaw) with a 
785 nm wavelength laser source, Raman measurements were obtained. All spectra were recorded 
using a 50x objective with a ~1 µm spot size at a power of 2.2 mW with a 10 second acquisition 
time. To attain control spectra (not enhancement factor control), the footprint of the MGN-paper 
with no analyte was collected. For each dip/swab test, an individual piece of MGN-paper was 
utilized. Upon completion of the respective test, a mapping of the MGN substrate was 
performed, in which multiple spectra were collected per substrate. These multiple spectra were 
acquired at different locations within the MGN substrate to the test the whole sample. For further 
analysis, each individual spectrum was baseline corrected to remove any contributions from the 
fluorescence background of the MGNs. This correction was performed using OriginPro 8 
software. Raman intensities were then determined from the baseline corrected spectra and plotted 
against the respected concentrations. 
D. 1,4-Benzenedithiol Dip Test with MGN-paper. 1,4-Benzenedithiol (BDT) dilutions were 
made in 100% ethanol. Pieces of MGN-paper were soaked in [BDT] for ~16 hours; followed by 
gentle rinsing with ethanol, drying with N2 stream, and air drying for 1.5 hours. Raman 
measurements were recorded on dried MGN-paper with BDT.  
E. Human Serum Albumin Dip Test with MGN-paper using Indocyanine Green Probe. 
Human serum albumin (HSA) (MW = 66478 g/mol) dilutions were prepared with 8.65 mM 
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Na2HPO4 pH 7.4 ± 0.1, being sure to only pipette for mixing. Indocyanine green (ICG) 
(photosensitive) solutions were prepared with milli-Q water (18 MΩ) as the solvent. For all 
assays, the HSA:ICG ratio was kept constant at 2:1. MGN-paper was soaked in [HSA] for 2 
hours, followed by immediate immersion into [ICG] for another 2 hours. The paper substrates 
were then dried at room temperature for 2 hours prior to Raman measurements. The power of the 
excitation laser was adjusted depending on the fluorescence background from ICG. For lower 
concentrations, 3.77 mW was used, while for 42 µM HSA, 388 µW power was used. For 
intensity comparisons over the various [HSA], the count outputs were normalized according to 
the powers used.  
A control experiment was performed with ICG alone on MGN-paper. 20 µM, 500 nM, 
and 500 pM aqueous ICG solutions were prepared, and MGN-paper was soaked in the ICG 
solutions for 2 hours (no HSA soaking), followed by air drying at room temperature for 2 hours. 
Raman measurements were performed at a very low power of 4.69 µW due to the extremely 
strong fluorescence of the ICG molecule. The spectra were normalized to their 1294 cm-1 peak 
for comparison to the SERS of the HSA/ICG dip test and the Raman of the ICG solid alone. A 
Raman spectrum of solid powdered ICG was collected at a low power of 4.69 µW due to the 
strong fluorescence of the ICG. The spectra were normalized to their 1294 cm-1 peak as 
described previously. As for the 500 nM and 500 pM ICG controls, 2.2 mW power was used as 
an attempt to obtain signal. Since there was no ICG signal for the 500 nM and 500 pM control 
samples, these spectra, in addition to the 20 µM ICG control, were normalized to their maximum 
peak to compare for the presence of SERS signal of ICG.  
F. 4-Aminothiophenol Swab Test on Bench Top with MGN-paper. 4-Aminothiophenol (4-
ATP) dilutions were made with 100% ethanol as the solvent. Prior to the swab test a 4 cm2 area 
95	
of bench top was cleaned with acetone, isopropyl alcohol, and 100% ethanol to eliminate any 
contamination. 100 µL volumes of [4-ATP] were dropped on a 4 cm2 area of bench top, allowed 
to dry, and then wiped with a piece of wetted MGN-paper (wetted with ethanol). The samples 
were allowed to dry and Raman spectra were recorded.  
G. Methyl Parathion Swab Test on Apple with MGN-paper. Methyl parathion dilutions were 
made with 100% ethanol. Prior to the swab test, the 4 cm2 area of the apple piece was cleaned 
with acetone, isopropyl alcohol, and 100% ethanol. In this test, multiple apples were studied with 
2-3 experiments performed per apple i.e. a 100 µL droplet of methyl parathion was applied on 
the apple and swabbed with MGN-paper. Each droplet was placed as to not cross-contaminate 
with a previous study. SERS spectra were collected from multiple locations on the MGN-paper, 
and experiments were repeated for reproducibility. The bare apples were cleaned with acetone, 
isopropyl alcohol, and 100% ethanol prior to applying methyl parathion. A baseline correction 
was performed for each spectrum to remove any contributions from the fluorescence background 
of MGNs prior to plotting using OriginPro 8. 
H. Finite Difference Time Domain (FDTD) Simulations of MGNs. Lumerical Inc. FDTD 
solutions software was used to perform single particle FDTD simulations on MGNs of varying 
core/protrusion ratios with water as surrounding media. Overall dimension of MGN (tip-to-tip 
distance) was kept constant at 50 nm, while the spherical core diameter was modified to 10, 25, 
and 40 nm. A total-field scattered-field (TFSF) plane wave source was injected along the x-axis, 
and propagation was observed along the y-axis. By collecting the scattering and absorption data 
from the simulation, the single particle extinction was calculated. Finally, the near-field profile 
data at 790 nm was collected and plotted using MATLAB software. 
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I. Protocols for MGN-glass SERS sandwich assay for PSA detection: All methods for the 
development and execution of the PSA detection platform are provided in Appendix A. 
Procedures include: MGN-glass preparation (A.1), synthesis of top probe antiPSA-pMBA-
MGNs (A.2), and experimental design of SERS Biodiagnostic MGN sandwich assay (A.3). 
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CHAPTER 4 
THERANOSTIC GOLD NANOANTENNAS FOR SIMULTANEOUS MULTIPLEXED 
RAMAN IMAGING AND PHOTOTHERMAL THERAPY IN VITRO AND IN VIVO VIA 
HUMAN XENOGRAFT STUDIES  
 
4.1 Summary 
 In this study, we demonstrate the theranostic capability of actively-targeted, site-specific 
multibranched gold nanoantennas (MGNs) in triple negative breast cancer (TNBC) cells in vitro 
and in vivo via xuman xenografts. By utilizing multiplexed surface enhanced Raman 
spectroscopic (SERS) imaging, enabled by the narrow peak widths of Raman signatures, we 
simultaneously targeted the epidermal growth factor receptor (EGFR) and immune checkpoint 
receptor programmed death ligand 1 (PD-L1) overexpressed on MDA-MB-231 TNBC cells. A 
mixture of MGNs functionalized with antiEGFR antibodies and Raman tag para-
mercaptobenzoic acid (pMBA), and MGNs functionalized with antiPDL1 antibodies and Raman 
tag 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) were incubated with cells. SERS imaging 
revealed a cellular traffic map of MGNs localization by surface binding and receptor-mediated 
endocytosis, enabling targeted diagnosis of both biomarkers. Further, cells incubated with 
antiEGFR-pMBA-MGNs and illuminated with an 808 nm laser for 15 min at 4.7 W/cm2 
exhibited photothermal cell death only within the laser spot. Control experiments with antibody 
conjugated MGNs in EGFR low-expressing MCF7 breast cancer cells, as well as, cells incubated 
with MGNs without antibodies, showed no cell death after laser illumination (indicated by 
live/dead cell fluorescence assay). Lastly, the cocktail of functionalized MGNs was administered 
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in vivo to immunodeficient mice growing 231 breast cancer tumors, and the SERS signal was 
monitored over time. By pre-blocking the EGFR and PD-L1 receptors, a ~30 % decrease in 
SERS signal was observed, demonstrating the active targeting capabilities of the theranostic 
MGNs. The overall investigation reveals an image-guided light-triggered therapeutic approach 
combining multiplexed optical imaging with spatiotemporal control and receptor-specific 
treatment with biocompatible theranostic nanoprobes. 
 
4.2 Introduction 
Theranostic nanostructures that combine both diagnostic and therapeutic components 
within a single nanoscale platform have attracted significant interest in the past decade,[1-4] as 
they enable both highly specific detection of disease markers and subsequent targeted, image-
guided treatment all within a single clinical procedure. Gold nanostructures are particularly 
suited for multifunctional theranostics due to their high biocompatibility, and straightforward 
surface chemistry enabling functionalization of multiple molecules including targeting moieties, 
contrast agents, and charge-neutralizing polymers. The theranostic capabilities of several shape- 
and size-controlled gold nanostructures have been studied in the past decade,[5, 6] [7-9] [10-13]  
and some are already in clinical trials.[14] However, the combination of multiplexed imaging 
enabling targeted detection of multiple receptors with a therapeutic modality has not been 
demonstrated successfully.  In this work, we show the theranostic functionality of near-infrared 
resonant multibranched gold nanoantennas (MGNs) in triple negative breast cancer (TNBC) cells 
in vitro by combining surface-enhanced Raman scattering (SERS) imaging with photothermal 
therapy (PTT). MGNs consist of an “antenna-like” spherical core that absorbs incident light, and 
the light is then routed through the protrusions and concentrated at the tips.[15] This unique 
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geometry of MGNs gives rise to the “nanoantenna effect” generating intense electromagnetic 
near fields in their vicinity which is not only advantageous for SERS but also useful for 
efficiently converting resonant light to heat for PTT.[16] Further, the one-step synthesis of 
MGNs in the presence of a biological buffer, 2-[4-(2-hydroxyethyl) piperazin-1-
yl]ethanesulfonic acid, HEPES (pH 7.4) promotes its biocompatibility. HEPES binds weakly to 
gold surfaces, which facilitates straightforward surface modification with Raman-active 
molecules and antibodies for targeted detection. In addition, their sub-100 nm size is ideal for 
cellular uptake, enabling rapid surface binding and endocytosis in cells.   
 SERS Imaging has rapidly progressed from a bench-scale spectroscopic tool to a pre-
clinical diagnosis technique.[17-20] Relative to other clinical imaging techniques, SERS offers 
high cellular-level spatial resolution[21, 22] and the capability to perform multiplexing 
facilitated by the narrow spectral characteristics of the vibrational signature of Raman 
molecules.[23, 24] This enables the detection of multiple receptors with high specificity but 
unlike fluorescence, SERS imaging is not limited by tissue autofluorescence and 
photobleaching.[25-27] The combination of this pre-clinical imaging technique with a 
therapeutic modality mediated by MGNs is highly desirable to allow the detection of multiple 
biomarkers of breast cancer and simultaneously induce externally controlled light-mediated 
therapy. 
In this work we targeted two key receptors, epidermal growth factor receptor (EGFR) and 
the immunomarker programmed death ligand 1 (PD-L1) in TNBC cells.  TNBC is highly 
aggressive and one of the most lethal types of breast cancer due to the lack of response to 
endocrine treatment and other targeted therapies.[28, 29] EGFR, a transmembrane glycoprotein 
that is a member of the erbB family of tyrosine kinase, have been implicated in the pathogenesis 
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and progression of up to 80% of TNBCs.[30, 31] EGFR gene amplification and gene mutation 
both contribute to the overexpression of this receptor, and recently monoclonal antibodies and 
small-molecule inhibitors targeting EGFR has shown improved outcomes in TNBC.[28]  This 
indicates the significance of EGFR as a potential therapeutic target for TNBC.  In addition to 
EGFR,[32, 33] the immune checkpoint ligand, PD-L1, has also been shown to be overexpressed 
in breast cancer cells.[34-36] The upregulation of immune checkpoint receptor programmed 
death protein 1, PD-1, expressed on activated CD8+ T-cells impedes effector T-cell function by 
binding to its ligand, PD-L1.[37-39]  Upon binding, interferons (IFN-γ) produced by activated T-
cells upregulates PD-L1 expression which contributes to immunosuppression in the tumor 
microenvironment. Cancer immunotherapy, particularly blockade of inhibitory pathways such as 
PD-L1, has recently driven a paradigm shift in the treatment of multiple cancers.[40] This 
underscores the significance of PD-L1 as a target receptor for immunoimaging. We successfully 
demonstrated simultaneous detection of both EGFR and PD-L1 in vitro and in vivo with a 
mixture of MGNs functionalized with Raman tag, para-mercaptobenzoic acid (pMBA) and 
antiEGFR antibodies, and Raman tag 5,5-dithio-bis-(2-nitrobenzoic acid (DTNB) and antiPD-L1 
antibodies. Further, antibody-conjugated MGNs demonstrated a higher uptake in cancer cells 
relative to passive uptake, and a significantly higher cell death via photothermal therapy. We also 
verified the active targeting capability of the antibody-conjugated MGNs by observing a ~30 % 
drop in SERS signal in vivo when pre-blocking with antiEGFR and antiPDL1 antibodies. We 
anticipate the findings of this work will translate to further theranostic studies in vivo, 
contributing insights into the emerging field of immunoimaging and immunotherapy. 
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4.3 Results and Discussion 
MGNs were synthesized via a one-step HEPES-mediated synthesis as described in our 
previously reported work.[15] The average size of the MGNs, including the core and protrusions, 
was ~65 ± 7 nm (branch-to-branch length) as visualized under transmission electron microscopy, 
TEM, (Figure 4.1a). The heterogeneity in dimension is correlated to the variable protrusion 
length and protrusion density occurring during the synthesis process.[15] The plasmon resonance 
of MGNs was tuned to ~800 nm prior to functionalization (Figure 4.1b) to enable absorption of 
tissue-penetrating near-infrared light (690–900 nm).  The near-infrared light absorption is 
advantageous for both SERS imaging and PTT, as an ~800 nm laser can be utilized to activate 
both processes. MGNs were further functionalized with antibodies to enable site-specific, 
targeted delivery of both diagnostic and therapeutic function in a model triple negative breast 
(TNBC) cancer cell line, MDA-MB-231. MGNs were therefore functionalized with antiEGFR 
antibodies via a heterobifunctional PEG linker, OPSS-PEG-NHS ester. In this bioconjugation 
chemistry, the thiols on the orthopyridyl disulphide (OPSS) group form a covalent link with the 
gold surface whereas the N-hydroxysuccinimide (NHS) ester reacts with the amines of the 
antibodies to form an amide bond. Further, the MGNs were tagged with a Raman molecule, para-
mercaptobenzoic acid (pMBA) to enable SERS imaging, and coated with an additional layer of 
polyethylene glycol (PEG) to neutralize any surface charge and minimize off-target interactions. 
Zeta potential of MGNs was -4.3 ± 1 mV after PEG coating, indicating their desirable near-
neutral surface. Detailed methods are provided in the supporting information. The successful 
functionalization of antibodies, pMBA, and PEG was monitored with a spectrophotometer, and a 
~32 nm red shift in the plasmon resonance was observed due to an increase in the local refractive 
index of the MGNs (Figure 4.1b).[41-43] The functionalization was further confirmed with TEM 
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(Figure 4.1c) which showed a uniform ~5 nm conformal layer of the three components around 
MGNs. The Raman footprint of the final functionalized MGNs, antiEGFR-pMBA-MGNs, was 
confirmed by examining the SERS spectra (Figure 4.1d-i) which showed dominant peaks at 1074 
cm-1 and 1580 cm-1 peaks corresponding to C-C stretching modes and ring stretching modes of 
pMBA.[44] The weaker peaks between 1000 – 1200 cm-1 correspond to the antibody and PEG 
branching, as determined through control experiments. 
  
Figure 4.1: Characterization of antibody labeled MGNs. (a) Low magnification TEM micrograph 
of MGNs. (b) Extinction spectra of MGNs showing a red-shift after functionalization with 
antibodies, Raman molecule, and PEG. (c) High resolution TEM images of MGNs both (i) 
before and (ii) after functionalization showing ~5 nm conformal layer. (d) SERS footprint of 
MGNs functionalized with (i) antiEGFR/pMBA/PEG, (ii) antiPDL1/DTNB/PEG, and (iii) 
MGNs mixture (1:1) combining (i) and (ii) that was utilized for multiplexed Raman imaging 
showing distinguishable peaks at 1074 cm-1 and 1580 cm-1 corresponding to pMBA, and at 1325 
cm-1 and 1551 cm-1 corresponding to DTNB. 
	
To further investigate the ability of MGNs for multiplexed SERS imaging, the PD-L1 
biomarker was targeted, as it has been found in numerous tumor types including breast cancer 
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and is overexpressed in MDA-MB-231 cells.[45, 46] MGNs were functionalized with antiPDL1 
antibodies via the same heterobifunctional linker, and Raman molecule 5,5-dithio-bis-(2-
nitrobenzoic acid (DTNB) via gold-thiol bond. The MGNs were further coated with an additional 
layer of PEG for stability. The Raman footprint of the functionalized MGNs, antiPD-L1-DTNB-
MGNs, was assessed with SERS (Figure 4.1d-ii), and dominant peaks at 1325 cm-1 and 1551 cm-
1 corresponding to symmetric stretching mode of the nitro group of DTNB, and ring stretching 
mode, respectively, was observable.[47] The SERS spectra of the mixture of MGNs utilized for 
multiplexing (antiEGFR-pMBA-MGNs + antiPDL1-DTNB-MGNs) at 1:1 ratio demonstrated 
distinguishable peaks from both pMBA and DTNB with minimal overlap (Figure 4.1d-iii) which 
enabled us to successfully detect both EGFR and PD-L1 receptors in vitro and in vivo with high 
sensitivity and specificity. 
By attaching an active targeting moiety, the distribution of surface receptors can be 
visualized via the MGN enhanced SERS signal with single cell resolution. To demonstrate these 
targeting capabilities, the Epidermal Growth Factor Receptor (EGFR), part of the ErB3 family of 
proteins, was chosen as a target in the TNBC cancer cell line MDA MB 231 cells.[48] While 
lacking the progesterone, estrogen, and Her2/neu receptors, multiple studies have demonstrated 
the overexpression of EGFR in the 231 cells.[32, 33] Further, to validate the overexpression of 
EGFR and demonstrate the validity of utilizing it as a target, a fluorescent secondary antibody 
assay was performed. MDA MB 231 cells were cultured to ~90 % confluency. The cells were 
then fixed, followed by washing, and incubated with blocking solution to any prevent non-
specific binding. The cells were washed again and then incubated with the primary monoclonal 
antiEGFR protein. Wells were washed, and only specifically bound antiEGFR remained on the 
surface of the 231 cells. Next, a secondary antibody specific for the Fc region of the primary 
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antiEGFR was added to the cells. This secondary antibody was labeled with phycoerythrin (PE), 
a fluorescent protein with excitation at 488 nm and emission 565-605 nm. Again, the cells were 
washed and then imaged using a Zeiss Confocal microscope (Figure 4.2). Acquiring the 
fluorescent image demonstrated the high signal arising from the secondary antibody bound to the 
primary antiEGFR (Figure 4.2a). Further by overlapping the fluorescent signal with the 
brightfield of the cells (Figure 4.2b), it was visualized that the secondary antibody and hence the 
primary anti-EGFR localized on the surface of the 231 cells (Figure 4.2c). The fluorescent signal 
was localized on the edges of the cells, suggesting surface binding, which would only occur via 
specific EGFR:antiEGFR binding events as the assay included a blocking step. These binding 
events and the success of the secondary antibody test confirmed the overexpression of EGFR on 
the surface of the 231 cells and verified the potential of using EGFR in active targeting 
mechanisms. 
 
Figure 4.2: Fluorescent secondary antibody assay confirming Epidermal Growth Factor Receptor 
(EGFR) overexpression in MDA MB 231 cells. (a) Confocal fluorescent imaging of MDA-MB-
231 cells after incubation with primary monoclonal antiEGFR, followed by a phycoerythin-
labeled secondary antibody specific for the primary antiEGFR (excitation at 488 nm and 
emission 565-605 nm). (b) Brightfield images of the cells were also captured, and the (c) overlap 
was performed demonstrating surface binding. 
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Figure 4.3: Cellular binding and uptake of antibody-coated MGNs by MDA-MB-231 cells. (a) 
Transmission electron micrographs of cells incubated with antiEGFR-pMBA-MGNs for 16 h 
show both (a) surface binding and (b) internalization by cells. Arrows denote organelles (blue = 
nucleus, white = mitochondria) with MGNs present in cytoplasm (red). (c-e) High magnification 
images show internalization occurs via intracellular vesicles ranging ~400-500 nm in size. Both 
on the surface and within these vesicles, the MGNs maintain their morphology. 
 
Once EGFR was demonstrated to be a valid target, we performed SERS imaging 
targeting the EGFR biomarker on MDA-MB-231 cells. Cells were cultured on 6-well plate 
dishes to ~90 % confluency, followed by incubation with antiEGFR-pMBA-MGNs (170 µg/mL) 
for 16 h at 37 °C and repeated washing. After fixation, cells were visualized in TEM to confirm 
surface binding and internalization of MGNs. The functionalized MGNs were both localized on 
the surface (Figure 4.3a) and internalized within (Figure 4.3b) the cells. MGNs were also found 
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in cytoplasmic vesicles, demonstrating endocytosis (Figure 4.3c-4.3e). We also note that MGNs 
maintained their structural integrity in cells and that they were not found within the nucleus or 
mitochondria, which is in agreement with what has previously been reported.[49, 50] 
 
Figure 4.4: SERS singleplex mapping of MDA-MB-231 cells with antiEGFR-pMBA-MGNs. (a) 
Brightfield image of cells after 16 h incubation with antiEGFR-pMBA-MGNs provides 
coordinates for Raman map. (b) Spatial Raman intensity map of the 1580 cm-1 peak 
corresponding to pMBA, with spectra recorded at 0.75 µm steps for the rectangular area in (a). 
(c) Selected SERS spectra corresponding to indicated points on SERS map in (b) representing (i) 
high or (ii) low pMBA signal as well as (iii) no signal or cell response. Arrow denotes 1580 cm-1 
peak of interest for pMBA. (d) Overlap of (a) and (b) showing direct correlation between SERS 
map and the localization of the MGNs. 
 
The targeted SERS mapping of MDA-MB-231 cells was performed by growing the cells 
on calcium fluoride (CaF2) disks to minimize autofluorescence, thus enabling higher resolution 
SERS mapping. Cells were incubated with antiEGFR-pMBA-MGNs (170 µg/mL) for 16 h at 37 
°C followed by repeated washing, fixation, and imaging with a Raman microscope. The bright 
spots in the brightfield confocal image (Figure 4.4a) show scattering from MGNs localization on 
the cell surface. The rectangular area of the brightfield image provides the x and y coordinates 
for the SERS mapping. The Raman spectra of the cells were collected at 0.75 µm steps, 
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providing a biochemical “traffic map” of the cells in the area. Static spectra were recorded with a 
1200 cm-1 center with 10 s acquisition times at 2 mW power. Raman intensity of the 1580 cm-1 
peak, which corresponds to the C-C stretching modes and ring stretching modes of pMBA, was 
plotted as a function of position after analysis and background subtraction creating a ~100 µm x 
100 µm SERS map (Figure 4.4b). The 1580 cm-1 peak of pMBA does not overlap with Raman 
peaks of intracellular lipid and provides an accurate means to demonstrate localization of 
antiEGFR-pMBA-MGNs by examining the intensity. SERS point spectra were collected from 
the SERS map at selected locations indicating high (Figure 4.4c-i), low (4.4c-ii), and no pMBA 
signals (4.4c-iii) which directly correspond to the amount of antiEGFR-pMBA-MGNs localized 
in and on the surface of the cells. The intense SERS signal in areas with high concentration of 
MGNs arises from the formation of SERS hot spots where strong electromagnetic and chemical 
enhancements occur.[51-53] Further, the brightfield image overlapped with the SERS map 
(Figure 4.4d) shows excellent correlation with the MGNs distribution demonstrating the efficacy 
of SERS in targeted imaging of the EGFR biomarker in TNBC cells. We also performed control 
studies where MGNs conjugated to pMBA without antibodies (pMBA-MGNs) at the same 
condition and concentration were incubated in MDA-MB-231 cells on CaF2 disks, and SERS 
maps were obtained (Figure 4.5). The relatively weak Raman signal observable in these control 
experiments suggests that highly specific detection of EGFR is achieved only by MGNs labeled 
with the targeting antibodies.  
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Figure 4.5: SERS singleplex mapping of MDA MB 231 cells with pMBA-MGNs. (a) Brightfield 
image of cells after 16 h incubation with pMBA-MGNs provides coordinates for Raman map. (b) 
Spatial Raman intensity map of the 1580 cm-1 peak corresponding to pMBA, with spectra 
recorded at 0.75 µm steps for the rectangular area in (a). (c) Overlap of (a) brightfield and (b) 
SERS map demonstrating low signal and minor surface binding of MGNs lacking targeting 
antibody. 
 
The immune checkpoint receptor PD-1 and its ligand PD-L1 have been shown to be 
overexpressed in many sub-types of breast cancer including in MDA-MB-231 TNBC cells.[34-
36] Immunotherapies with checkpoint blockade have already demonstrated tremendous success 
in multiple cancers and are now in clinical trials.[46, 54, 55] Therefore, multiplexed targeted 
detection of PD-L1 combined with EGFR offers a transformational approach to ultimately 
impact personalized immunotherapies. We performed multiplexed SERS imaging by 
simultaneously incubating cells with a mixture of antiPDL1-DTNB-MGNs and antiEGFR-
pMBA-MGNs in a 1:1 ratio (refer to Methods). Because the vibrational signature of DTNB and  
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Figure 4.6: SERS multiplex mapping of MDA-MB-231cells with (1:1) mixture of antiEGFR-
pMBA-MGNs to antiPDL1-DTNB-MGNs. (a) Brightfield image of cells after 16 h incubation 
provides coordinates for multiplex Raman map. (b) Overlap of spatial Raman intensity maps of 
both 1325 cm-1 peak for DTNB and 1580 cm-1 peak for pMBA, recorded at 0.75 µm steps. (c) 
Magnified view of the blue rectangular area from “b” shows Raman intensity plot of both 
ISERS1325 and ISERS1580 indicating a cellular “traffic map” with various points selected (d) 
demonstrating (i) signal from both probes, (ii) DTNB alone, (iii) pMBA alone, and (iv) no signal 
from probes or intracellular lipids (dashed box). Arrows denote peaks of interest, 1325 cm-1 peak 
for DTNB and 1580 cm-1 peak for pMBA. 
 
pMBA do not overlap, this approach allows us to detect both PD-L1 and EGFR by mapping the 
signal of DTNB (1325 cm-1) and pMBA (1580 cm-1) respectively. Brightfield image (Figure 
4.6a) shows an image of cells with light scattering from MGNS localized on cell surface. A 
Raman spectral map of ~100 µm x 100 µm was measured with 0.75 µm steps, and the intensity 
of 1325-1 peak (ISERS1325) and 1580 cm-1 peak (ISERS1580) was plotted together as a function of 
position (Figure 4.6b). Strong signal is observable from both DTNB and pMBA, and the high 
spatiotemporal resolution of Raman allows us to qualitatively evaluate the localization of 
individual receptor bound MGNs. The intensities of the 1325 cm-1 peak and of the 1580 cm-1 
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peak are plotted individually (Figure 4.7a, 4.7c) and overlapped (4.7b) as a function of position. 
A magnified view of local traffic map of multiplexed SERS footprint is shown in Figure 4.6c 
correlating the distribution of PD-L1 and EGFR in the cells. Note that strong signal is observed 
where multiple MGNs cluster giving rise to SERS enhancements via hot spots. Specific locations 
on the magnified SERS map (Figure 4.6c) and corresponding SERS spectra (Figure 4.6d) 
indicate spatial localization from both probes (Figure 4.6d-i), DTNB alone (4.6d-ii), pMBA 
alone (4.6d-iii), or signal only from cellular lipids at 1440 cm-1 (4.6d-iv).[56] We note that the 
intrinsic Raman peaks of biological lipids are typically very weak, necessitating the use of 
labeled MGNs for characterizing receptor expression. 
 
Figure 4.7: SERS multiplex mapping of MDA MB 231 cells with (1:1) mixture (antiEGFR-
pMBA-MGNs to antiPDL1-DTNB-MGNs) additional plots. After 16 h incubation with (1:1) 
cocktail, spatial Raman intensity maps of (a) 1325 cm-1 peak for DTNB and (c) 1580 cm-1 peak 
for pMBA were recorded at 0.75 µm steps. Coordinates for map were provided by brightfield 
image from Fig. 4a and the (b) overlap of “a” and “c” with the brightfield shows localization of 
the mixture of antibody labeled MGNs on the surface. 
 
Further, to demonstrate that the observed Raman signal results from specific binding of 
antibody-conjugated MGNs rather than due to clustering via non-specific binding, we performed 
a control study where 4 µg/mL monoclonal antiPDL1 (1 h, 37 °C) was introduced in cells to 
block the PD-L1 receptors prior to incubating with a 1:1 mixture of antiPDL1-DTNB-MGNs and 
antiEGFR-pMBA-MGNs (170 µg/mL). The brightfield image of the cells (Figure 4.8a) as well 
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as a SERS map (Figure 4.8b) at every 0.75 µm step indicated that the blocking of receptors 
results in significantly fewer MGNs binding to cells (Figure 4.8c). The multiplexed SERS 
“traffic map” presented for the experimental group (Figure 4.6b) and control group (Figure 4.8b) 
demonstrate that MGNs are both sensitive and specific in detecting biomarkers of cancer when 
conjugated with targeting moieties. In addition, SERS imaging provides a qualitative assessment 
of the distribution of both biomarkers in the cellular environment. We note that due to the 
possible co-localization of EGFR and PD-L1 on the cell surfaces, a quantitative evaluation of the 
distribution of these receptors with SERS maps would be more challenging and would require 
sub-10 nm resolution. This technology has the potential to move into in vivo tissue models and 
determine the volume detection of receptors on a tumor sample, which could be utilized in the 
determination of candidacy for certain individualized medicine movement.[54, 55, 57]  
116		
 
Figure 4.8: Blocking PD-L1 SERS multiplex mapping of MDA MB 231 cells with (1:1) mixture 
(antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs). Cells were pre-blocked with monoclonal 
antiPDL1 for 1 h. (a) Brightfield image of cells after 16h incubation with (1:1) mixture provides 
coordinates for multiplex Raman map. (b) Overlap of spatial Raman intensity maps of both 
ISERS1325 for DTNB and ISERS1580 for pMBA recorded at 0.75 µm steps. (c) Overlap of brightfield 
and SERS map (both ISERS1325 and ISERS1580) to compare the effects of blocking on surface 
binding. 
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Figure 4.9: Live phase contrast images of (a) MDA-MB-231 breast cancer cells without any 
MGNs, (b) after 16 h of incubation with antiEGFR-pMBA-MGNs, and (c) after 16 h of 
incubation with pMBA-MGNs without antibodies. (d) Phase contrast images of control breast 
cancer cell line MCF7 (d) without any MGNs, (e) after incubation with antiEGFR-pMBA-
MGNs, and (f) after incubation with pMBA-MGNs without antibodies, with incubation times 
also 16 h durations.  
 
Antibody-conjugated theranostic MGNs not only enable high resolution cellular mapping 
of cancer cells, they are ideal for inducing targeted cell death via photothermal therapy (PTT). 
We incubated MDA-MB-231 cells with antiEGFR-pMBA-MGNs and also performed control 
experiments where MGNs without antibodies (pMBA-MGNs) were utilized. Phase contrast 
images before (Figure 4.9a) and after incubating with MGNs demonstrated that cells incubated 
with antiEGFR-pMBA-MGNs (Figure 4.9b) at 170 µg/mL for 16 h at 37 °C had a higher 
receptor-specific uptake relative to cells that were incubated with pMBA-MGNs without any 
antibodies (Figure 4.9c). We note that both antibody conjugated MGNs and MGNs without 
antibodies were functionalized with a final layer of PEG to minimize cellular toxicity and non-
specific binding. This concentration of 170 µg/mL MGNs was measured by thermogravimetric 
analysis[15, 58] (TGA) and was determined to be appropriate for enabling MGNs to be localized 
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on the cell surface and achieve the necessary temperature increase to allow photothermal 
therapy.[59] As a result, this MGN concentration was utilized throughout this study.  
The increased uptake of antiEGFR-pMBA-MGNs in cells clearly shows that (i) EGFR 
receptors are overexpressed in MDA-MB-231 cells as supported by our florescence assay in 
Figure 4.2, (ii) active targeting of MGNs is enabled likely by both surface-bound receptors and 
receptor-mediated endocytosis,[60-63] and (iii) MGNs without antibodies have a low passive 
uptake in cells within 16 h of incubation.[60, 64] To further demonstrate the efficacy of MGNs 
in specifically targeting EGFR-overexpressing breast cancer cells, MCF7 was chosen as a 
control cell line, due to its very low EGFR expression.[65, 66] Unlike the spindle morphology of 
the MDA-MB-231 cells, these MCF7 cells have more of a brick-shaped morphology and tend to 
grow in closer proximity to one another (Figure 4.9d). Phase contrast images clearly 
demonstrated that MGNs are not bound to cells either via active targeting (Figure 4.9e) or via 
passive uptake (Figure 4.9f) demonstrating that antiEGFR conjugated MGNs are ideal for 
achieving highly specific and sensitive PTT with minimal off-target cell death. We note that the 
morphology of both cell lines is unchanged in the presence of the MGNs and that no cytotoxic 
effects were observable.   
119		
 
Figure 4.10: Confocal fluorescence images of live cells stained with Calcein-AM (Green) and 
dead cells stained by propidium iodide (Red) showing cell death via photothermal therapy 4 h 
post illumination with an 808 nm laser, 2 x 2 mm spot size, and 4.7 W/cm2 pump fluence.  
Localized cell death was only observed with (a) antiEGFR-pMBA-MGNs, and no cell death was 
observed with (b) pMBA-MGNs. No cell death was observed for the control MCF7 cells with (c) 
antiEGFR-pMBA-MGNs, and (d) pMBA-MGNs. Note: The necrotic cells are only found within 
the laser spot. 
 
Photothermal therapy was performed in both MDA-MB-231 cells and control, MCF7, 
cells with antiEGFR-pMBA-MGNs and pMBA-MGNs (Figure 4.10). The plasmon resonance of 
the antiEGFR-pMBA-MGNs was tuned to overlap with an 808 nm diode laser utilized for PTT, 
and the concentration of nanoparticles utilized was analogous to that used in SERS 
measurements (170 µg/mL). All culture dishes were illuminated for 15 min with the 808 nm 
laser at 4.7 W/cm2 with a spot size of ~2 mm x 2 mm. A live/dead cell assay with 
calcein/propidium iodide stains clearly demonstrated that site-specific necrotic cell death was 
only observable when EGFR overexpressing MDA-MB-231 cells were incubated with antiEGFR 
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conjugated MGNs and illuminated with laser (Figure 4.10a). Cells incubated with pMBA-MGNs 
(no antibodies) showed no observable cell death due to the low passive uptake of MGNs in cells 
(Figure 4.10b). Control experiments with EGFR low-expressing MCF7 cells also demonstrated 
no cell death with both antiEGFR-pMBA-MGNs (Figure 4.10c) and pMBA-MGNs (Figure 
4.10d). PTT with antibody conjugated MGNs demonstrates that active targeting enables higher 
cellular accumulation, minimal non-specific binding and off-site toxicities, and a highly specific 
and sensitive spatiotemporal control of cell death externally triggered with low near-infrared 
laser powers. Our control experiments also show that the 808 nm laser alone did not induce any 
cell death (Figure 4.11a), and in the absence of laser, the antiEGFR-pMBA-MGNs were not 
cytotoxic to the cells (Figure 4.11b). 
 
Figure 4.11: Photothermal therapy control assays, laser alone and antiEGFR-pMBA-MGNs 
alone. Confocal fluorescence images with live/dead cell stain (calcein AM/propidium iodide) 
showing no cell death in the MDA MB 231 cultures due to unwanted effects. (a) No observable 
cell death was detected when the 231 cells were illuminated in the absence of antiEGFR-pMBA-
MGNs. (b) Further the antiEGFR-pMBA-MGNs were not toxic to the cells following 16 h of 
incubation and repeated washing. 
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Figure 4.12: Longitudinal multiplex SERS imaging in vivo with actively targeted MGNs, and the 
effect of receptor blockage. (a) Portable SERS imaging system with maneuverable hand-held 
probe allowed for fast, non-invasive SERS measurements on the surface of the Human 
xenografts (MDA MB 231) growing in athymic mouse. Readings were monitored before and at 
time intervals after retro-obrital injection of the mixture of (antiEGFR-pMBA-MGNs to 
antiPDL1-DTNB-MGNs). (b) The appearance of the 1325 cm-1 peak for DTNB and 1580 cm-1 
peak for pMBA can be observed after 6 h. (c) Longitudinal studies were performed monitoring 
the signal of the two SERS probes for an experimental group and a control receptor blocked 
group of mice. The control group was pre-blocked with both antiEGFR and antiPDL1 through 
intraperitoneal injection 2 h prior to injection of MGNs. Raman intensity for both the 1325 cm-1 
peak for DTNB and 1580 cm-1 peak for pMBA were normalized to the 1440 cm-1 lipid peak after 
smoothing and background subtraction. A ~30% drop in signal is observed due to the receptor 
blockage on the surface of the tumor. n=4 for each group subset.  
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After demonstrating that the mixture of antibody coated MGNs were capable of 
distinguishing two separate targets on the cellular level, we next investigated the performance of 
the cocktail of antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs in vivo utilizing human 
xenograft models in athymic nude mice. Theranostic gold nanoparticles are attracting interest for 
in vivo applications because of their adaptability to offer combinational theranostics[12, 67, 68] 
or multi-modal imaging.[47, 69, 70] We moved our functionalized MGNs studies in vivo by 
growing MDA MB 231 breast cancer tumors in the mammary fat pad of the mouse, injecting 
cells in the subcutaneous layer for tumor growth. The mixture was injected at 2:1 antiEGFR-
pMBA-MGNs to antiPDL1-DTNB-MGNs for the in vivo  and ex vivo studies due to the intense 
SERS signal  of DTNB at the [MGNs] concentrations used for these studies.[47, 71] Using a 
portable SERS imaging system and a handheld probe, a longitudinal study was performed on the 
mouse subjects over 72 h time course, measuring the intensity of the two SERS tags of the 
functionalized MGNs (Figure 4.12a).  At the site of the tumor, non-invasive, topical 
measurements were acquired before and at time intervals after retro-obrital injection. The 
appearance of the 1325 cm-1 peak for DTNB and 1580 cm-1 peak for pMBA are observed after 6 
h as indicated by the arrows in Figure 4.12b. After background subtraction and normalizing to an 
endogenous peak of the tumor tissue (lipid, 1440 cm-1), the SERS intensity was plotted for both 
the DTNB and pMBA peaks with maximum SERS intensity occurring at 6 h post retro-orbital 
injection (Figure 4.12c). Further, the active targeting capabilities of the antibody coated MGNs 
were investigated by having a control group study that was pre-blocked with antiEGFR and 
antiPDL1 monoclonal antibodies through intraperitoneal injection, 2 h prior to MGN injection. A 
drop in SERS signal of ~30% was observed due to the receptor blockage on the surface of the 
tumor (Figure 4.12c). Thus, the antibody coated MGNs not only have the multiplex ability to 
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detect two receptors simultaneously in vivo, the targeting capabilities ensure site specificity and 
avoidance of off-target accumulation as well. 
For further analysis and to demonstrate the spatial resolution of the SERS imaging 
technology, ex vivo experiments were performed on the xenograft tumors post removal at 6 h 
after actively targeted MGNs injection (2:1 mixture). The tumor was removed from the mouse, 
frozen, and sectioned for imaging. Bright-widefield imaging of silver stained tissue section from 
mammary fat pad tumor showed antibody coated MGNs accumulation as indicated by the white 
arrows in Figure 4.13a. A control tumor section silver stained, which had no MGNs injected into 
the mouse was also captured (Figure 4.13b). Side by side visualization confirmed presence of 
actively targeted MGNs at 6 h post injection. Additionally, vasculature and tissue morphology 
were not modified by MGN injection and accumulation as seen by side by side comparison of 
tumors both with and without actively targeted MGNs added respectfully (Figure  4.13c-4.13d). 
 Lastly, a spatial SERS map of the tumor cross-section was collected, 6 h post injection 
with actively targeted MGNs. Brightfield micrograph of tumor slice provided x and y 
coordinates for SERS mapping of tissue cross-section (Figure 4.13e). Acquiring Raman chemical 
footprints at 50 µm steps, the rectangular area in Figure 4.13e was measured, followed by Direct 
Classical Least Squares (DCLS) component mapping of the 1325 cm-1 peak corresponding to 
DTNB of the antiPDL1-DTNB-MGNs (Figure 4.13f). DCLS utilizes characteristics of the peak 
geometry as parameters to determine similarity for spectra in a large dataset. As seen by Figure 
4.13f, signal was localized on the periphery of the tumor cross section where more vasculature is 
concentrated when comparing to necrotic core. This ability to monitor and trace surface receptor 
coverages through MGNs enhanced tags is a prime advantage of SERS spectroscopy because of 
its combination of multiplex technology with high spatiotemporal resolution. 
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Figure 4.13: Ex vivo analysis and SERS spatial mapping of MDA MB 231 tumors after excision 
from mice injected with actively targeted MGNs. Tumor removed from mouse at maximum 
SERS signal (max accumulation), 6 h post retro-orbital injection with actively targeted MGNs. 
(a) Bright-widefield imaging of silver stained tissue section from mammary fat pad tumor 
(human xenograft). White arrows indicate MGNs accumulation. (b) For comparison, also 
provided is a control tumor slice silver stained, which had no MGNs injected to the mouse. (c-d) 
Images of tumor sections for Histology (H and E) staining for side by side comparison of +/- 
actively targeted MGN addition, also visualized with bright-widefield microscopy. (e-f) Ex vivo 
SERS spatial mapping of tumor section from tumor removed 6 h post injection with actively 
targeted MGNs. (e) Brightfield image of tumor tissue slice provides coordinates for Raman map. 
(f) Spatial Raman map demonstrating the Direct Classical Least Squares (DCLS) component 
analysis of the 1325 cm-1 peak corresponding to DTNB of the antiPDL1-DTNB-MGNs 
incorporated in the cocktail MGN injection. Spectra recorded at 50 µm steps for the rectangular 
area in (e). 
 
4.4 Conclusions 
Overall in this work, we demonstrate the theranostic capabilities of MGNs conjugated 
with antibodies and Raman tags in vitro and in vivo by combining multiplexed diagnosis of 
biomarkers EGFR and PD-L1 in triple negative breast cancer cells via SERS followed by 
photothermal therapy in the cellular studies. The strong SERS signal enabled by both 
electromagnetic and chemical enhancement by MGNs, as well as the narrow vibrational 
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signatures of Raman allowed us to create cellular “traffic maps” facilitating highly sensitive and 
specific detection of both biomarkers. In addition, the SERS enhancement allowed for the 
detection of the MGN probes amidst all of the signal from biological tissue in vivo, and the 
blocking study revealed the active targeting advantage of the antibody coated MGNs. Further, 
the nanoantenna effect with MGNs gives rise to enhanced light-to-heat conversion when 
illuminated with a near-infrared light and subsequent photothermal cell death only within the 
laser spot, avoiding off-target toxicities. We envision this work will not only impact the design 
of new theranostic nanoprobes capable of imaging multiple biomarkers of cancer and light-
controlled therapeutic response but also provide an avenue to diagnose TNBC tumors that 
typically do not respond to endocrine and targeted treatments. Further, the successful detection 
of immune checkpoint ligand PD-L1 will ultimately enable theranostic MGNs to provide a 
quantitative measure of immunomarkers and allow predictive, personalized image-guided 
immunotherapies with minimal toxicity.[54, 55, 57] 
 
4.5 Methods 
A. MGN Synthesis. Reagents purchased from Sigma-Aldrich include both (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) (HEPES) and gold(III) chloride trihydrate (HAuCl4) for MGN 
synthesis. For functionalization, Raman tags 4-mercaptobenzoic acid (pMBA) and 5,5’-
Dithiobis(2-nitrobenzoic acid) (DTNB) were purchased from TCI America with methoxy- 
polyethlyene glycol-thiol (mPEG-SH, Mw 5000 g/mol, Jenkem Technology) obtained for particle 
surface passivation. Lastly, for sterile aqueous buffers, sodium bicarbonate (NaHCO3, Acros 
Organics) and sodium phosphate dibasic (Na2HPO4, Fisher Scientific) were utilized for linker 
chemistry and particle resuspension, respectively.   
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 The following chemistry was scaled for 60 mL batches of the three types of particles used 
in the study: antiEGFR-pMBA-MGNs, antiPDL1-DTNB-MGNs, and pMBA-MGNs. The 
process could be scaled up or down depending on yield requirements by modifying volumes, but 
the number of centrifuge spins and centrifuge speeds should be maintained. Also, maintaining a 
cold temperature for the functionalized MGNs prevents aggregation over the course of the 
synthesis process and keeps the particles stable. Lastly, mixing by vortexing should be avoided 
during the chemistry and be replaced by mixing through inversion, pipetting, and stir plate as 
noted over the course of the procedure.  
 MGNs were synthesized through the seedless, one-step HEPES growth protocol, as 
previously described.[15, 59, 72] A scaled up 60 mL batch of MGNs was prepared by 
synthesizing two 30 mL batches simultaneously and combining after the reaction reached 
completion. Briefly, 18 mL of Milli-Q water (18 MΩ) was added to 12 ml 200 mM HEPES (pH 
7.40 ± 0.1), mixing by gentle inversion. Quickly, 300 µl of 20 mM tetrachloroauric(III) acid 
(HAuCl4) was added, again mixing my inversion and leaving to react at room temperature for 75 
minutes. Plasmon resonance of the MGNs, through the functionalization process, was monitored 
using UV-vis spectroscopy with optimal initial resonance of the solution phase MGNs at 780 ± 
10 nm. This resonance is best because of its spectral overlap with the 785 nm laser utilized for 
Surface Enhanced Raman Spectroscopy (SERS) and the 808 nm laser used for photothermal 
therapy (PTT).  
B. OPSS-PEG-NHS Ester Chemistry with Antibody.  
OPSS-PEG-antiEGFR: Orthopyridyl-disulfide poly(ethylene glycol)-N-hydroxysuccinimide 
ester (OPSS-PEG-NHS ester, Mw 2000 g/mol, JenKem Technology) and Human EGF R/ErbB1 
antibody (antiEGFR, R & D Systems) were purchased in lyophilized forms. Chemistry to form 
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the amide linkage from the ester group of OPSS-PEG-NHS with amine groups on the antibody 
structure was modified and troubleshooted from previously reported methods.[71, 73, 74] OPSS-
PEG-NHS was resuspended in 100 mM pH 8.6 ± 0.1 Sodium Bicarbonate (NaHCO3) buffer to a 
concentration of 160 mg/mL, only immediately prior to reaction with antiEGFR as the ester is 
sensitive to water hydrolysis. Also reconstituted in 100 mM NaHCO3 (pH 8.6 ± 0.1) buffer, the 
antiEGFR protein was prepared at a concentration of 1 mg/mL. The higher pH bicarbonate 
buffer is used for the OPSS-antibody reaction as the amide reaction is favored at higher pH.[75-
77] Preparing on ice as to prevent protein aggregation, the 160 mg/mL OPSS-PEGS-NHS 
solution was added at a (1:9) volumetric ratio[74] to the 1 mg/mL antiEGFR. For scaling, 
specifically the 60 mL antiEGFR-pMBA-MGNs batch required an 80 µL OPSS-PEG-antiEGFR 
reaction. After ensuring OPSS-PEG-NHS was completely resuspended through pipetting, 8 µL 
of 160 mg/mL OPSS-PEG-NHS was added to 72 µL of 1 mg/mL antiEGFR, mixed, and left to 
react for 24 h on an inverter at 4 °C. 
OPSS-PEG-antiPDL1: Human CD274 (B7-H1, PD-L1) antibody (antiPDL1, BioLegend) was 
acquired from BioLegend already resuspended at 1 mg/mL stock in phosphate-buffered solution, 
pH 7.2. The OPSS-PEG-antiPDL1 reaction was prepared in the same manner as the OPSS-PEG-
antiEGFR reaction and then further diluted 5-fold with 100 mM NaHCO3 (pH 8.6 ± 0.1) buffer 
to ensure that the linker-antibody reaction occurred at the favorable pH 8.6. Thus, the 80 uL 
reaction, 8 µL of 160 mg/mL OPSS-PEG-NHS to 72 µL of 1 mg/mL antiPDL1, was prepared 
and then diluted to 400 µL. Reaction was also mixed by pipetting and left to react for 24 h on an 
inverter at 4 °C.  
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C. Synthesis of Actively Targeted (Antibody) MGNs (antiEGFR-pMBA-MGNs and 
antiPDL1- DTNB-MGNs). 
Quantification of MGNs and Calculations for Determining Concentration and Scalability: At 
points during the functionalization process, a known quantity of MGNs was required to allow for 
proper labelling efficiencies. To determine MGN concentration, an equation was developed from 
previous Thermogravimetic Analyzer[15, 58] and UV-vis spectroscopy side by side, correlative 
studies (Equation 4.1). Extinction spectra of MGNs was recorded with a 1 cm pathlength cuvette 
at 60-fold dilution. A simultaneous thermogravimetric analyzer (TGA) study was performed on 
the same sample to quantify mass of MGNs per volume. Refer to previously shown 
Thermogravimetric data in Chapter 2, Figure 2.9. The following equation was utilized for 
synthesis and scaling: 
  𝑀𝐺𝑁 $%$& = (.*+	$%$- × /0123412536.78 × 92-:1253	;<415=7>          (4.1) 
Equation 4.1 assumes Beers law applies and that the extinction is linearly related to 
concentration (mg/ml).[78, 79] From a large multitude of synthesis replicates, the tendency of 
linearity between the concentration of MGNs and extinction has been verified by repeated 
agreement with mathematical calculations. Equation was utilized in calculations for all 
functionalized MGN chemistries.	
antiEGFR-pMBA-MGNs: Again, functionalization chemistry was monitored for shifts in 
plasmon resonance due to phase retardation effects from the change in immediate local refractive 
index due to the layering around the MGNs.[41-43] To begin, 60 mL MGNs at 170 µg/mL (Ext. 
= 1.79) at max plasmon resonance ~780 nm in the NIR region were synthesized. Ideal for 
nanomedicine work because of the weak absorption by biological tissue and proteins, MGN 
resonance in this regime allows for better penetration depth during therapy for future in vivo 
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studies.[80] MGNs were kept on ice through functionalization process. 4-mercaptobenzoic acid 
(pMBA), dissolved in 100 % ethanol, was added to the MGNs in a small volume with high 
concentration, adapting from previous methods for SERS-tag labelling to gold nanoparticles.[71, 
81-83] With slow stirring, 6 µL of 10 mM pMBA was injected to 60 mL of MGNs, mixing for 
10 min at 4 0C and monitoring the shift in resonance due to the binding event via thiol linkage. 
Next, the 60 mL was split into 20 mL aliquots (x3), and centrifuged at 6000 rpm for 20 min. 
Supernatant was completely decanted to remove any unbound pMBA, and pellets were 
combined in 3 mL total volume with Milli-Q (MQ) water. The resonance and concentration were 
again recorded, and the functionalized MGNs were further diluted to 1.14 mg/mL (Ext. = 12.0) 
with Milli-Q water for a total volume of 6.5 mL of particles.  
Chemistry ratio for OPSS-PEG-antibody to SERS-tag-MGNs was modified and 
troubleshooted from other literature methods.[73, 74, 77, 84] Briefly, 80 µL of OPSS-PEG-
antiEGFR reaction ([antiEGFR]Final = 0.9 mg/mL) was added to 5.95 mL pMBA-labeled-MGNs 
at 1.14 mg/mL (Ext. = 12.0), pipetting to mix. Antibody with MGNs reaction was then left to 
react for 24 h on an inverter at 4 C. Post 24 h incubation, PEGylation chemistry[59, 85, 86] was 
performed to passivate any free surface area to negate charge effects by the antiEGFR-pMBA-
MGNs. To the aqueous MGNs mixture, 700 µL of 5 µM polyethlyene glycol-thiol (mPEG-SH, 
Mw 5000 g/mol) was added in a cold reaction vessel and slowly stirred for 10 min at room 
temperature. The ~6.75 mL volume was split into 2.25 mL aliquots (x3) and filled to 4.5 mL 
volumes with Milli-Q water, mixing by inversion to wash any unbound OPSS-PEG-NHS or 
mPEG-SH. Particles were then centrifuged at 4000 rpm for 10 min, and supernatant was 
completely removed under sterile conditions. Pellets were resuspended in 200 µL of sterile 8.6 
mM pH 7.40 ± 0.1 (Na2HPO4) monophosphate buffer, with resonance and concentration again 
130		
measured. If necessary, dilute final [antiEGFR-pMBA-MGNs] with the sterile monophosphate 
buffer to 5 mg/mL, rechecking concentration. For cellular assays, functionalized MGNs were 
further diluted to 170 µg/mL with normal media (no FBS) as this concentration was previously 
shown to have strong SERS and photothermal activity.[15, 59]  
antiPDL1-DTNB-MGNs: To synthesize the complementary MGNs particles, the 
functionalization method was repeated with similar steps but substituting antiPDL1 as the 
targeting moiety and 5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB) as the SERS tag. Slight 
modification in method was due to the 5-fold dilution of the OPSS-PEG-antiPDL1 reaction to 
obtain a higher pH. An initial 60 mL MGNs at 170 µg/mL (Ext. = 1.79), plasmon resonance 
~780 nm, was again synthesized. With slow stirring, 6 µL of 10 mM DTNB was added to 60 mL 
of MGNs reacting for 10 min at 4 °C. After centrifugation and resuspension with MQ water to 
1.14 mg/mL (Ext. = 12.0) for a total volume of 6.5 mL of particles, the antiPDL1 targeting 
moiety was added to the MGN solution. Pipetting to mix, 400 µL of OPSS-PEG-antiPDL1 
reaction ([antiPDL1]Final = 0.18 mg/mL) was added to 5.95 mL DTNB-labeled-MGNs at 1.14 
mg/mL (Ext. = 12.0). The reaction was again left to react for 24 h at 4 °C on inverter. The final 
PEGylation, wash, centrifugation, and sterile resuspensions steps were the same for antiPDL1-
DTNB-MGNs as for the antiEGFR-pMBA-MGNs. After resuspending in 200 µL of sterile 8.6 
mM Na2HPO4 pH 7.40 ± 0.1, resonance and concentration were recorded, and dilution to 5 
mg/mL was performed if necessary. antiPDL1-DTNB-MGNs were also incorporated in normal 
media (no FBS) for cellular assays. 
(1:1) cocktail prep of antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs: In preparing a (1:1) 
mixture of the two types of antibody-labeled MGNs, a 60 mL batch of each of the respective 
particle was prepared. After final resuspension steps in sterile 8.6 mM Na2HPO4 pH 7.40 ± 0.1, 
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the resonance and concentration of the two antibody-labeled MGNs were determined 
respectively. Each solution was diluted to 5 mg/mL. Then the antiEGFR-pMBA-MGNs were 
mixed at an equivalent (1:1) volumetric ratio with the antiPDL1-DTNB-MGNs, assuming there 
was no change in the overall MGNs concentration. Plasmon resonance and concentration of the 
(1:1) cocktail were measured, and the particles were diluted in normal media (no FBS) to 170 
µg/mL with equal volumetric ratio. 
D. Synthesis of MGNs lacking Targeting Moiety (pMBA-MGNs). MGNs without targeting 
moiety, but SERS tag and PEG bound, pMBA-MGNs, were synthesized via modified version of 
previous procedures.[59, 85, 86] With slow stirring, 6 µL of 10 mM 4-mercaptobenzoic acid 
(pMBA) was added to 60 mL of MGNs (170 µg/mL (Ext. = 1.79), resonance ~780 nm) reacting 
for 10 min at 4 °C. Next, 6 mL of 50 µM polyethlyene glycol-thiol (mPEG-SH, Mw 5000 g/mol) 
was added on ice, incubating for 5 min, before splitting to 20 mL aliquots (x3), and centrifuging 
at 6000 rpm for 20 min. Excess pMBA and PEG were removed by full decanting, and pellets 
were combined in 3 mL total volume with Milli-Q (MQ) water. Plasmon resonance and 
concentration were again recorded, and the functionalized MGNs were diluted to 1.14 mg/mL 
(Ext. = 12.0) with MQ water for a total volume of 6.5 mL of particles. To be certain of surface 
neutrality of the pMBA-MGNs, a second addition of mPEG-SH was performed. To the aqueous 
5.95 mL pMBA-labeled-MGNs at 1.14 mg/mL (Ext. = 12.0), 200 µl of 5 µM mPEG-SH was 
added in a cold vessel for 10 minutes with constant stirring at room temperature. Next, the ~6 
mL volume was split into 2 mL aliquots (x3) and filled to 4 mL volumes with Milli-Q water. The 
particles were mixed by inversion for washing, followed by centrifuging at 4000 rpm for 10 min 
to remove excess pMBA or PEG. Sterile decanting was again performed with complete removal 
of the supernatant followed by resuspension in 200 µL of sterile 8.6 mM pH 7.40 ± 0.1 
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(Na2HPO4) monophosphate buffer. Concentration and final resonance of the pMBA-MGNs were 
quantified, diluting to 5 mg/mL if necessary. pMBA-MGNs were also maintained at 170 µg/mL 
with normal media (no FBS) for cellular assays. 
E. Characterization of Antibody-Labelled MGNs. To monitor the functionalization process of 
the MGNs and to characterize their optical properties, several spectroscopy techniques were 
measured both before after functionalization with antibodies, Raman tag, and PEG (denoted 
antibody-tag-MGNs). Both MGNs and antibody-tag-MGNs were imaged with an Osiris 
transmission electron microscope (TEM) at 200 keV to ensure the proper morphology and 
functionalization of the particles. Further, a Varian Cary 5000 UV-vis NIR spectrophotometer 
(Agilent Technologies) was used to measure the extinction and plasmon resonance of the MGNs 
using a 1 cm path length cuvette. Lastly, Raman spectroscopy of the particles was recorded to 
observe relative labeling efficiency of the Raman tag and to ensure that the antibody was bound 
to the MGNs via the OPSS-PEG-NHS linker chemistry. After the completion of synthesis and 
functionalization chemistry, 20 µL droplets of 5 mg/mL of the antibody-tag-MGNs (3 different 
samples) were placed on plain glass slides and dried at room temperature for 1 h in the hood. 
Raman spectra of the solid state samples of antiEGFR-pMBA-MGNs, antiPDL1-DTNB-MGNs, 
and (1:1) mixture were recorded using an Invia Raman microscope (Renishaw) with a 785 nm 
wavelength laser source with 1200 lines/mm grating in high confocal mode. Static spectra (1200 
cm-1 center) were recorded using a 100x objective with a ~1 µm spot size at a power of 2 mW 
with a 10 s acquisition time. SERS footprint plotted after fluorescence and background 
subtraction, normalizing to tallest peak to show peak proximity and location for pMBA, DTNB, 
and their combination.  
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F. Fluorescent Secondary Antibody Assay Testing Epidermal Growth Factor Receptor 
Overexpression in MDA MB 231 cells. MDA-MB-231 cells, purchased from ATCC (HTB-26), 
were cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Gibco) supplemented with 10% 
fetal bovine serum (FBS, ATCC) and 1% penicillin/streptomycin (Gibco) and maintained at 37 
0C and 5% CO2. For optimal experimental design, cellular assays were performed only after 
allowing for 14 days of culture to ensure that the cells were in their native state, maintaining 
media changes every 2 days. MDA MB 231 cells were seeded on a 96-well plate, 12,500 cells 
per well, and allowed to grow to ~90 % confluency (48 h). Cells were then fixed with 
cytofix/cytoperm (BD Biosciences), incubating for 20 min at room temperature. Fixative was 
removed, and the cells were washed with MilliQ (MQ) water (x2). Next, the cells were blocked 
to prevent any non-specific binding by incubating with 1x animal free blocking solution (Cell 
Signaling Technology) for one h at 4 °C. Blocking solution was removed, following by washing 
with MQ water (x2). Cells were next incubated with Human EGF R/ErbB1 antibody 
(monoclonal mouse antiEGFR, R & D Systems, 100 µg/mL) diluted in 8.6 mM pH 7.40 ± 0.1 
(Na2HPO4) monophosphate buffer for 24 h at 4 °C. After 24 h, the cells were washed with 
monophosphate buffer (x2), and next incubated with secondary antibody (Mouse IgG2B PE-
conjugated, R & D Systems, 2 µg/mL) diluted in 8.6 mM pH 7.40 ± 0.1 (Na2HPO4) 
monophosphate buffer for 2 h at 4 °C. This secondary antibody is specific for the Fc region of 
the primary antiEGFR and is complexed with phycoerythrin (PE), a fluorescent protein with 
excitation at 488 nm and emission 565-605 nm. Again, the cells were washed with 
monophosphate buffer (x2) and then visualized under fluorescent microscopy using a Zeiss LSM 
710 confocal microscope, leaving in monophosphate buffer during imaging and storage at 4 °C. 
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G. Transmission Electron Microscope Imaging of Surface Binding and Uptake of 
Antibody-Labeled MGNs for MDA MB 231 Cells. Cells were again cultured for 14 days prior 
to experiment maintaining media changes every 2 days. While finishing antiEGFR-pMBA-MGN 
synthesis, 350,000 cells were seeded on 35 mm cell culture dishes, 48 h prior to day of 
experiment. After 48 h of growth, checking that the cells had a ~90 % confluent layer, new 
media (no FBS) supplemented with 170 µg/mL antiEGFR-pMBA-MGNs was added, and the 
cells were further incubated for another 16 h at 37 0C. Next, the cells were washed with 
cacodylate buffer before fixing in 2.5% gluteraldehyde in 0.1M cacodylate buffer at room 
temperature for 1 hour, followed by 4°C overnight. Sample processing and imaging was handled 
by the Vanderbilt Cell Imaging Shared Resource-Research Electron Microscope facility. 
Additional processing was performed to maintain cellular organelle structure. The 
samples were post-fixed in 1% osmium tetraoxide at room temperature then washed with 0.1M 
cacodylate buffer (x3). Post fixation, the samples were dehydrated through a graded ethanol 
series followed by incubation in 100% ethanol and propylene oxide (PO) with two exchanges of 
pure PO. Finally, cell samples were embedded in epoxy resin and polymerized at 60°C for 48 
hours. For thin section preparation, ultra-thin slices (70-80 nm) were cut from block and added to 
copper grids for imaging. The grids were further stained with 2% uranyl acetate and lead citrate. 
Imaging was performed using a Philips/FEI Tecnai T12 electron microscope operating at 200 
keV. 
H. SERS Singleplex Mapping of MDA MB 231 cells (Active vs. Passive): For SERS mapping 
experiments, 231 cells were seeded on Calcium Fluoride disks (CaF2, 20 x 2 mm Raman grade, 
Crystran Ltd.) after cells had been in culture for 14 days. CaF2 disks were placed inside 35 mM 
cell culture dishes, and 350,000 cells were seeded in the dishes. After 48 h of growth, checking 
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that the cells had a ~90 % confluent layer, the disks were removed from the culture dishes and 
placed in a secondary container for the MGN incubation step. Now incubating only on the disks, 
the cells were incubated with new media (no FBS, nDMEM) supplemented with either 170 
µg/mL antiEGFR-pMBA-MGNs or 170 µg/mL pMBA-MGNs for 16 h at 37 0C. Next, the cells 
were washed with nDMEM (x2) and then placed back in complete media (with FBS, cDMEM) 
to equilibrate for 2 h at 37 0C. Cells were then fixed with cytofix/cytoperm (BD Biosciences), 
incubating for 20 min at room temperature. Fixative was removed, and the cells were washed 
with MilliQ (MQ) water (x2). All volume was removed, and the cells were dried at 4 0C 
overnight.[69]  
 Both the MGNs coated with antibody (antiEGFR-pMBA-MGNs, 170 µg/mL) case and 
the non-targeted MGNs (pMBA-MGNs, 170 µg/mL) assay were treated the same for SERS 
mapping and data collection, as well as processing. After allowing the samples to dry overnight 
at 4 °C, the cells on the CaF2 disks were visualized using an inVia Raman (Renishaw) brightfield 
microscope. Using an 100x objective, a video montage of the cells was captured, and the 
resulting brightfield image provided x,y coordinates for the Raman instrument to record SERS 
chemical footprints of a rectangular area of ~100 µm by 100 µm. Recording spectra with 0.75 
µm steps, the invia Raman microscope took measurements of the cells with a 785 nm 
wavelength laser source with 1200 lines/mm grating in high confocal mode. Static spectra (1200 
cm-1 center) were recorded using a 100x objective with a ~1 µm spot size at a power of 2 mW 
with a 10 s acquisition time. SERS intensity map analysis of the 1580 cm-1 peak corresponding 
to the functionalized MGN localization was performed using Wire 3.4 for cosmic ray removal, 
MATLAB for smoothing, background subtraction, and intensity plotting, and, lastly, Adobe 
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Photoshop graphic software for overlap with brightfield image. Refer to Analysis of SERS maps 
section for complete data processing procedure. 
I. SERS Multiplex Imaging of MDA MB 231 cells (No Block and Blocking PD-L1 
Receptor). 
Multiplex with (1:1) Cocktail with 231 cells: Again, CaF2 disks were seeded with 231s inside 35 
mm culture dishes with 350,000 cells as previously stated. Checking for ~90 % confluent layer 
after 48 h growth, the disks were removed and placed into a new container. Cells were incubated 
with new media (no FBS, nDMEM) supplemented with 170 µg/mL (1:1) cocktail antiEGFR-
pMBA-MGNs to antiPDL1-DTNB-MGNs for 16 h at 37 0C. Next, cells were washed with 
nDMEM (x2) followed by placement back in complete media (with FBS, cDMEM) to 
equilibrate for 2 h at 37 0C. After 2 h, fixing with cytofix/cytoperm (BD Biosciences), incubating 
for 20 min at room temperature, removing fixative, and washing with MilliQ (MQ) water (x2). 
Volume was completely removed, followed by drying overnight at 4 0C. 
After drying overnight, the cells on the disk were visualized using an inVia Raman 
(Renishaw) brightfield microscope, collecting a video montage of the cells using an 100x 
objective. Brightfield image corresponded to x,y coordinates for rectangular area of ~100 µm by 
100 µm. Spectra were recorded with 0.75 µm steps again with the invia Raman microscope. 
Measurement conditions for the multiplex cell studies were the same as for singleplex: 785 nm 
wavelength laser source, 1200 lines/mm grating in high confocal mode, static spectra (1200 cm-1 
center), 100x objective with a ~1 µm spot size, power of 2 mW, and 10 s acquisition time. SERS 
intensity multiplex map analysis of the 1580 cm-1 peak for the antiEGFR-pMBA-MGNs and the 
1325 cm-1 peak corresponding to the antiPDL1-DTNB-MGNs were performed using the same 
software and method as singleplex: Wire 3.4 for cosmic ray removal; MATLAB for smoothing, 
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background subtraction, and intensity plotting; and Adobe Photoshop graphic software for 
overlap with brightfield image. Analysis of SERS maps section has full data processing 
procedure included. 
Multiplex with (1:1) Cocktail with 231 cells after Blocking PD-L1 Receptor: To test the fidelity 
of the multiplex technology, a blocking PD-L1 receptor control experiment was performed to 
determine the specificity and mapping capability of this (1:1) cocktail of functionalized 
antibody-specific MGNs. 231s were seeded on CaF2 disks with the same method as with the 
multiplex study: 350,000 cells added to 35 mm culture dish with disk inside dish, allowing 48 h 
for cells to grow to ~90 % confluency. After removing to new container, the cells were pre-
blocked by incubating with nDMEM supplemented with 4 µg/mL Human CD274 (B7-H1, PD-
L1) antibody (monoclonal antiPDL1) for 1 h at 37 0C.[48, 87, 88] Cells were washed with 
nDMEM (x2), followed by placement in nDMEM supplemented with 170 µg/mL (1:1) cocktail 
antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs for 16 h at 37 0C. After washing again 
with nDMEM (x2), cells were placed back in cDMEM to equilibrate for 2 h at 37 0C. Fixation 
process followed same protocol as for (1:1) cocktail multiplex case, using fixative from BD 
Biosciences and drying at 4 °C overnight. 
Brightfield video montage of 231 cells was collected with 100x objective of inVia Raman 
(Renishaw) microscope, corresponding to x,y coordinates for rectangular area of ~100 µm by 
100 µm. Spectra were recorded with 0.75 µm steps with same measurement conditions for block 
studies as for the non-block multiplex assay. SERS intensity multiplex map analysis of ISERS1580 
and ISERS1325 to determine the effect of blocking PD-L1 receptor on distribution of antiEGFR-
pMBA-MGNs and antiPDL1-DTNB-MGNs for the 231 cells was also performed using same 
software and method as non-block multiplex, refer to Analysis of SERS maps section. 
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J. Analysis of SERS Imaging Maps (Singleplex, Multiplex, PD-L1 Block). Running Wire 3.4 
software with an Invia (Renishaw) Raman microscope, all SERS maps were a collection of ~100 
µm x 100 µm cellular areas with 0.75 um steps. Snake path acquisition was utilized, creating a 
dataset of ~15,000 spectra. The dataset was a matrix with (x,y) coordinates, wavenumber cm-1, 
and Raman intensity. Using the wire 3.4 software, cosmic ray removal was performed with 
nearest neighbor method implemented to ensure the scaling of the spectra was not jeopardized. 
To make the handling of the dataset easier following cosmic ray removal, the wire 3.4 wxd file 
was converted into a text file and imported into MATLAB R2016a software. A custom code was 
built using MATLAB software to perform smoothing and background fluorescent subtraction. 
Following the modified polyfit method[89], an automated approach was applied to perform 
background subtraction of fluorescence using polynomial fitting to uncover SERS peaks even at 
low intensity regimes.[89] The software runs an iterative process fitting the selected polynomial 
to the data to remove background, coming as close to baseline to subtract out all fluorescence 
without losing any Raman peaks or jeopardizing data fidelity. Prior to implementing the 
modified polyfit method on the data set, truncation was performed, and the data underwent 
smoothing and data differentiation using the Savitzsky and Golay method.[90-92] The S and G 
filter used order of 5 and coefficient value of 61. After smoothing, a 7th order polynomial was 
utilized for fluorescent background subtraction through an iterative process with a threshold of 
0.0001. The threshold of the fit could be modified to lengthen or shorten processing time.   
There are multiple methods for multivariate analysis that were beyond the scope of this 
study.[93, 94] Specific analysis depends on the phase/state of the sample and whether calibration 
curves with known concentrations of analytes corresponding to signal can be obtained. Analysis 
should be selected based on the parameters of the study and what data is required. For future 
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studies, component mapping methods such as direct classical least squares (DCLS), principal 
component analysis (PCA), or k-means clustering could be incorporated while having another 
strong identifier spectra to normalize or quantify against.[23, 93, 94] However, due to the SERS 
effect, the Raman tags were very distinguishable and allowed for simple intensity analysis of the 
various peaks in accordance to what has been done in the literature previously.[21, 95-98] Thus, 
after the dataset was smoothed and subtracted for fluorescence, the intensity as a function of 
position for either the 1580 cm-1 peak of pMBA (ISERS1580) or the 1325 cm-1 peak of DTNB 
(ISERS1325) was plotted using MATLAB, with (x,y) coordinates corresponding to the brightfield 
image. Next, using Adobe Photoshop graphic software, overlaps of ISERS1580 and brightfield were 
performed for the singleplex case for both plus and minus antibody MGNs.  For the multiplex 
and blocking studies, a spatial map overlap of ISERS1580 and ISERS1325 was completed (in 
MATLAB) as well as layering all 3 components (ISERS1580, ISERS1325, and brightfield, in 
Photoshop). Lastly, the MATLAB code also had a built-in spectral plotter and exporter that 
allowed for the visualization of the SERS footprint at any respective spatial location. Raman 
footprints representing ISERS1580 and ISERS1325 data were obtained using this built-in plotter and 
data exporter. 
K. Spatially Controlled Photothermal Ablation of Breast Cancer Cells Utilizing Actively-
Targeted MGNs. Both MDA-MB-231 (HTB-26) and MCF7 (HTB-22) breast cancer cell lines 
were purchased from ATCC. The 231s were cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, ATCC) and 1% 
penicillin/streptomycin (Gibco). MCF7s were cultured in Eagles’s Minimum Essential medium 
(EMEM, ATCC) supplemented with 10% fetal bovine serum (FBS, ATCC), 1% 
penicillin/streptomycin (Gibco), and 0.01 mg/mL human recombinant insulin (Invitrogen). Both 
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cell lines were maintained at 37 0C and 5% CO2 and were cultured for 14 days prior to seeding 
for photothermal therapy (PTT) experiments with media changes every 2 days. Culturing on 35 
mm culture dishes for PTT experiment, 231s were seeded at 350,000 cells 48 h prior to MGN 
incubation step, while MCF7s were seeded at 700,000 cells 144 hr prior to MGN addition. Both 
cells lines were cultured to ~90 % confluent layers on day of MGN addition, and their growths 
and morphologies were confirmed through phase contrast imaging performed with a Zeiss 
Observer Z1 microscope. 
The two cell lines were incubated with new media (no FBS, nDMEM or nEMEM) 
supplemented with either 170 µg/mL antiEGFR-pMBA-MGNs or 170 µg/mL pMBA-MGNs for 
16 h at 37 0C. Next, the cells (231s and MCF7s) were washed with nDMEM or nEMEM (x2), 
and then place back in complete media (with FBS, cDMEM or cEMEM) prior to irradiation with 
laser. The localization of antiEGFR-pMBA-MGNs and pMBA-MGNs was compared for the two 
cell types through visualization with a Zeiss Observer Z1 microscope.  
Custom photothermal therapy laser optics were purchased from Thorlabs and built to 
provide controlled light to heat conversion. The optics included an 808 nm laser diode 
(L808P1WJ), a current controller (LDC240C), a thermoelectric controller (TEDC200C), a 
collimating lens (C230TME-B), and a silver polished mirror (PF-10-03-P01).  The photothermal 
set up was also completed with an aluminum block wrapped with anti-reflecting black films and 
a 37 0C heating mantle to simulate biological conditions. Calipers and a power meter (Thorlabs, 
PM130D) were used to measure the laser spot size (2 x 2 mm) and power density (4.7 W/cm2) 
used in the study.  
 After allowing to equilibrate at 37 0C for 2 h, the cells were illuminated for 15 min at 4.7 
W/cm2 pump fluence with an 808 nm laser, spot size of 2 x 2 mm. The cells were then place 
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back in the 37 0C incubator. After 4 h, fresh complete media was added with Calcein AM (5 µM) 
and Propidium Iodide (PI, 1 µM) (Live/Dead stain) and incubated for 20 min at 37 0C. After 20 
min, media was changed again, and the cells were left at 37 0C until imaging. A Zeiss LSM 710 
confocal microscope was utilized for fluorescent imaging of the cells to view the stain 
(Live/Dead) and visualize any cell death via necrosis.  
 Additional controls were performed on the MDA MB 231 cells to show that the 808 nm 
laser alone did not induce any cell death and that the antiEGFR-pMBA-MGNs were not 
cytotoxic to the cells. For laser alone control, 231s were cultured to ~90 % confluency in the 35 
mm culture dish and put through the whole PTT procedure but without particles present, steps 
include: incubating with nDMEM for 16 h at 37 0C, washing with nDMEM (x2), incubating with 
cDMEM through illumination, 15 min at 4.7 W/cm2 pump fluence, and staining with calcein/PI 
after 4 h at 37 0C. Lastly, 231 cells at 90 % confluency were incubated with nDMEM 
supplemented with 170 µg/mL antiEGFR-pMBA-MGNs for 16 h at 37 0C, washing with 
nDMEM (x2), incubating with cDMEM but without illumination, and then staining with 
calcein/PI after 4 h at 37 0C. These controls were verified through fluorescent imaging with a 
Zeiss LSM 710 confocal microscope. 
L. In vivo and ex vivo Protocols. All methods for in vivo and ex vivo experiments with human 
breast (MDA MB 231) tumor xenografts in athymic mice are provided in Appendix B. 
Procedures include: mammary fat pad tumor growth (B.1), synthesis of actively targeted MGNs 
(B.2), SERS longitudinal assays with portable Raman (B.3), histology and silver staining (B.4) 
and SERS mapping (B.5) of ex vivo tumor sections. 
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CHAPTER 5 
SUMMARY AND OUTLOOK 
 
Overall in this work, tunable multibranched gold nanoantennas (MGNs) were synthesized 
with plasmon resonance in the first NIR window to allow for better tissue penetration during in 
vivo studies. We were able to modulate the MGNs geometry, which allowed for great 
maneuverability in the resulting resonance range. Further, due to the presence of multiple sharp 
protrusions, the MGNs demonstrated a refractive index sensitivity of 373 nm/RIU, as well as, 
intense photothermal efficiencies, rising the temperature of surrounding medium to ~54 °C 
within 5 minutes of laser illumination. These light to heat conversion capacities of the MGNs 
were also shown to deliver actively targeted photothermal therapy to EGFR overexpressing 
MDA MB 231 cells in vitro. Having both imaging and therapeutic components in one platform is 
beneficial for future in vivo theranostic studies with a single systemic injection.  
Beyond liquid phase MGNs, we moved into solid MGN-substrates for ultrasensitive, 
flexible, and versatile detection. We incorporated MGNs on inexpensive filter paper to design 
MGN-paper dipsticks and swabs for SERS mediated sensing of various protein and biochemical 
analytes. A detection limit of 100 fM of human serum albumin complexed with indocyanine 
green using MGN-paper dipsticks was achieved. Incorporating protein detection via SERS 
beacon technology with the concept of junction field strength, we designed a sandwich 
architecture detection assay using MGN-glass and obtained a 5 fg/mL detection limit for prostate 
specific antigen (PSA). These initial tests were proof of concept studies envisioning a diagnostic 
tool for early detection of prostate cancer through blood or serum analysis of PSA levels. To 
improve MGN-substrates for future biomolecular SERS detection, the incorporation of a planar 
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yet flexible substrate that is not overly porous, potentially a polymer film, would be beneficial. In 
this approach, the benefits of the flexible, versatile, and robust material are combined with the 
capacity to have complex architectures as with the planar systems.  
The ability to trace surface receptor coverages through MGNs enhanced SERS-tags is 
advantageous because of the combination of multiplex technology with high spatiotemporal 
resolution. We showed the theranostic capability of actively targeted MGNs in triple negative 
breast cancer (TNBC) cells in vitro and in vivo via human xenografts. Enabled by the narrow 
peak widths of Raman signatures, we simultaneously targeted the epidermal growth factor 
receptor (EGFR) and immune checkpoint receptor, programmed death ligand 1 (PD-L1). We 
acquired 2-dimensional (2-D) SERS cellular “traffic maps” facilitating highly sensitive and 
specific detection of EGFR and PD-L1. In addition, the SERS enhancement provided detection 
of the MGNs probes amidst signal from biological tissue in vivo, and a receptor blocking study 
revealed ~30 % decrease in SERS signal verifying the active targeting properties of the antibody 
coated MGNs. Moving forward, SERS 3-D volume maps visualize receptor distribution on a 
global perspective and have the potential to provide valuable information in determining 
candidacy for the treatment of the cancer. Furthermore, current ongoing studies in utilizing 
antiPDL1 as a therapeutic agent provide potential for combinational theranostic probes with 
multiple therapeutic or diagnostic modalities. 
The work presented demonstrates the versatile and adaptable potential of the synthesized 
theranostic MGNs to provide a quantitative measure of biomolecules and to allow for predictive, 
personalized, and image-guided immunotherapies with minimal toxicity. These theranostic 
nanoplatforms offer a multifunctional tool that will facilitate the transition to individualized 
cancer medicine. 
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APPENDIX A 
PROCEDURES FOR MGN-GLASS SERS BIODIAGNOSTIC ASSAY FOR 
ULTRASENSITIVE DETECTION OF PROSTATE SPECIFIC ANTIGEN (PSA) 
 
A.1 MGN-glass Preparation 
A.1.1 Synthesis 
1. Reagents and Materials 
• cellulose paper 
 cellulose filter paper (Grade #2, 42.5 mm, 8 µm pores) (Whatman) 
• glass 
 microscope glass slides (25.4x76.2mm (1”x3”) (PEARL) 
• PVP 
 Poly(4-vinylpyridine) MW~60000 g/mol (Sigma Aldrich) 
• HEPES:  
 (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Sigma-Aldrich) 
• Gold Salt:  
 gold(III) chloride trihydrate (HAuCl4) (Sigma-Aldrich) 
 
2. Timeline Day 1: Piranha clean, PVP coat glass, also Make HEPES 
   Day 2: PVP curing and MGN Prep (250 mL batches) 
   Day 3: MGN centrifuging/concentration and soaking glass in MGNs 
   Day 4: Rinse and Dry to receive final product. 
3. Protocol 
 Day 1: 
To synthesis the large volumes of MGNs required to prepare the MGN-glass, a large 
batch of HEPES buffer is required. Solution phase MGNs at 780 ± 10 nm are ideal 
beasuse of the first NIR biological window. Thus, 200 mM HEPES pH 7.4 ± 0.1 was 
utilized for synthesis, and 250 mL of HEPES was prepared using the method described in 
section A.2.2. For step by step buffer process, refer to this section.  
 
Plain microscope glass from PEARL was utilized as the substract to coat with the MGNs. 
First the surface of the glass had to be completely to ensure strong functionlaziation with 
the Poly(4-vinylpyridine) layer. Also noted, one side of the glass piece has to scratch to 
denote that it is the bottom aside as building a sandwich assay in only one direction nso 
bottom side will not be involved nor coated. Thus, the glass was pre-cut into ~4 mm x 4 
mm square glass pieces and then soaked in piranha solution (3:1 Sulfuric Acid:Hydrogen 
Peroxide) at 55 0C on a hot plate, covering to protect from any bubbles. Next the glass 
pieces were soaked in MQ water for 10 min at room temperature, followed by washing 
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with MQ water first and Isopropyl Alcohol second. Glass was next dried with Nitrogen 
stream and stored at room temperature in parafilmed petri dish untl further usage.  
 
Next, using Poly(4-vinylpyridine) (PVP) MW~60000 g/mol (Sigma Aldrich), 1 wt % 
PVP solution was prepared. 0.45 g of PVP was dissolved in 45 mL total volume, using 90 
% ethanol as solvent. Much vortexing and even sonication was required to get the PVP to 
go into solution. Finally, the glass pieces were faced scratched side down in a plastic petri 
dish and were submerged in the 45 mL of 1 wt % PVP solution. The dish was covered 
and left at room temperate for 24 h for surface functionalization to occur. Yield is usually 
about ~15 pieces of 4x4 mm glass per 300 mL MGN batch. This could be improved in 
the future with possible different soaking techniques. 
 
 
Day 2:  
A scaled up 250 mL batch of MGNs was prepared by synthesizing nine 30 mL batches 
simultaneously and combining after the reaction reached completion. The synthesis could 
also be achieved by reacting in a 500 mL round bottom in one huge 250 mL reaction 
volume. However, it has been the experience that smaller batches tend to give narrower 
plasmon resonances due to more monodisperse MGNs. Thus, the more exact plasmon 
tuning, smaller batches in large numbers are preferred. If polydispersity is not an issue for 
the technology purpose, then the large batch chemistry could also be incorporated. 
Briefly, 18 mL of Milli-Q water (18 MΩ) was added to 12 ml 200 mM HEPES (pH 7.40 
± 0.1), mixing by gentle inversion. Quickly, 300 µl of 20 mM tetrachloroauric(III) acid 
(HAuCl4, Sigma-Aldrich, #520918) was added, again mixing my inversion and leaving 
to react at room temperature for 75 minutes. Plasmon resonance of the MGNs, through 
the functionalization process, was monitored using UV-vis spectroscopy with optimal 
initial resonance of the solution phase MGNs at 780 ± 10 nm. The MGN batches were 
stored at 4 °C overnight until coated step. 
 
Next, now that the PVP had functionalized the glass for 24 h, the glass pieces were rinsed 
with 90 % ethanol and dried with a nitrogen stream. The glass pieces were then left to 
cure at room temperature for 24 h on the benchtop with lid closed.  
 
 
Day 3:  
Post 24 h PVP cure time, the glass pieces were stored in the petri dish, parafilming to 
maintain shelf life until usage for MGN coating. The 250 mL MGNs volume was 
removed from 4 °C and sonicated 10 min prior to centrifugation to disturb any clusters 
forming in the solutiom phase MGNs. The 250 mL MGN volume was then concentrated 
down to ~ 3 mL by centrifugation (6000 rpm for 20 min) with an additional spin of the 
supernatant to capture all of the MGNs. Next, the PVP-coated glass (15 pieces) was 
soaked in the concentrated MGNs solution for 24 h with constant 77 RPM shaking on 
benchtop plate shaker. The soaking occurred in 35 mm culture dishes at room 
temperature. 
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Day 4:  
After the 24 h MGN soak, the pieces were rinsed gently with MQ water and dried with 
Nitrogen stream. The MGN-glass pieces were stored in a petri dish, parafilming to 
maintain shelf life. The MGN-glass batches have maintained performed for 3-4 months 
with proper storage at room temperature. If imaging through transmission elecetron 
microscopy, the MGN-glass samples need to be sputtered with 3-5 nm to increase the 
conductance of the glass and create for better visualization.  
 
 
A.1.2 Characterization 
 
1. To study the optical properties of the MGN-glass, several spectroscopy techniques were 
utilized in its probing. A Varian Cary 5000 UV-vis NIR spectrophotometer (Agilent 
Technologies) was used to measure the extinction of the MGNs in solutions using a 1 cm 
path length cuvette. Further, extinction spectra of the MGN-glass was also recorded in 
solid state. The MGN-glass was visualized using a Zeiss Merlin SEM, sputtering samples 
were with ~3-5 nm layer of Au prior to SEM. Moreover, prior to incorporating in the 
sandwich assay, SERS spectra of the MGN-glass alone were acquired to determine if the 
MGN-substrate material itself had its own spectral characteristics. Using an inVia Raman 
(Renishaw) brightfield microscope, spectra were recorded with: 785 nm wavelength laser 
source, 1200 lines/mm grating, extended spectra, 50x objective with power of 2 mW, and 
30 s acquisition time. SERS footprint plotted after fluorescence and background 
subtraction using Wire 3.4 software. Lastly, Finite Difference Time Domain (FDTD) 
studies were performed on dimer geometries of MGNs to determine what would be the 
best nanoantenna structure to incorporate into the MGN-glass substrates. For full details, 
refer to Chapter 3 methods for MGNs dimer FDTD simulations (refer to Chapter 3.5). 
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A.2 Synthesis of antiPSA-pMBA-MGNs for Sandwich Assay Top Probe 
A.2.1 Reagents and Materials 
 
• HEPES 
 (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Sigma-Aldrich) 
• Gold Salt  
 gold(III) chloride trihydrate (HAuCl4) (Sigma-Aldrich) 
• Raman tag, pMBA 
 4-mercaptobenzoic acid (pMBA) (TCI America) 
• OPSS-PEG-NHS ester  
 Orthopyridyl-disulfide poly(ethylene glycol)-N-hydroxysuccinimide ester  
 (OPSS-PEG-NHS ester, Mw 2000 g/mol, JenKem Technology)  
• Monophosphate 
 sodium phosphate dibasic (Na2HPO4, Fisher Scientific)  
• Bicarbonate  
 sodium bicarbonate (NaHCO3, Acros Organics)  
• Tris 
 [Tris(hydroxymethyl)aminomethane] (Sigma-Aldrich) 
• CaCl2  
 Calcium Chloride (Sigma-Aldrich) 
• NaCl  
 Sodium Chloride (Sigma-Aldrich) 
• 10x PBS  
 Phosphate Buffered Saline pH 7.4 (Gibco) 
• antiPSA, monoclonal  
 Human Kallikrein 3/PSA antibody (monoclonal mouse raised antibody,  
 R & D Systems)  
• antiPSA, polyclonal 
 Human Kallikrein 3/PSA antibody (polyclonal goat raised antibody,  
 R & D Systems)  
• Recombinant Human PSA 
  Recombinant Human Kallikrein 3/PSA protein (antigen, R & D Systems)  
• FL-secondary antibody for antiPSA  
 Mouse IgG2A PE-conjugated (monoclonal rat raised antibody,  
 R & D Systems, Phycoerythrin) 
• BSA 
 Bovine Serum Albumin (Sigma-Aldrich) 
• IgG from Human Serum 
 Purified Immunolglobulin G (Sigma Aldrich) 
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A.2.2 Buffer Preparation 
 
1. 200 mM HEPES pH 7.40 ± 0.1 buffer for MGNs Synthesis  
 -HEPES prep must be with Aqua Regia cleaned glass as it is for MGN synthesis. 
 Glassware and Materials:  (x1) 600 mL Beaker 
     (x1) 250 mL Graduated Cylinder 
     (x1) stir bar 
o Add ~11.916 g of HEPES (Sigma Aldrich, #H4034) to 600 mL beaker. 
o Add 190 mL MQ water. 
o Let stir for ~40 min with large stir bar to dissolve.  
o Always checking pH with stir bar stirring. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Prepare 1 M NaOH solution from solid pellets and MQ water. 
o Add 1 mL 1 M NaOH, check pH, continually stirring.  
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 1 mL 1 M NaOH (20-25 mL) and monitoring to pH 7.40 ± 0.1. 
o Take out stir bar, fill to 250 mL with MQ water in graduated cylinder. 
o Vortex again and record final pH reading of buffer. 
o Put buffer in sterile 50 mL conical tubes (x5) and store at room temperature.  
o HEPES buffer not autoclaved for MGN synthesis. 
 
2. 8.6 mM Na2HPO4 pH 7.40 ± 0.1 Monophosphate buffer for MGN Resuspension 
 -Buffer autoclaved post preparation for sterility: 
 Glassware and Materials:  (x1) 50 mL Centrifuge tube 
     (x1) 125 mL Erlenmeyer flask 
     (x1) stir bar 
     (x1) aluminum foil 
     (x1) autoclave tape 
o Add ~48 mg of Na2HPO4 (Fisher Scientific, S374) to 50 mL Tube. 
o Add 32 mL MQ water. 
o Let stir for ~40 min with conical stir bar to dissolve.  
o Always checking pH with conical stir bar stirring, vortex after each addition. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Add 1 µL 5 M HCl, check pH, vortexing to mix in between readings. 
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 1 µL 5 M HCl (10-15 µL) and monitoring to pH 7.40 ± 0.1. 
o Take out stir bar, fill to 40 mL with MQ water. 
o Vortex again and record final pH reading of buffer. 
o Put the buffer in a clean Erlenmeyer flask (125 mL). 
o Cover with foil, add autoclave tape, and put in secondary container. 
o Autoclave using liquid cycle. 
o Post-autoclaving, let cool, and put in sterile 50 mL conical tube in biohood. 
o Store at 4 0C. 
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3. 100 mM NaHCO3 pH 8.6 ± 0.1 Bicarbonate buffer for antiPSA Resuspension 
 -Buffer autoclaved post preparation for sterility: 
 Glassware and Materials:  (x1) 50 mL Centrifuge tube 
     (x1) 125 mL Erlenmeyer flask 
     (x1) stir bar 
     (x1) aluminum foil 
     (x1) autoclave tape 
o Add ~335 mg of NaHCO3 (Acros Organics, #123360050) to 50 mL Tube. 
o Add 32 mL MQ water. 
o Let stir for ~40 min with conical stir bar to dissolve.  
o Always checking pH with conical stir bar stirring, vortex after each addition. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Prepare 1 M NaOH solution from solid pellets and MQ water. 
o Add 2 µL 1 M NaOH, check pH, vortexing to mix in between readings. 
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 2 µL 5 1 M NaOH (6-8 µL) and monitoring to pH 8.60 ± 0.1. 
o Take out stir bar, fill to 40 mL with MQ water. 
o Vortex again and record final pH reading of buffer. 
o Put the buffer in a clean Erlenmeyer flask (125 mL). 
o Cover with foil, add autoclave tape, and put in secondary container. 
o Autoclave using liquid cycle. 
o Post-autoclaving, let cool, and put in sterile 50 mL conical tube in biohood. 
o Store at 4 0C. 
 
4. TCN pH 7.4 ± 0.1 for PSA Resuspension (50 mM Tris, 10 mM CaCl2, 150 mM NaCl) 
 -Buffer autoclaved post preparation for sterility: 
 Glassware and Materials:  (x1) 50 mL Centrifuge tube 
     (x1) 125 mL Erlenmeyer flask 
     (x1) stir bar 
     (x1) aluminum foil 
     (x1) autoclave tape 
o Add ~243 mg of Tris solid (Sigma-Aldrich, #252859) to 50 mL Tube. 
o Add ~44 mg of CaCl2 solid (Sigma-Aldrich, #C4901) to 50 mL Tube. 
o Add ~351 mg of NaCl solid (Sigma-Aldrich, #S7653) to 50 mL Tube. 
o Add 25 mL MQ water. 
o Let stir for ~1 h with conical stir bar to dissolve.  
o Always checking pH with conical stir bar stirring, vortex after each addition. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Add 25-50 µL 5 M HCl, check pH, vortexing to mix in between readings. 
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 25 µL 5 M HCl (300-350 µL) and monitoring to pH 7.40 ± 0.1. 
o Take out stir bar, fill to 40 mL with MQ water. 
o Vortex again and record final pH reading of buffer. 
o Put the buffer in a clean Erlenmeyer flask (125 mL). 
o Cover with foil, add autoclave tape, and put in secondary container. 
o Autoclave using liquid cycle.  
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o Post-autoclaving, let cool, and put in sterile 50 mL conical tube in biohood. 
o Store at 4 0C. 
 
5. 1x PBS pH 7.4 ± 0.1 buffer for IgG Resuspension 
 -Buffer autoclaved post preparation for sterility: 
 Glassware and Materials:  (x1) 50 mL Centrifuge tube 
     (x1) 125 mL Erlenmeyer flask 
     (x1) stir bar 
     (x1) aluminum foil 
     (x1) autoclave tape 
o Add 4 mL 10x PBS pH 7.4 stock (Gibco) to 50 mL Tube. 
o Add 32 mL MQ water. 
o Let stir for ~40 min with conical stir bar to dissolve.  
o Always checking pH with conical stir bar stirring, vortex after each addition. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Add 1 µL 5 M HCl, check pH, vortexing to mix in between readings. 
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 1 µL 5 M HCl (3-6 µL) and monitoring to pH 7.40 ± 0.1. 
o Take out stir bar, fill to 40 mL with MQ water. 
o Vortex again and record final pH reading of buffer. 
o Put the buffer in a clean Erlenmeyer flask (125 mL). 
o Cover with foil, add autoclave tape, and put in secondary container. 
o Autoclave using liquid cycle. 
o Post-autoclaving, let cool, and put in sterile 50 mL conical tube in biohood. 
o Store at 4 0C. 
 
 
A.2.3 Protein Resuspension 
 
1. antiPSA, Monoclonal 
 Sterile Conditions: 
ü antiPSA monoclonal antibody (R & D Systems), part #MAB13442. 
 Was shipped as 500 µg amount. 
ü Let the antibody thaw on ice for ~20-30 min. 
ü Pellet the solid down in the centrifuge before moving to biohood. 
ü Check that appearance of white solid is observable in tube. 
ü In the biohood, dissolve the 500 µg of antiPSA monoclonal antibody in 500 µL 
 100 mM NaHCO3 (pH 8.6 ± 0.1) buffer by gently pipetting, no vortexing. 
ü Pipette until solid is completely resuspended, but avoid bubbles as they are  
 indicator of protein aggregation. 
ü Aliquot in 15 µL aliquots (1 mg/mL), putting the aliquots on ice.  
 Should get about ~33 aliquots. Store at -20 0C. 
ü Avoid repeating the freeze/thaw process of the protein more than once if possible. 
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2. antiPSA, Polyclonal 
 Sterile Conditions: 
ü antiPSA polyclonal antibody (R & D Systems), part #AF1344. 
 Was shipped as 100 µg amount. 
ü Let the antibody thaw on ice for ~20-30 min. 
ü Pellet the solid down in the centrifuge before moving to biohood. 
ü Check that appearance of white solid is observable in tube. 
ü In the biohood, dissolve the 100 µg of antiPSA polyclonal antibody in 100 µL 
 100 mM NaHCO3 (pH 8.6 ± 0.1) buffer by gently pipetting, no vortexing. 
ü Pipette until solid is completely resuspended, but avoid bubbles as they are  
 indicator of protein aggregation. 
ü Aliquot in 10 µL aliquots (1 mg/mL), putting the aliquots on ice.  
 Should get about ~10 aliquots. Store at -20 0C. 
ü Avoid repeating the freeze/thaw process of the protein more than once if possible. 
 
3. Prostate Specific Antigen 
 Sterile Conditions: 
ü Recombinant Human Kallikrein 3/PSA (R & D Systems), part #1344-SE. 
 Was shipped as 10 µg amount. 
ü Let the antibody thaw on ice for ~20-30 min. 
ü Pellet the solid down in the centrifuge before moving to biohood. 
ü Check that appearance of white solid is observable in tube. 
ü In the biohood, dissolve the 10 µg of PSA protein in 100 µL 
 TCN buffer by gently pipetting, no vortexing. 
ü Pipette until solid is completely resuspended, but avoid bubbles as they are  
 indicator of protein aggregation. 
ü Aliquot in 10 µL aliquots (100 µg /mL), putting the aliquots on ice.  
 Should get about ~10 aliquots. Store at -20 0C. 
ü Avoid repeating the freeze/thaw process of the protein more than once if possible. 
 
4. Immunoglobulin G 
 Sterile Conditions: 
ü Immunoglobulin G from human serum (Sigma-Aldrich), part #I4506. 
 Was shipped as 10 mg amount. 
ü Let the antibody thaw on ice for ~20-30 min. 
ü Pellet the solid down in the centrifuge before moving to biohood. 
ü Check that appearance of white solid is observable in tube. 
ü Need to measure out 2 mg of IgG protein. 
ü In the biohood, dissolve the 2 mg of IgG protein in 1 mL 
 1x PBS pH 7.4 buffer by gently pipetting, no vortexing. 
ü Pipette until solid is completely resuspended, but avoid bubbles as they are  
 indicator of protein aggregation. 
ü Aliquot in 50 µL aliquots (2 mg /mL), putting the aliquots on ice.  
 Should get about ~20 aliquots. Store at -20 0C. 
ü Avoid repeating the freeze/thaw process of the protein more than once if possible. 
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A.2.4 Functionalization Chemistry 
 
1. antiPSA-pMBA-MGNs Chemistry 
Procedure for functionalization chemistry for biodiagnostic top probe is a modified 
version of what was explained previously in vitro in Chapter 4 methods for antiEGFR-
pMBA-MGNs (refer to Chapter 4.5). 
 
2. Differences Between Two Chemistry Protocols 
i.)  30 mL batch functionalized MGNs instead of 60 mL. 
ii.)  pMBA + MGNs reaction was for 2 min instead of 10 min at 4 0C  
  as stated in section 4.5. 
iii.)  For OPSS-PEG-NHS + antiPSA (pAb) reaction, this was a polyclonal  
  antibody for top probe, not moncolonal as stated in section 4.5. 
iv.)  OPSS-PEG-antiPSA + pMBA-MGNs reaction was for 30 min instead of  
  24 hr at 4 0C as stated in section 4.5. 
v.)  No PEGylation chemistry was performed on the antiEGFR-pMBA-MGNs. 
vi.)  Final product resuspension volume was 600 µL instead of 200 µL. 
 
3. Brief Review of Procedure 
MGNs Synthesis: 30 mL batch of MGNs was prepared. Briefly, 18 mL of Milli-Q water 
(18 MΩ) was added to 12 ml 200 mM HEPES (pH 7.40 ± 0.1), mixing by gentle 
inversion. Quickly, 300 µl of 20 mM tetrachloroauric(III) acid (HAuCl4, Sigma-Aldrich,	
#520918) was added, again mixing my inversion and leaving to react at room temperature 
for 75 minutes. Plasmon resonance of the MGNs, through the functionalization process, 
was monitored using UV-vis spectroscopy with optimal initial resonance of the solution 
phase MGNs at 780 ± 10 nm. 
 
antiPSA-pMBA-MGNs: Again, functionalization chemistry was monitored for shifts in 
plasmon resonance due to phase retardation effects from the change in immediate local 
refractive index due to the layering around the MGNs. To begin, 30 mL MGNs at 170 
µg/mL (Ext. = 1.79) at max plasmon resonance ~780 nm in the NIR region were 
synthesized. MGNs were kept on ice through functionalization process. 4-
mercaptobenzoic acid (pMBA), dissolved in 100 % ethanol, was added to the MGNs in a 
small volume with high concentration, slow stirring, 3 µL of 10 mM pMBA was injected 
to 30 mL of MGNs, mixing for 2 min at 4 °C. 
 
30 mL was split into 5 mL aliquots (x6), centrifuged at 6000 rpm for 20 min. Supernatant 
was completely decanted to remove any unbound pMBA, and pellets were combined in 
1.5 mL total volume with Milli-Q (MQ) water. The resonance and concentration were 
again recorded, and the functionalized MGNs were further diluted to 1.14 mg/mL (Ext. = 
12.0) with Milli-Q water for a total volume of 3 mL of particles.  
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For OPSS-PEG-antiPSA procedure, refer to OPSS-PEG-antiEGFR procedure (section 
4.5) as they were the same except OPSS-PEG-antiPSA is prepped in 40 µL, while the 
OPSS-PEG-antiEGFR was prepared at 80 µL volume. Both were prepared at (1:9) 
volume ratio of antibody to OPSS-PEG-NHS linker and reacted for at 4 0C for 24 h. 35 
µL of OPSS-PEG-PSA reaction (polyclonal [antiPSA]Final = 0.9 mg/mL) was added to 
2.6 mL pMBA-labeled-MGNs at 1.14 mg/mL (Ext. = 12.0), pipetting to mix. Antibody 
with MGNs reaction was then left to react for 30 min on an inverter at 4 0C.   
 
Post 30 min incubation, the ~2.6 mL volume was split into 1.3 mL aliquots (x2) and 
filled to 2.6 mL volumes with Milli-Q water, mixing by inversion to wash any unbound 
OPSS-PEG-NHS. Particles were then centrifuged at 4000 rpm for 10 min, and 
supernatant was completely removed under sterile conditions. Pellets were resuspended 
in 600 µL of sterile 8.6 mM pH 7.40 ± 0.1 (Na2HPO4) monophosphate buffer, with 
resonance and concentration again measured. If necessary, dilute final [antiPSA-pMBA-
MGNs] with the sterile monophosphate buffer to 1.5 mg/mL, rechecking concentration. 
For biodiagnostic PSA assays, functionalized MGNs were further diluted to 686 µg/mL 
with sterile monophosphate buffer. The particle prep for the antiPSA-pMBA-MGNs was 
finished on day of sandwich assay, and then stored at 4 0C on ice until usage. These 
antiPSA-pMBA-MGNs act as the tope probe in the biodiagnostic sandwich assay for 
detection.  
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A.3 SERS Biodiagnostic MGN Sandwich Assay: Experimental Design 
A.3.1 Timeline and Overview of Biodiagnostic SERS Assay 
 
Day 1: 
Tasks - buffer prep, protein resuspension and aliquoting, HEPES prep: 
 Proteins to aliquot - PSA, antiPSA (mAb), antiPSA (pAb), IgG 
 Buffers - monophosphate buffer, bicarbonate buffer, TCN buffer,  
  1x PBS pH 7.4,  
  HEPES - 200 mM HEPES pH 7.4 
 
Day 2: 
Tasks - OPSS-PEG-antiPSA (mAb) 24 h reaction: 
  Start OPSS-PEG-antiPSA (mAb) 24 h reaction. Product used to attach   
   monoclonal antiPSA to MGN-glass. 
 
Day 3: 
Tasks - OPSS-PEG-antiPSA (pAb) 24 h reaction, MGNs synthesis, bind mAb + MGN-glass: 
  Day 1 of top probe synthesis: start OPSS-PEG-antiPSA (pAb) 24 h reaction.  
   Product used for chemistry with pMBA-MGN and  
    OPSS-PEG-antiPSA (pAb) 
   Prepare 30 mL batch of MGNs for combination chemistry 
  Start OPSS-PEG-antiPSA (mAb) + MGN-glass for 24 hr reaction 
 
Day 4: 
Tasks - Finish top probe synthesis, Sandwich assay, SERS measurements of Sandwich assay: 
  Day 2 of top probe synthesis: after attaching pMBA to form pMBA-MGNs, start  
    OPSS-PEG-antiPSA (pAb) + pMBA-MGNs for 30 min reaction.  
    Finish functionalization chemistry of antiPSA-pMBA-MGNs. 
  Perform the actual MGN biodiagnostic sandwich assay for PSA detection.  
  Acquire Raman spectra of sandwich assay samples, after let dry for 1-2 h at 4 0C 
 
 
A.3.2 Experimental Procedure of Sandwich Assay 
 
 Day 1: 
For the 1st day of the Biodiagnostic assay, sterile buffers are first prepared for protein 
resuspension including: 200 mM HEPES pH 7.40 ± 0.1, 8.6 mM Na2HPO4 pH 7.40 ± 
0.1, 100 mM NaHCO3 pH 8.6 ± 0.1, TCN pH 7.4 ± 0.1, and 1x PBS pH 7.4 ± 0.1. Refer 
to section A.2.2 for exact steps on buffer preparation. After buffers were prepared, the 
four proteins were reconstituted and resuspended. These proteins include: recombinant 
Human PSA, antiPSA (mAb), antiPSA (pAb), and IgG. Refer to section A2.3 for exact 
steps on protein resuspension. 
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Day 2: 
On day 2 of Biodiagnostic assay, the OPSS-PEG-antiPSA (mAb) reaction for the 
monoclonal antiPSA to bind the bottom MGN-glass was initiated. For each sample, 13 
µL of the OPSS-PEG-antiPSA is required. Thus, for 6 samples, will prep 130 µL to have 
extra. 
	
	 Making one large rxn for all 6 bottom probes 
 Immediately proceed to the reaction step. 
 OPSS-PEG-antiPSA (mAb) binding monoclonal #1 [1 = 160 mg/mL OPSS-PEG-NHS] 
 Add 13 µL of 160 mg/mL OPSS-PEG-NHS (resuspend in sterile bicarb buffer) 
 Add 117 µL of 1 mg/mL of Anti-PSA monoclonal antibody (resuspend in bicarb buffer) 
 Pipette up and down gently to mix 
 Let react at 4 0C for 24 h 
 
Day 3: 
Day 3 of Biodiagnostic assay includes the first day of top probe synthesis.  
The OPSS-PEG-antiPSA (pAb) reaction was initiated. This polyclonal antibody is used 
for top probe MGN synthesis. Also for top probe synthesis, 30 mL batch of MGNs was 
synthesized as well. Lastly, OPSS-PEG-antiPSA (mAb) was dropped on MGN-glass 
samples to prepare the bottom probe antiPSA (mAb) in binding to the MGN-glass 
surface.  
 
 MGNs synthesis -  
 Briefly, 18 mL of Milli-Q water (18 MΩ) was added to 12 ml 200 mM HEPES (pH 7.40 
 ± 0.1), mixing by gentle inversion. Quickly, 300 µL of 20 mM tetrachloroauric(III) acid 
 (HAuCl4, Sigma-Aldrich, #520918) was added, again mixing my inversion and leaving 
 to react at room temperature for 75 minutes. Ideal plasmon resonance at ~780 nm in 
 solution phase to begin functionalization chemistry.  
 
 Immediately proceed to the reaction step. 
OPSS-PEG-antiPSA (pAb) Binding monoclonal #1 [1 = 160 mg/mL OPSS-PEG-NHS] 
Add 4 µL of 160 mg/mL OPSS-PEG-NHS (resuspend in sterile bicarb buffer). 
Add 36 µL of 1 mg/mL of Anti-PSA polyclonal antibody (resuspend in sterile bicarb). 
Pipette up and down gently to mix. 
Let react at 4 0C for 24 h. 
 
bind mAb + MGN-glass:	OPSS-PEG-antiPSA (mAb) binding with MGN-Glass.  
Just Drop 13 µL of OPSS-PEG-antiPSA (mAb) (0.9 mg/mL) per MGN-glass piece. 
Spread the volume as to cover the whole glass piece.  
Let bind mAb + MGN-glass react at 4 0C for 24 h. 
Did not do any washing to MGN/glass before OPSS-PEG-antiPSA soaking.  
  
Day 4: 
 The fourth day is the busiest in the assay. The top probe chemistry has to be finished. The 
 actual sandwich assay is performed, and the SERS measurements, determining the results 
 of the actually assay are also recorded on this day after drying the samples. 
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Overview of steps for Day 4: 
 -Soak at 4 0C with MGN/glass and OPSS-PEG-antiPSA (mAb) (24 h) 
 -Did 13 µL here of 0.9 mg/mL antibody 
 -2 h soak at 4 0C with MGN/glass-antibody with PSA (in TCN, no Brij-35) 
 -Did 13 µL of [PSA] 
 -1 h soak at 4 0C with with blocking buffer (1 wt % BSA in monophosphate buffer) 
 -Did 13 µL 1 mg/mL BSA in monophosphate buffer (no Tween-20) 
 -Rinse with monophosphate buffer (100 µL monophosphate (x3)) 
 -1 h soak at 4 0C with top polyclonal probe func-MGNs (antiPSA-pMBA-MGNs) 
 -Did 13 µL of final Combo MGNs, 0.69 mg/mL 
 -Rinse with monophosphate buffer (100 µL monophosphate (x3)) 
 -Then dried for 1-2 h at 4 0C and record SERS spectra 
 
 1.) get ice and MQ water.  
 2.) Sonicate MGNs for 10-15 min 
 3.) take UV-vis of MGNs for initial plasmon resonance 
 4.) Put all of your buffers on ice: TCN, monophosphate, 1x PBS 
 5.) Make up 1 wt % BSA (in monophosphate, only pipetting), leave on ice 
  Add 0.1 g BSA (Sigma, A3059-10g) in 15 mL tube (ended up 0.1002 g) 
  Fill to 10 mL line with  
  monophosphate buffer 
 pipette to mix. (no vortex). 
  Leave BSA on ice for later usage. 
 
 6.) Thaw PSA, thaws on ice (aliquot found in -20  0C) 
7.) Thaw IgG, thaws on ice (aliquot found in -20  0C) 
8.) Make up PSA dilutions (dilute with TCN, only pipetting), leave on ice 
  Step 8: Make up PSA dilutions: The PSA comes in 8 µL aliquots at 100 µg/mL.   
 The whole dilution process needs to be done on ice because this is a protein.  In   
 addition, only pipetting, no vortex b/c this is a protein.  You will make serial   
 dilutions with the TCN buffer found in 4 0C fridge. 
 
 Thaw x4, 8 µL 100 mg/mL aliquots and combine. 
 
 Make up serial dilutions in large eppies (5). 
 
 100 µg/mL (32 µL) (A) 50 µg /mL (32 µL) (B)   
    16 µL of 100 µg/mL   
    16 µL of TCN    
    pipette to mix.   
 
 1 µg/mL (300 µL)  100 ng/mL (300 µL)  (C) 
 6 µL of 50 µg/mL  30 µL of 1 µg/mL  
 294 µL of TCN  270 µL of TCN 
 pipette to mix.   pipette to mix. 
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 10 ng/mL (300 µL)  1 ng/mL (300 µL) (D)   
 30 µL of 100 ng/mL  30 µL of 10 ng/mL  
 270 µL of TCN  270 µL of TCN  
 pipette to mix.   pipette to mix. 
 
 Leave the protein tubes on ice so that PSA doesn’t aggregate 
 
9.) Make up IgG dilutions (dilute with 1x PBS, only pipetting), leave on ice 
 Step 9: Make up IgG dilutions: The IgG comes in 50 µL aliquot at 2 mg/mL. The  whole 
 dilution process needs to be done on ice because this is a protein.  In addition, only  
 pipetting, no vortex b/c this is a protein. You will make serial dilutions with the 1x PBS 
 buffer found in 4 0C  fridge. 
 
 Make up serial dilutions in small eppies (7). 
 
 2 mg/mL (50 µL) 
 
 1 mg/mL (60 µL)  100 µg/mL (300 µL) (E) 50 µg/mL (300 µL)  
 30 µL of 2 mg/mL  30 µL of 1 mg/mL  150 µL of 100 µg/mL 
 30 µL of 1x PBS  270 µL of 1x PBS  150 µL of 1x PBS 
 pipette to mix.   pipette to mix.   pipette to mix. 
        
 1 µg/mL (300 µL)  100 ng/mL (300 µL) 
 6 µL of 50 uGu/mL  30 µL of 1 µg/mL  
 294 µL of 1x PBS  270 µL of 1x PBS 
 pipette to mix.   pipette to mix. 
 
 10 ng/mL (300 µL)  1 ng/mL (300 µL) (F)   
 30 µL of 100 ng/mL  30 µL of 10 ng/mL   
 270 µL of 1x PBS  270 µL of 1x PBS  
 pipette to mix.   pipette to mix.   
 
 Leave the protein tubes on ice so that PSA doesn’t aggregate  
 
 
10.) make pMBA (start in glovebox, can vortex) 
11.) start antigen soak (2 h), 13 µL of [PSA] per MGN/glass (no wash prior to antigen) 
        start IgG soak (2 h), 13 µL of [IgG] per MGN/glass (no wash prior to IgG soak) 
 Step 11: PSA/IgG (antigen) soak  
 Drop 13 µL of the various [PSA] on its corresponding MGN/glass piece, 
 Drop 13 µL of the various [IgG] on its corresponding MGN/glass piece, 
 
 Drop the 13 µL in the center and spread as usual, then leave for 2 hr at 4 0C (lid closed). 
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 One piece of MGN/glass is meant for one PSA/IgG concentration 
     A.) 100 µg/mL PSA 
     B.) 50 µg/mL   PSA 
     C.) 100 ng/mL PSA 
     D.) 1 ng/mL PSA 
     E.) 100 µg/mL IgG (No PSA) 
     F.) 1 ng/mL IgG (No PSA) 
 No washing before or after this step 
 
12.) Finish functionalization chemistry to finish prep of antiPSA-pMBA-MGNs 
  Before adding to the glass, need to dilute to make sure that they have   
  MGNs = 686 µg/mL 
   
  For step by step procedure for antiPSA-pMBA-MGNs chemistry for 30 mL batch, 
  refer to section A.2.4 for exact methods for functionalization chemistry.  
 
13.) next do blocking buffer soak (1 h) (no wash prior to BSA soak)  
  (13 µL per MGN-glass) 1 wt % BSA in monophosphate 
 Step 13: BSA soak  
 Drop 13 µL of the 1 wt % BSA MGN/glass piece, 
  
 Drop the 13 µL in the center and spread as usual, then leave for 1 h at 4 C (lid closed). 
 
 
14.) wash with monophosphate (3 small rinses in wash, 100 µL per rinse) 
15.) next do antiPSA-pMBA-MGNs (pAb) (1 h) (13 µL at 686 µg/mL = MGNs) 
 Step 15: antiPSA-pMBA-MGNs  
 Drop 13 µL of 686 ug/ml antiPSA-pMBA-MGNs 
  
Drop the 13 µL in the center and spread as usual, then leave for 1 hr at 4 C (lid closed). 
16.) wash with monophosphate (3 small rinses in wash, 100 µL per rinse) 
17.) dry at 4 C (1-2 h) (with lid slightly ajar) 
18.) Collect SERS point maps for the biodiag MGN-glass samples 
 
 
A.3.3 Raman Measurements of Sandwich Assay 
 
1. After allowing samples to dry for 2 h at 4 C, SERS spectra of the MGN-glass 
biodiagnostic sandwich assay were recorded. Using an Invia Raman microscope 
(Renishaw) with a 785 nm wavelength laser source, point maps of the Biodiagnostic 
samples were captured for the differing [PSA]. A video montage of the MGN-glass 
samples was captured, and the resulting brightfield image provided x,y coordinates (for 
point spectra) for the Raman instrument to record SERS chemical footprints. All spectra 
were recorded with: 785 nm wavelength laser source, 1200 lines/mm grating, extended 
spectra, 50x objective with power of 2 mW, and 30 s acquisition time. For further 
analysis, each individual spectrum was baseline corrected to remove any contributions 
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from the fluorescence background of the MGNs. Wire 3.4 was utilized for data 
processing of the sandwich assay results. Cosmic ray removal was performed with 
nearest neighbor method implemented to ensure the scaling of the spectra was not 
jeopardized. Data truncation and smoothing was also performed using Wire3.4 software. 
Lastly, background subtraction was performed in Wire using a polynomial fit. 
ISERS1580 peak corresponding the pMBA in the antiPSA-pMBA-MGNs, was determined 
from the baseline corrected spectra and then plotted against the respected [PSA]. 
 
 
A.3.4 Biodiagnostic Control Assays: Testing Specificity and No Antigen 
 
1. To ensure that the biodiagnostic assay is operating with the proper fidelity. Multiple 
controls were required. The Bovine Serum Albumin (BSA) alone control is the control 
where the whole biodiagnostic experiment is completed except for incorporating TCN 
buffer instead of PSA for the antigen incubation step (2 h). For this control, we see no 
signal. This observation makes sense, considering we want the biodiagnostic assay to 
limit the amount of non-specific binding that occurs which would result in false positive 
results. 
 
2. Lastly, Specificity control was performed, repeating the biodiagnostic assay except 
incubating with non-specific protein, Immunoglobulin G (IgG), instead of the target 
antigen (PSA). The control was attempted with multiple [IgG] concentrations, and no 
signal was observed. Thus, the lack of signal from either the BSA control assay or the 
IgG specificity control, demonstrates that the SERS sandwich assay has low probability 
for false positives with non-specific binding. The absence of signal from the IgG control 
demonstrates that the PSA detection will outcompete non-specific proteins when it comes 
time to move the assay into serum studies. The specificity of the two antibody layers for 
the binding event of the correct antigen (PSA), provide the assay with high fidelity while 
the two MGNs in a junction event, as part of the MGN-glass sandwich assay, provide 
unmatched detection limits 
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APPENDIX B 
PROCEDURES FOR IN VIVO SERS IMAGING AND EX VIVO TUMOR STUDIES 
 
B.1 Mammary Fat Pad Tumor Growth 
1. Human MDA-MB-231 cells, purchased from ATCC (HTB-26), were cultured in 
Dulbecco’s Modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal 
bovine serum (FBS, ATCC) and 1% penicillin/streptomycin (Gibco) and maintained at 
37 0C and 5% CO2. For optimal experimental design, cellular and in vivo assays were 
performed only after allowing for 14 days of culture to ensure that the cells were in their 
native state, maintaining media changes every 2 days.  
2. MDA-MB-231 cells were kept in culture at ~50-70 % confluency, not letting them 
become too confluent and entering their exponential growth phase. 
3. On day of 231 injection for the immune-compromised nude mice, the cells should be ~75 
% confluent. 
4. Also, the athymic nude mice should only be ~3.5 weeks upon 231 injection to obtain 
optimal results as far as human xenograft adhering and continuing to grow.  
5. Day of injection, the cells were dislodged from the culture flask using trypsin, followed 
by quenching with complete media (cDMEM). 
6. The cell number was determined using a scepter cell counter using optical density. 
7. Next, the cells were centrifuged at 100 g for 8 min, washing twice with nDMEM to 
remove any FBS from interfering during xenograft growth in the mice. 
8. The cells were resuspended in nDMEM at 2E7 cells/mL and left on ice until injection. 
9. Ensuring that the mice are ready for injection, the Matrigel (Corning) was thawed ~2 h 
prior to injection so was in liquid form, but still cold when it comes times for usage. 
10. Matrigel was added (1:1) volume ratio to the cell stock to give overall 1E7 cells/mL. 
11. Next, performing a subcutaneous injection in the mammary fat pad around the 5th nipple 
(left side), 100 µL of the cell solution were injected, observing a bulb forming upon 
successful injection (total cells injected = 1E6 cells).  
12. Tumors should form in ~14 days, monitoring the mice for any forms of discomfort and 
checking the tumor size 3-4 times per week with calipers.  
13. The tumors are ready for imaging when diameter is ~6-7 mm. 
14. If the tumors become larger than 15 mm in diameter in any direction, then the mice must 
be sacrificed. 
15. Having consistent tumor size on day of imaging is vital to having consistent results. 
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B.2 Synthesis of Actively Targeted MGNs Cocktail for in vivo Experiments 
B.2.1 Reagents and Materials 
 
• HEPES:  
  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Sigma-Aldrich) 
• Gold Salt:  
  gold(III) chloride trihydrate (HAuCl4) (Sigma-Aldrich) 
• Raman tag, pMBA 
  4-mercaptobenzoic acid (pMBA) (TCI America) 
• Raman tag, DTNB 
  5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB)  (TCI America) 
• OPSS-PEG-NHS ester:  
  Orthopyridyl-disulfide poly(ethylene glycol)-N-hydroxysuccinimide ester  
  (OPSS-PEG-NHS ester, Mw 2000 g/mol, JenKem Technology)  
• mPEG-SH (5000 g/mol)  
  methoxy- polyethlyene glycol-thiol (mPEG-SH, Mw 5000 g/mol,   
  Jenkem Technology)  
• Bicarbonate:  
  sodium bicarbonate (NaHCO3, Acros Organics)  
• 10x PBS:  
  Phosphate Buffered Saline pH 7.4 (Gibco) 
• antiEGFR  
  Human EGF R/ErbB1 antibody (monoclonal mouse raised antibody, 
  R & D Systems)  
• antiPDL1  
  Human CD274 (B7-H1, PD-L1) antibody (monoclonal mouse  
  raised antibody, BioLegend) 
• FL-secondary antibody for antiEGFR  
  Mouse IgG2B PE-conjugated (monoclonal rat raised antibody,  
  R & D Systems, Phycoerythrin) 
• Fixative solution 
  cytofix/cytoperm (BD Biosciences) 
• Blocking solution 
  1x animal free blocking solution (Cell Signaling Technology)  
 
 
B.2.2 Buffer Preparation 
 
1. 200 mM HEPES pH 7.40 ± 0.1 buffer for MGNs Synthesis  
 -HEPES prep must be with Aqua Regia cleaned glass as it is for MGN synthesis. 
 Glassware and Materials:  (x1) 600 mL Beaker 
     (x1) 250 mL Graduated Cylinder 
     (x1) stir bar 
o Add ~11.916 g of HEPES (Sigma Aldrich, #H4034) to 600 mL beaker. 
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o Add 190 mL MQ water. 
o Let stir for ~40 min with large stir bar to dissolve.  
o Always checking pH with stir bar stirring. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Prepare 1 M NaOH solution from solid pellets and MQ water. 
o Add 1 mL 1 M NaOH, check pH, continually stirring.  
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 1 mL 1 M NaOH (20-25 mL) and monitoring to pH 7.40 ± 0.1. 
o Take out stir bar, fill to 250 mL with MQ water in graduated cylinder. 
o Vortex again and record final pH reading of buffer. 
o Put buffer in sterile 50 mL conical tubes (x5) and store at room temperature.  
o HEPES buffer not autoclaved for MGN synthesis. 
 
2. 100 mM NaHCO3 pH 8.6 ± 0.1 Bicarbonate buffer for antiEGFR Resuspension 
 -Buffer autoclaved post preparation for sterility: 
 Glassware and Materials:  (x1) 50 mL Centrifuge tube 
     (x1) 125 mL Erlenmeyer flask 
     (x1) stir bar 
     (x1) aluminum foil 
     (x1) autoclave tape 
o Add ~335 mg of NaHCO3 (Acros Organics, #123360050) to 50 mL Tube. 
o Add 32 mL MQ water. 
o Let stir for ~40 min with conical stir bar to dissolve.  
o Always checking pH with conical stir bar stirring, vortex after each addition. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Prepare 1 M NaOH solution from solid pellets and MQ water. 
o Add 2 µL 1 M NaOH, check pH, vortexing to mix in between readings. 
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 2 µL 5 1 M NaOH (6-8 uL) and monitoring to pH 8.60 ± 0.1. 
o Take out stir bar, fill to 40 mL with MQ water. 
o Vortex again and record final pH reading of buffer. 
o Put the buffer in a clean Erlenmeyer flask (125 mL). 
o Cover with foil, add autoclave tape, and put in secondary container. 
o Autoclave using liquid cycle. 
o Post-autoclaving, let cool, and put in sterile 50 mL conical tube in biohood. 
o Store at 4 0C. 
 
3. 1x PBS pH 7.4 ± 0.1 buffer for MGN Resuspension 
 -Buffer autoclaved post preparation for sterility: 
 Glassware and Materials:  (x1) 50 mL Centrifuge tube 
     (x1) 125 mL Erlenmeyer flask 
     (x1) stir bar 
     (x1) aluminum foil 
     (x1) autoclave tape 
o Add 4 mL 10x PBS pH 7.4 stock (Gibco) to 50 mL Tube. 
o Add 32 mL MQ water. 
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o Let stir for ~40 min with conical stir bar to dissolve.  
o Always checking pH with conical stir bar stirring, vortex after each addition. 
o Calibrate pH meter with pH 7 and 10 standards, check pH. 
o Add 1 µL 5 M HCl, check pH, vortexing to mix in between readings. 
o Wash electrode in between readings with MQ water and dab dry. 
o Keep adding 1 µL 5 M HCl (3-6 µL) and monitoring to pH 7.40 ± 0.1. 
o Take out stir bar, fill to 40 mL with MQ water. 
o Vortex again and record final pH reading of buffer. 
o Put the buffer in a clean Erlenmeyer flask (125 mL). 
o Cover with foil, add autoclave tape, and put in secondary container. 
o Autoclave using liquid cycle. 
o Post-autoclaving, let cool, and put in sterile 50 mL conical tube in biohood. 
o Store at 4 0C. 
 
 
B.2.3 Protein Resuspension 
 
1. antiEGFR, Monoclonal 
 Sterile Conditions: 
ü antiEGFR monoclonal antibody (R & D Systems), part #MAB1095. 
 Was shipped as 500 µg amount. 
ü Let the antibody thaw on ice for ~20-30 min. 
ü Pellet the solid down in the centrifuge before moving to biohood. 
ü Check that appearance of white solid is observable in tube. 
ü In the biohood, dissolve the 500 µg of antiEGFR monoclonal antibody in 500 µL 
 100 mM NaHCO3 (pH 8.6 ± 0.1) buffer by gently pipetting, no vortexing. 
ü Pipette until solid is completely resuspended, but avoid bubbles as they are  
 indicator of protein aggregation. 
ü Aliquot in 15 µL aliquots (1 mg/mL), putting the aliquots on ice.  
 Should get about ~33 aliquots. Store at -20 0C. 
ü Avoid repeating the freeze/thaw process of the protein more than once if possible. 
 
2. antiPDL1, Monoclonal 
 Sterile Conditions: 
ü antiPDL1 monoclonal antibody (BioLegend), part #329728. 
 Was shipped already reconstituted in phosphate-buffered solution pH 7.2 
  5 mg, in 5.21 mL buffer for ~1 mg/mL antiPDL1 stock 
ü Aliquoted in 100 µL aliquots (1 mg/mL), putting the aliquots on ice. 
 Should get about ~50 aliquots. Store at 4 0C as recommended by vendor.  
ü Avoid repeating the freeze/thaw process of the protein more than once if possible. 
 
 
 
 
 
 
169	
	
B.2.4 Functionalization Chemistry 
 
1. (2:1) cocktail prep of antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs 
Procedure for functionalization chemistry for in vivo is a modified version of what was 
explained previously in vitro for Chapter 4 methods for (1:1) cocktail prep of antiEGFR-
pMBA-MGNs to antiPDL1-DTNB-MGNs (refer to Chapter 4.5). 
 
2. Differences Between Two Chemistry Protocols 
i.)  300 mL batch functionalized MGNs per SERS tag/antibody combination  
  instead of 60 mL per combination.  
ii.)  Resuspension for final MGN product was in 1x PBS pH 7.4 ± 0.1 for  
  in vivo  studies, changed from 8.6 mM (Na2HPO4) pH 7.40 ± 0.1. 
iii.)  Final product resuspension volume was 850 µL instead of 200 µL. 
 
3. Brief Review of Procedure 
MGNs Synthesis: 
300 mL batch per SERS tag/antibody combination is enough for ~7 mice at (2:1) 6 
mg/mL, 200 µL injections. For each nanoprobe, A scaled up 300 mL batch of MGNs was 
prepared by synthesizing ten 30 mL batches simultaneously and combining after the 
reaction reached completion. Briefly, 18 mL of Milli-Q water (18 MΩ) was added to 12 
ml 200 mM HEPES (pH 7.40 ± 0.1), mixing by gentle inversion. Quickly, 300 µl of 20 
mM tetrachloroauric(III) acid (HAuCl4, Sigma-Aldrich,	 #520918) was added, again 
mixing my inversion and leaving to react at room temperature for 75 minutes. Plasmon 
resonance of the MGNs, through the functionalization process, was monitored using UV-
vis spectroscopy with initial resonance of the solution phase MGNs at 780 ± 10 nm. 
 
antiEGFR-pMBA-MGNs: Again, functionalization chemistry was monitored for shifts in 
plasmon resonance due to phase retardation effects from the change in immediate local 
refractive index due to the layering around the MGNs. To begin, 300 mL MGNs at 170 
µg/mL (Ext. = 1.79) at max plasmon resonance ~780 nm in the NIR region were 
synthesized. MGNs were kept on ice through functionalization process. 4-
mercaptobenzoic acid (pMBA), dissolved in 100 % ethanol, was added to the MGNs in a 
small volume with high concentration, slow stirring, 30 µL of 10 mM pMBA was 
injected to 300 mL of MGNs, mixing for 10 min at 4 °C. 
 
300 mL was split into 50 mL aliquots (x6), centrifuged at 6000 rpm for 20 min. 
Supernatant was completely decanted to remove any unbound pMBA, and pellets were 
combined in 15 mL total volume with Milli-Q (MQ) water. The resonance and 
concentration were again recorded, and the functionalized MGNs were further diluted to 
1.14 mg/mL (Ext. = 12.0) with Milli-Q water for a total volume of 31 mL of particles.  
 
For OPSS-PEG-antiEGFR in vivo procedure, refer to OPSS-PEG-antiEGFR in vitro 
procedure (section 4.5) as they were the same except OPSS-PEG-antiEGFR for in vivo is 
prepped in 480 µL, while the OPSS-PEG-antiEGFR in vitro was prepared at 80 µL 
volume. Both were prepared at (1:9) volume ratio of antibody to OPSS-PEG-NHS linker 
and reacted for at 4 0C for 24 h. 480 µL of OPSS-PEG-PSA reaction (monoclonal 
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[antiEGFR]Final = 0.9 mg/mL) was added to 29.75 mL pMBA-labeled-MGNs at 1.14 
mg/mL (Ext. = 12.0), pipetting to mix. Antibody with MGNs reaction was then left to 
react for 24 h on an inverter at 4 0C.   
 
Post 24 h incubation, PEGylation chemistry was performed. To the aqueous MGNs 
mixture, 2.1 mL of 5 µM polyethlyene glycol-thiol (mPEG-SH, Mw 5000 g/mol) was 
added in a cold reaction vessel and slowly stirred for 10 min at room temperature. The 
~31.85 mL volume was split into 5.30 mL aliquots (x6) and filled to 10 mL volumes with 
Milli-Q water, mixing by inversion to wash any unbound OPSS-PEG-NHS or mPEG-SH. 
Particles were then centrifuged at 4000 rpm for 10 min, and supernatant was completely 
removed under sterile conditions. Pellets were resuspended in 850 µL of sterile 1x PBS 
pH 7.4 ± 0.1 with resonance and concentration again measured. If necessary, dilute final 
[antiEGFR-pMBA-MGNs] with the sterile 1x PBS buffer to 6 mg/mL, rechecking 
concentration. For in vivo longitudinal study, functionalized MGNs were utilized at 6 
mg/mL concentration. The particle prep for the antiEGFR-pMBA-MGNs was finished 
night before zero time point day and then stored at 4 0C on ice until usage. 
 
antiPDL1-DTNB-MGNs: To synthesize the complementary MGNs particles, the 
functionalization method was repeated with similar steps but substituting antiPDL1 as the 
targeting moiety and 5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB) as the SERS tag. Slight 
change in method was due to the 5-fold dilution of the OPSS-PEG-antiPDL1 reaction for 
a higher pH. A big batch of 300 mL MGNs at 170 µg/mL (Ext. = 1.79), resonance ~780 
nm, was again synthesized. With slow stirring, 30 µL of 10 mM DTNB was added to 300 
mL of MGNs reacting for 10 min at 4 °C. After centrifugation and resuspension with MQ 
water to 1.14 mg/mL (Ext. = 12.0) for a total volume of 31 mL of particles, the antiPDL1 
targeting moiety was added to the MGN solution. 2.4 mL of OPSS-PEG-antiPDL1 
reaction ([antiPDL1]Final = 0.18 mg/mL) was added to 29.75 mL DTNB-labeled-MGNs 
at 1.14 mg/mL (Ext. = 12.0). The reaction was left to react for 24 h at 4 °C on inverter. 
The final PEGylation, wash, centrifugation, and sterile resuspensions steps were same for 
antiPDL1-DTNB-MGNs as for the antiEGFR-pMBA-MGNs for in vivo studies. After 
resuspending in 850 µL of sterile 1x PBS pH 7.4 ± 0.1, resonance and concentration were 
checked, and dilution to 6 mg/mL was performed if necessary. 
 
(2:1) cocktail prep of antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs: In preparing 
a (2:1) mixture of the two types of antibody-labeled MGNs, a 300 mL batch of each of 
the respective particle was prepared. After final resuspension steps in sterile 1x PBS pH 
7.4 ± 0.1, the resonance and concentration of the two antibody-labeled MGNs were 
determined respectively. Each solution was diluted to 6 mg/mL. Then the antiEGFR-
pMBA-MGNs were mixed at an (2:1) volumetric ratio with the antiPDL1-DTNB-MGNs, 
assuming there was no change in the overall MGNs concentration. Plasmon resonance 
and concentration of the (2:1) cocktail were measured, and the particles were maintained 
at a concentration of 6 mg/mL in PBS, on ice at 4 °C, until retro-orbital injection time. 
Typical volume would be 1350 µL of antiEGFR-pMBA-MGNs + 675 µL of antiPDL1-
DTNB-MGNs to create 2025 µL of (2:1) mixture, dividing into 280 µL aliquots (x7). 
Later, each mouse would receive 200 µL of 6 mg/mL (2:1) mixture retro-orbital injection 
under anesthesia (60 µg/g mouse injection). 
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B.3 SERS Longitudinal Assay with Portable Raman and Athymic Mice for Both 
Experimental and Receptor-Blocked Groups 
1. A longitudinal SERS multiplex in vivo imaging study was performed on the immune-
deficient mice subjects over 72 h time course, measuring the intensity of the two SERS 
tags of the functionalized MGNs 
2. Using 6 mg/mL (2:1) antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs mixture for 
retro-orbital injection of the athymic mice. 
3. The particle prep for (2:1) cocktail of actively targeted MGNs was completed the night 
before day 1 of in vivo imaging and was stored at 4 0C on ice until usage.  
4. The mixture was injected at 2:1 antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs for 
the in vivo  and ex vivo studies.  
5. Using a portable SERS imaging system and with maneuverable handheld probe, SERS 
measurements on the surface of the Human xenografts (MDA MB 231) growing in the 
athymic mouse were recorded using a 785 nm laser diode at 80 mW power. Mice were 
also under isoflurane anesthesia during SERS. Since SERS acquisitions are so fast 
temporally, the mouse was only under for ~6 min, making the measurements easier on 
the subjects.  
6. Note: Probe consists of glass-tubing on the inside of the chord. Thus, it must never be 
bent or wrapped in any way as it will cause the system to lose signal strength.   
7. At the site of the tumor, non-invasive, topical measurements were acquired before and at 
time intervals after retro-obrital injection. While recording, mice were under heating 
blanket, and any signs of discomfort were monitored.  
8. On day 1 of imaging experiment, 0 h time point was recorded, which showed a strong 
lipid peak (1440 cm-1). 
9. This 0 h point measurement was followed by 200 µL of 6 mg/mL (2:1) mixture retro-
orbital injection under anesthesia (60 µg/g mouse injection).  
10. SERS measurements were recorded at 0, 6 12, 24, 48, and 72 h, putting the mouse under 
anesthesia during imaging. 
11. Post 72 h imaging, the mouse was euthanized, and the organs were retrieved for Ionized 
Coupled Plasma Mass spectroscopy (ICP-MS) to study the biodistribution of the actively 
targeted MGNs. Further, organ retrieval was studied for 6 h max accumulation for the 
experimental and additionally, 6 and 72 h for the receptor blocking control. Data not 
shown.  
12. After background subtraction and normalizing to an endogenous peak of the tumor tissue 
(lipid, 1440 cm-1), the SERS intensity was plotted for both the DTNB and pMBA peaks 
with maximum SERS intensity occurring at 6 h post retro-orbital injection. 
13. A custom code was built using MATLAB software to perform smoothing and 
background fluorescent subtraction.  
14. Truncation was performed on data sets to focus on 800-1650 cm-1 region of interest.  
15. Smoothing and filtering were performed using Savitsky and Golay method. 
16. Background subtraction of fluorescence was performed using the modified polyfit 
method, automated approach to iterate many times to find the proper fit for each spectra 
with a polynomial mathematical function of choice. 
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17. The software runs an iterative process fitting the selected polynomial to the data to 
remove background, coming as close to baseline to subtract out all fluorescence without 
losing any Raman peaks or jeopardizing data fidelity. 
18. Further, the active targeting capabilities of the antibody coated MGNs were investigated 
by having a control group study that was pre-blocked with antiEGFR and antiPDL1 
monoclonal antibodies through intraperitoneal injection, 2 h prior to MGN injection.  
19. Through intraperitoneal injection, 400 µl of 1 mg/mL mixture of antiEGFR:antiPDL1 
antibodies (20 µg/g mouse injection) was injected 
20. After 2 h, time point zero was recorded, followed by 200 µL of 6 mg/mL (2:1) mixture 
retro-orbital injection under anesthesia (60 µg/g mouse injection).  
21. SERS measurements were recorded at 0, 6 12, 24, 48, and 72 h, putting the mouse under 
anesthesia during imaging. 
22. Followed by euthanizing and collecting organs at 6 h and 72 h for ICP-MS for the block 
studies. Data not shown. 
23. Raman intensity for both the 1325 cm-1 peak for DTNB and 1580 cm-1 peak for pMBA 
were normalized to the 1440 cm-1 lipid peak after smoothing and background 
subtraction.  
24. A ~30 % drop in signal is observed due to the receptor blockage on the surface of the 
tumor.  
25. n=4 for each group subset.  
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B.4 Histology (H and E) and Silver Staining of ex vivo Tumor Sections 
1. After the longitudinal study revealed the accumulation of actively targeted MGNs 
 using 6 mg/mL (2:1) antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs mixture for 
 retro-orbital injection of the athymic mice, we decided to investigate further the 
 interaction between the functionalized MGNs and the tumor micro-environment. 
2. For ex vivo studies, another round of in vivo tests with the 231 cell xenografts were 
carried out with 200 µL, 6 mg/mL (2:1) mixture of actively targeted MGNs injected. 
3. Since we found out from the longitudinal SERS study that the maximum accumulation 
occurs at 6 h, we decided to investigate the tumor physiology at this time point.  
4. After 6 h post retro-orbital injection, the mouse was sacrificed, and the tumor was 
removed through dissection. 
5. The tumor was next sliced in half to form two separate hemispheres and preserved in 
OTC freeze, leaving the sample in a cassette over dry ice. Sample was then stored at  
 -80 °C until processing. 
6. Sample processing was handled by Vanderbilt Translational Pathology Shared Resource 
(TPSR). 
7. The TPSR core created ultra-thin ~10 µm slices of the breast xenograft tissue in the 
center and periphery of the tumor for comparison. 
8. Next histology stains for both (H and E) staining and silver staining were performed.  
9. Haematoxylin and Eosin stains are modulated by pH, and due to the gradients in pH of 
different macromoleucles, one can distinguish nuclei, cytoplasm, muscles, collagen, 
mitochondria, and more. 
10. Thus, the (H and E) stain provides necessary information about the overall physiology of 
the tumor tissue and how it is behaving in terms of normal physiological behavior. H and 
E cannot, however, tell whether there is the presence of gold nanoparticles. It can tell (if 
nanoparticles are known to be present) whether the particle accumulation is having a 
detrimental or benign effect on the cells, and if their presence is affecting the tissue 
morphology.  
11. To determine whether there was MGN accumulation or not for the (2:1) mixture of 
actively targeted MGNs, a silver stain was performed on the xenograft slices as well. 
12. The silver stain enhances nanoparticle contrast of the gold nanoparticles making them 
more apparent in brightfield imaging and easy to observed where there is localization in 
the tumor tissue and vasculature 
13. After staining, the slides were imaged using a bright widefield microscope. In order to 
have the capacity to see the global image that is the whole tissue slice, a widefield 
microscope was required.  
14. For comparison, also visualized was a control tumor slice silver stained, which had no 
MGNs injected to the mouse, but was removed at 6 h as well to be consistent.  
15. Using a 5x objective and a zoom out setting of 8, both 231 xenografts with and without 
(2:1 antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs) mixture were recorded. 
16. Side by side visualization confirmed presence of actively targeted MGNs at 6 h post 
injection (observed by silver stain). Additionally, vasculature and tissue morphology 
were not modified by MGN injection and accumulation as seen by side by side 
comparison of tumors both with and without actively targeted (as seen by H and E stain). 
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B.5 Ex vivo SERS Mapping of Tumor Sections 
1. As performed with the histology ex vivo studies, the ex vivo SERS mapping of tumor 
sections required another longitudinal study to again reveal the accumulation of actively 
targeted MGNs at the tumor site. 
2. Using 6 mg/mL (2:1) antiEGFR-pMBA-MGNs to antiPDL1-DTNB-MGNs mixture for 
retro-orbital injection of the athymic mice, we wanted to test the full potential of the 
SERS mapping by tracing MGN localization because of receptor coverage at maximum 
accumulation, 6 h.  
3. For ex vivo SERS, mice with ~7 mm mammary fat pad xenografts (231 cells) were 
injected with 200 µL, 6 mg/mL (2:1) mixture of actively targeted MGNs injected 
4. 6 h post retro-orbital injection, the mouse was sacrificed, and the tumor was removed. 
5. The tumor was again sliced in half to form two separate hemispheres and preserved in 
OTC freeze. Storing at -80 °C in cassette. Slicing and preparation was performed by 
Vanderbilt TPSR. 
6. Upon receiving the ~10 µm thick slice of the breast xenograft tissue 
7. To minimize background fluorescence and other noise, the tissue sections were placed on  
Calcium Fluoride disks (CaF2, 20 x 2 mm Raman grade, Crystran Ltd.) specifically for 
SERS measurement.  
8. The tissue samples were visualized using an inVia Raman (Renishaw) brightfield 
microscope. Using an 50x objective, a video montage of the 231 tissue cross-section was 
captured, and this resulting brightfield image provided x,y coordinates for the Raman 
instrument to record SERS chemical footprints of a rectangular area of ~5 mm by 5 mm.  
9. Recording spectra with 50 µm steps, the invia Raman microscope took measurements of 
the tissue with a 785 nm wavelength laser source with 1200 lines/mm grating in high 
confocal mode. Static spectra (1200 cm-1 center) were recorded using a 50x objective at a 
power of 10 mW with a 10 s acquisition time.  
10. Running Wire 3.4 software, SERS map was a collection of ~5 mm x 5 mm tissue cross-
section. Raster acquisition was utilized, creating a dataset of ~30,000 spectra. The dataset 
was a matrix with (x,y) coordinates, wavenumber cm-1, and Raman intensity. Using the 
wire 3.4 software, cosmic ray removal was performed with nearest neighbor method 
implemented. Next, the wire 3.4 wxd file was converted into a text file and imported into 
MATLAB R2016a software. Code was built using MATLAB software to perform 
smoothing and background fluorescent subtraction. Following the modified polyfit 
method, an automated approach was applied using polynomial fitting to uncover SERS 
peaks even at low intensity regimes.  
11. Prior to implementing the modified polyfit method on the data set, truncation was 
performed, and data underwent smoothing and data differentiation using the Savitzsky 
and Golay method. The S and G filter used order of 5 and coefficient value of 61. 
12. After smoothing, a 7th order polynomial was utilized for fluorescent background 
subtraction through an iterative process with a threshold of 0.0001. 
13. Direct Classical Least Squares (DCLS) component mapping of the 1325 cm-1 peak 
corresponding to DTNB of the antiPDL1-DTNB-MGNs was performed. DCLS utilizes 
peak geometries as parameters to determine similarity for spectra in a large dataset.  
14. The analysis revealed localization of the signal on the periphery of the tumor cross 
section where more vasculature was concentrated when comparing to necrotic core.  
